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Development of chemical tools to target DEAD-box proteins 
 
Krister Jernstedt Barkovich 
Abstract 
The complexity of the three-dimensional structures formed by RNA is essential for its 
function and as a result, a large number of protein co-factors are required to maintain 
RNA homeostasis. The largest family of enzymatic RNA chaperones are the DEAD-box 
proteins, which utilize ATP hydrolysis to modify RNA substrates. DEAD-box proteins are 
required for all stages of RNA metabolism and are implicated in diseases including 
cancer, viral pathogenesis, and developmental delay. Yet despite the biochemical and 
structural characterization of these enzymes over the past three decades, the specific 
functions and substrates of DEAD-box proteins remains poorly understood. Chemical 
inhibition would be an excellent tool for the elucidation of DEAD-box protein biology 
because of its rapid onset of inhibition, however specific small molecule inhibitors do not 
exist for most DEAD-box proteins. 
 
To develop a generalizable strategy for the inhibition of DEAD-box proteins, we 
developed two chemical genetic strategies – one analog-sensitive and one electrophile-
sensitive – that rely on genetic perturbations of the target of interest coupled with 
specific chemical inhibitors. Our efforts to develop an analog-sensitive strategy yielded 
novel space-creating mutations off the N6-position of the adenine of ATP that were 
poorly tolerated in vivo, and analog-sensitive inhibitors that could not be optimized to 
bind with high affinities. For the electrophile-sensitive strategy, we identified a residue of 
 viii 
low conservation within the DEAD-box protein active site for mutation to cysteine and 
specifically targeted it with electrophile-containing AMP-derivatives. These small 
molecules specifically bind to and inhibit electrophile-sensitive, but not wild-type, DEAD-
box proteins. Together, these results indicate that DEAD-box proteins can be targeted 
using chemical genetic tools and provide a path towards the development of specific 
small molecule inhibitors of any member of the DEAD-box protein family. 
 
We additionally sought to identify novel nucleotide-competitive cell-permeable small 
molecules that bind and inhibit DEAD-box proteins. To this end, we identified a series of 
di-substituted quinazolines based on the AAA+ ATPase inhibitor DBeQ that dose-
dependently inhibit DDX3 in an ATP-dependent manner.  
 
In a separate project, we explored the limited efficacy of clinical CDK4/6 inhibitors as 
monotherapy. We identified that the small molecule inhibitor ribociclib has limited 
efficacy as a monotherapy in cell culture, and found that CDK4 is bound in high 
molecular weight complexes in cells, which are mostly resistant to inhibition by type I 
kinase inhibitors. We then developed a series of small molecule derivatives of ribociclib 
that attempt to expand the clinical efficacy of ribociclib by targeting these high molecular 
weight complexes. 
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RNA and RNA homeostasis 
After the discovery of the double helical structure of DNA in 1953,1 the next question 
became how information from this linear genetic code was converted into the cellular 
machinery of proteins.2 This led to the discovery of a transient RNA population, now 
called messenger RNA (mRNA), by two independent groups in 1961 using pulse-
labelling of radiolabeled uridine.3,4 Similar experiments also identified a transient 
population of large RNAs that were synthesized in the nucleus then exported to the 
cytoplasm, where they existed in a long-lived fraction that showed rapid sedimentation 
in sucrose gradient centrifugation.5,6 These RNA populations were found to be the 
precursor to ribosomal RNA (pre-rRNA) and mature rRNAs. Monitoring of the size of the 
pre-rRNA as it matured into final rRNAs of the ribosome led to the discovery that 
ribosomal RNA undergoes multiple processing steps prior to 40S and 60S ribosomal 
subunit export to the cytoplasm.7 Later experimental work determined that mRNAs also 
undergo nuclear processing or “splicing” at a specialized ribonucleoprotein complex 
called the spliceosome,8-10 where non-coding regions of RNA (‘introns’) are removed 
and the mature mRNA is produced. More than a half-century later, RNA species are 
known to be intimately involved in numerous cellular processes, including gene 
expression and regulation and protein translation.2  
 
RNA is unique as a biologic macromolecule due to its simple linear sequence and its 
capacity to form complex secondary and tertiary structures that present surfaces for 
interactions with other macromolecules including DNA and protein.2 The complexity of 
the three-dimensional structures formed by RNA is essential for its role in translation, 
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splicing, scaffolding, and localization.11 For example, transfer RNAs (tRNAs) are 
specifically modified through methylation and pseudouridinylation to maintain a specific, 
function conformation,12,13 and disruption of ribosomal RNA or small nuclear RNA 
structure through alterations in RNA processing and folding are detrimental to its 
function as the structural element of the ribosome and spliceosome, respectively.14,15 
The large number of possible RNA base-pairings and alternative folding patterns means 
that the maintenance of proper RNA folding presents a significant cellular challenge.16 
As such, RNA homeostasis requires a sizable number of protein co-factors to maintain 
proper RNA folding and function. These RNA chaperones include heterogeneous 
nuclear ribonucleoproteins (hnRNPs) and cold-shock domain proteins, which can bind, 
stabilize and/or modify RNA in an ATP-independent manner, and the ATP-dependent 
DExD/H-box proteins.16 
 
DEAD-box proteins 
The largest family of enzymatic RNA chaperones in humans are the DEAD-box 
proteins, which utilize ATP to disrupt RNA-RNA and RNA-protein interactions.17 Named 
for their conserved Walker B motif consisting of adjacent aspartate-glutamate-alanine-
aspartate (D-E-A-D) residues, DEAD-box proteins are required for all stages of RNA 
metabolism including transcription, processing and splicing, export, translation and 
decay (Figure 1.1).18 For example, eighteen DEAD-box proteins have been implicated in 
ribosome biogenesis, six in translation, and six in splicing.18  
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Prokaryotic and eukaryotic helicases are broadly categorized into six superfamilies 
(SF1-SF6) of which SF3-SF6 are hexameric or toroidal, meaning they function in 
hexameric or higher order structures, while superfamlies one and two (SF1 and SF2) 
are not, but remain structurally related.19 The SF2 superfamily encompasses the largest 
number and widest variety of helicases in terms of structure and function and includes 
the RecQ-like and Swi2/Snf2-like family of DNA helicases/translocases, which function 
in genome stability and nucleosome remodeling,20,21 and most RNA helicases, including 
the DEAD-box and DExH-box protein families. 
 
The minimal DEAD-box protein is formed by two RecA-like domains separated by a 
flexible linker.22 The domain interface forms the ATP-binding site, which consists of 
canonical ATPase motifs first described by Walker and colleagues,23,24 as well as the 
DEAD-box protein-specific Q-motif that functions to stabilize the adenine of ATP and 
make this family of enzymes ATP-specific.25 Unlike the structurally related DExH-box 
family of RNA helicases, DEAD-box proteins remodel their substrates non-processively 
though local-strand separation26 and require only a single ATP hydrolysis event for 
substrate release.27,28 Additionally, DEAD-box proteins display biochemical activity 
against both RNA-RNA and RNA-protein complexes,29 and can act as both strand 
annealers and unwinders.30 The DEAD-box proteins are best exemplified by eIF4A, the 
first human DEAD-box protein discovered, that acts to unwind secondary structure in 
the 5’-UTR of mRNAs during 43S preinitiation complex scanning.31 Other notable 
human DEAD-box proteins include DDX3, which is implicated to act as a part of the 
eIF4F complex in 43S scanning and translational activation,32,33 and DDX5 (p68) and 
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DDX17 (p72) which act as transcriptional co-activators.34 Yet despite these well-studied 
examples, our understanding of the specific functions that DEAD-box proteins perform 
in vivo, as well as detailed understanding of substrate specificity, remain poorly 
understood.18 
 
DEAD-box Proteins in Disease 
Owing to their influential role in nearly all aspects of biology, DEAD-box proteins are 
commonly implicated in disease, including viral pathogenesis, cancer, and disorders of 
impaired development (Figure 1.2). 
 
Viral infection 
Owing to their limited genomic size, viruses often co-opt human cellular proteins that 
are required for their replication process. RNA viruses often require these cellular 
components, which include many DEAD-box proteins, for replication and translation of 
their genome.35 
 
DDX1 is implicated as a pro-viral factor for human coronavirus and HIV infection. The 
unwinding activity of the DEAD-box protein DDX1 is required for coronavirus 
subgenomic mRNA (sgmRNA) synthesis and DDX1 knockdown or loss of catalytic 
activity reduced levels of sgmRNAs.36 DDX1 also functions with the HIV Rev Response 
Element (RRE) to enhance the RNA export activity of Rev37 and DDX1 silencing in HIV-
infected human cells reduces virus particle production.38  
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DDX3 is also a target of many viruses including hepatitis C virus (HCV), HIV-1, and 
West Nile virus (WNV). DDX3 is bound by the HCV core protein and is required for HCV 
RNA replication.39 DDX3 knockdown results in significant repression of genome-length 
HCV RNA and suppression of HCV infection.40 In HIV infection, DDX3 co-localizes with 
HIV-1 Tat to cytoplasmic foci and is required for Tat function41 as well as Rev-RRE 
export, similar to DDX1.42 DDX3 is also required for translation initiation of the HIV-1 
genomic RNA.43 DDX3 knockdown by shRNA suppresses the nuclear export of HIV-1 
RNAs and translation of the HIV-1 genome, and reduces HIV-1 viral replication.43,44 
DDX3 has also been identified at WNV replication sites along with other human P-body 
components LSM1, GW182 and XRN1 and knockdown of these proteins resulted in 
reduced viral RNA levels and infection.45 Interestingly, in hepatitis B virus (HBV) and 
vaccinia virus (VACV) infection, DDX3 contributes to antiviral innate immune signaling 
pathways leading to interferon-beta production through an interaction with IRF346 and 
DDX3 knockdown inhibits IRF3 activation.47 
 
DDX5 is also implicated in the pathogenesis of several viral infections. A yeast-two 
hybrid screen found that DDX5 specifically interacts with the sudden acute respiratory 
syndrome coronavirus (SARS-CoV) helicase nsp13 and knockdown of DDX5 resulted in 
reduced coronavirus replication in cell culture.48 DDX5 was additionally shown to 
interact with the HCV NS5B protein and siRNA-mediated knockdown of DDX5 resulted 
in reduced transcription of negative-strand RNA from positive-strand HCV RNA.49 
Similar to DDX1 and DDX3, DDX5 was also found to interact with HIV-1 Rev to 
enhance HIV-1 replication,50 although DDX5 knockdown paradoxically led to increased 
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HIV infectivity and higher viral RNA levels.51 The closely related subfamily member 
DDX17 was also identified as an HIV-1 Rev interacting protein, and knockdown of 
DDX17 led to decreased viral mRNA levels.51 DDX17 was found to recognize and bind 
specific cytoplasmic RNA stem-loops in the Rift Valley fever virus (RVFV) genome and 
thus can also serve an anti-viral role.52  
 
The DEAD-box protein DDX6 also plays a role in HIV and HCV infection. HIV-1 mRNA 
was found to associate with components of the miRNA machinery (RNA Induced 
Silencing Complex, RISC) including DDX6/RCK, GW182, LSM1 and XRN1, and 
knockdown of DDX6 or DGCR8, which is required for miRNA processing, resulted in 
increased production of infectious virions, indicating the miRNA processing machinery 
plays an antiviral role in HIV infection.53 Conversely, DDX6 activity is important for 
optimal HCV replication, as DDX6 overexpression enhanced HCV replication and an 
ATPase-dead mutant had a dominant-negative effect, reducing HCV viral yields.54 The 
DDX6-interacting proteins LSM1-7 were also found to specifically interact with cis-acting 
HCV RNA elements in the viral RNA UTRs, and depletion of these cellular components 
reduced HCV replication.55 
 
In a study of HIV-1 Rev interacting partners, the DEAD-box proteins DDX21, DDX24, 
and DDX47 were also identified, as were DExH-box proteins DHX9 and DHX36.51 Later 
studies confirmed these results and found that DDX21 and DDX24 are pro-viral factors 
in HIV infection as DDX21 stimulates Rev activity56 and DDX24 is required for efficient 
packaging of HIV-1 RNA.57 
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Cancer 
Owing to their role in essential cellular processes required for growth and differentiation, 
several DEAD-box proteins have been identified to play important roles in cancer. A 
common theme within the DEAD-box protein literature is that their function is extremely 
context specific. This often means that literature conclusions are seemingly at-odds 
because the result of gene overexpression or knockdown is highly dependent on tissue 
of origin and treatment.58  
 
The DDX1 gene was mapped to chromosome 2p24 adjacent to MYCN and the two 
genes are commonly co-amplified in subsets of neuroblastoma59 and retinoblastoma,60 
although the literature is conflicted as to how DDX1 gene amplification affects patient 
survival.61,62 Some reports suggest an oncogenic role for DDX1 in cancer 
development63 while others imply a tumor-suppressive role,64 likely indicating its 
function in tumor growth and maintenance is context-specific.  
 
DDX3X is commonly mutated in malignancy – including medulloblastoma,65-68 a diverse 
number of blood cancers,69-72 and head and neck squamous cell carcinoma.73,74 These 
mutations are mostly loss-of-function suggesting a tumor-suppressive role for DDX3 in 
cancer.75 However, small interfering RNA-mediated knockdown of DDX3 in several 
cancer cell lines increased cellular adhesion but decreased cell motility and invasive 
capacities in vitro, and reduced metastasis in vivo.76 Additionally, DDX3 was found to 
regulate cell growth through control of cyclin E translation in HeLa cells,77 and 
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overexpression of DDX3 in MCF10A cells caused a epithelial-mesenchymal-like 
transformation and increased colony formation,78 suggesting an pro-growth/tumor role. 
Therefore, the function of DDX3 in malignancy is likely also context dependent. 
 
DDX5 and DDX17 are overexpressed in a wide variety of cancers including breast79 and 
prostate cancer,80 where DDX5 and DDX17 function as steroid hormone receptor 
transcriptional co-activators,81 as well as in colon cancer82,83 and glioma.84 In contrast to 
these oncogenic functions, DDX5 also functions as a transcriptional co-activator of the 
p53 tumor suppressor85 and is required for p53-mediated induction of p21 expression 
after DNA damage.86 As DDX5 and DDX17 undergo extensive post-translational 
modifications, it is possible that these seemingly opposing roles in malignancy are due 
to differential modification.58 
 
The DEAD-box protein eIF4A functions in translation initiation by assisting in 5’-UTR 
scanning by the 43S pre-initiation complex.87,88 It is tightly controlled through 
interactions with co-factors eIF4G and eIF4B and the 7me-G cap-binding protein eIF4E, 
which is negatively regulated by 4E-BP downstream of the master regulator of cell 
growth, mTOR. There is ample genetic evidence for misregulation of this pathway 
leading to cancer, as loss of TSC1/2, a negative regulator of mTOR, results in tuberous 
sclerosis,89 overexpression of eIF4E enhances lymphomagenesis in a Myc-driven 
model of cancer,90 and Myc oncogenic activity is suppressed by ribosomal protein 
haploinsufficiency.91 Additionally, active-site mTOR inhibitors that reduce eIF4E/eIF4A-
dependent translation show significant anti-tumor activity92 and incomplete inhibition of 
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this pathway is a common mechanism of primary resistance to clinical mTOR active-site 
inhibitors.93  
 
Disorders of Impaired Development 
Since many DEAD-box proteins are essential genes, mutations in several RNA 
helicases have been identified as causes of disorders of impaired development. 
Mutants of DDX3X have been identified as a common cause of unexplained intellectual 
disability in girls, including some cases of Toriello-Carey syndrome, which results in 
agenesis of the corpus callosum and a characteristic facial phenotype.94-96 Mutations in 
senataxin, an SF1 RNA helicase are a cause of ataxia oculomotor apraxia type 2 
(AOA2) and a rare autosomal dominant form of juvenile amyotrophic lateral sclerosis 
(ALS4).97,98 
 
Although not directly causative, several DEAD-box proteins are intimately involved in 
other neurological disorders. DDX20/Gemin3 is an essential component of the survival 
of motor neuron (SMN) complex, which is required for proper assembly of Sm-class 
ribonucleoproteins.99,100 Mutation of SMN1, another component of this complex, causes 
spinal muscular atrophy, a disorder characterized by muscle wasting.101 DDX6 is a 
known interacting partner of ataxin-2, and altered ataxin-2 levels interfere with the 
assembly of stress granules and cellular P-bodies, leading to spinocerebellar ataxia 
type 2 (SCA2).102 
 
Chemical Inhibitors of DEAD-box Proteins 
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The first identified DEAD-box protein inhibitors were natural products discovered for 
their cytotoxicity (Figure 1.3A). A recent paper identified two marine natural products, 
elisabatin A from the Caribbean sea plume Pseudopterogorgia elisabethae, and 
allolaurinterol from the marine red algae Laurencia obtuse, that inhibit the DEAD-box 
protein eIF4A in an ATP-competitive manner.103 Pateamine A (PatA), a natural product 
isolated from a marine sponge, Mycale hentscheli, was also found to bind eIF4A104 and 
potently inhibit cap-dependent translation.105 Interestingly, PatA stimulates eIF4A 
ATPase activity and RNA binding, possibly by antagonizing an inhibitory interdomain 
interaction,106 although it is unclear based on this mechanism why PatA has inhibitory 
function. It has been hypothesized that PatA disrupts the formation of eIF4F (which 
consists of eIF4A, eIF4G, and eIF4E), leading to inhibition of translational 
initiation.104,105 
 
The natural product hippuristanol, a polyoxygenated steroid isolated from the coral Isis 
hippuris, was identified in a chemical-genetic screen to identify inhibitors of eukaryotic 
translation.107 It inhibits cap-dependent translational initiation by targeting eIF4A without 
perturbing its ATP-binding properties.108 This activity is highly selective, as activity of the 
closely related DEAD-box protein DDX3 was unchanged by high doses of hippuristanol. 
The binding site of hippuristanol was mapped to the C-terminus of eIF4A by 1H-15N-
HSQC, leading to the hypothesis that it antagonizes RNA-binding by disrupting proper 
interdomain interactions within eIF4A.109 Hippuristanol continues to be used as a tool for 
the inhibition of cap-dependent translation in cell culture. 
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An additional natural product silvestrol, a rocaglate isolated from the dioecious shrub 
Aglaia silvestris, was first described in 2004.110 Silvestrol and related derivatives were 
later found to also inhibit cap-dependent translation by targeting eIF4A.111 As would be 
suggested by previous reports on the importance of the mTOR-4EBP-eIF4E axis in 
cancer, silvestrol and its rocaglate derivatives display potent anti-tumor activity.112 
Synthetic silvestrol analogs have been synthesize to improve its pharmacological 
properties,113,114 and these derivatives show significant promise in several models of 
cancer.115-117 In contrast to pateamine A and hippuristanol, rocaglates function by 
trapping eIF4A on RNA substrates containing specific polypurine motifs, thereby 
blocking scanning by the 43S pre-initiation complex and reducing overall translation.118 
 
The discovery of small molecule inhibitors of DEAD-box proteins other than eIF4A has 
been much less successful and mostly synthetic molecules have been identified (Figure 
1.3B-C). Using molecular docking against the crystal structure of the DDX3-AMP 
complex, several rhodanine-based compounds were identified as ATP- and RNA-
noncompetitive DDX3 inhibitors,119 despite molecular modeling suggesting these 
compounds bind the ATP-binding site. A second paper by the same research group 
expanded on these findings and used additional molecular modeling to develop more 
potent triazine inhibitors.120 Additional studies using molecular modeling have identified 
kaempferol, a natural product derived from the shrub Sophora interrupta, and the salt of 
the NSAID ketorolac as inhibitors of DDX3, although these studies have little 
biochemical data to back their claims.121,122 Additionally, in our hands, none of these 
compounds inhibit the biochemical activity of DDX3 (Figure 2.3C).  
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Research groups at University of Maryland, Baltimore County identified a ring-expanded 
nucleoside analog (NZ51) that reduces HIV-1 replication and inhibits the biochemical 
activity of DDX3.123 Using molecular modelling, NZ51 was fit into the ATP-binding site of 
DDX3, although further structural information has not been obtained.124 These groups 
also synthesized a series of 5:7:5-fused diimidazodiazepine compounds (RK-33) based 
on NZ51 that are potently cytotoxic.125,126 Molecular modeling determined RK-33 also 
binds the ATP-binding site of DDX3, a biotinylated version of RK-33 pulled down DDX3 
from lysates, and substoichiometric RK-33 inhibits RNA duplex unwinding by Ded1p.127 
Unfortunately, RK-33 does not inhibit the biochemical activity of DDX3 in our hands 
(Figure 2.3C). The most likely explanation for these findings is that RK-33 and related 
compounds are DNA/RNA intercalators, and thus inhibit RNA duplex unwinding by 
Ded1p by disrupting the recognition of duplex RNA by Ded1p. DDX3 is pulled out of 
lysates by biotinylated RK-33 because both are bound to nucleic acids, and RK-33 and 
derivatives are cytotoxic because they disrupt cellular DNA and RNA pools. 
 
More recent work by Takeda Pharmaceuticals used high-throughput screening to 
identify small molecule inhibitors of eIF4A3, a component of the exon-junction complex 
(EJC)128,129 and Brr2, a spliceosomal RNA helicase (Figure 1.3C).130 Indole-2-carboxylic 
acid hit compounds bound to eIF4A3 in an ATP-competitive manner, but showed little 
activity in RNA duplex unwinding assays at concentrations less than 100µM.128 Novel 
1,4-diacylpiperazines were additionally explored as potential leads and found to potently 
inhibit eIF4A3 ATPase activity in an ATP-noncompetitive manner at submicromolar 
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doses.129 Interestingly, these compounds bind competitively with hippuristanol, 
suggesting conservation of this binding pocket across the eIF4A family and showed 
cellular activity in assays of nonsense-mediated decay (NMD).131 Brr2-targeting 4,6-
dihydropyrido[4,3-d]pyrimidine-2,7(1H,3H)-diones also displayed ATP non-competitive 
binding and weakly inhibited the duplex unwinding activity of Brr2 at low micromolar 
doses.130  
 
Taken together, these results indicate that selective chemical inhibition of DEAD-box 
proteins is achievable through HTS of diverse chemical libraries, although the hits of 
these screens are generally ATP-noncompetitive. As a result, all current DEAD-box 
protein inhibitors that show reasonable and reproducible biochemical activity are 
allosteric inhibitors that targeting cryptic allosteric sites within a DEAD-box protein of 
interest. The selectivity of these compounds suggests that these allosteric sites are not 
conserved across the DEAD-box family, so these small molecules are unlikely to be 
good structural starting points for discovery of inhibitors for other members of the 
DEAD-box family. 
 
Thesis Work Overview 
Owing to the diverse diseases in which DEAD-box protein function is dysregulated, 
chemical inhibition of this family of enzymes may provide useful clinical treatments for 
disease.132 Additionally, small molecule inhibitors may help answer outstanding basic 
questions within the DEAD-box protein field. As such, we sought to develop a general 
strategy for the inhibition of DEAD-box proteins using small molecules. 
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Without a chemical starting point, we first turned to an analog-sensitive chemical 
genetic approach.133 First, we identified several conserved hydrophobic residues 
adjacent to the N6-position of the adenine of ATP and found that mutation of these 
residues to smaller amino acids was tolerated, although these enzymes showed up to a 
1,000-fold reduction in activity and yeast expressing these mutants in DED1 displayed 
temperature-sensitivity. We then identified a series of anilinoquinazolines that 
preferentially inhibited analog-sensitive DDX3 versus wild-type. However, continued 
chemical derivatization of these compounds did not yield compounds with a binding 
affinity greater than 100µM. 
 
To combat the low potency of analog-sensitive DEAD-box protein inhibitors, we next 
attempted an electrophile-sensitive chemical genetic approach for the specific inhibition 
of DEAD-box proteins. We identified a residue of low conservation within the P-loop of 
DEAD-box proteins, and found that mutation of this residue to cysteine was tolerated in 
vitro and in vivo. We then synthesized analogs of AMP with an electrophile appended to 
the monophosphate that potently and irreversibly bind to and inhibit electrophile-
sensitive DEAD-box proteins.  
 
As an alternate strategy, we also screened a series of compounds based on DBeQ, a 
small molecule inhibitor of the AAA+ ATPase inhibitor p97/VCP.134 Derivatives of this 
molecule are currently in development as novel anti-cancer therapeutics.135 We 
identified a series of disubstituted quinazolines that displayed ATP-competitive inhibition 
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of DDX3 at doses as low as 3µM, and found that these compounds compete with AMP-
acrylamide binding to electrophile-sensitive DDX3.  
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Figure 1.1. DEAD-box proteins function in all stages of RNA metabolism. 
 
DEAD-box proteins are involved in all steps of RNA metabolism within the cell, including 
transcription, ribosome biogenesis, and pre-mRNA splicing in the nucleus, RNA export 
from the nucleus, organelle-specific RNA metabolism in the mitochondrion, and miRNA 
processing, snRNP biogenesis, non-sense mediated decay (NMD), translation, RNA 
storage and RNA decay in the cytoplasm. Numbers in parentheses indicate number of 
unique human DEAD-box proteins involved in each cellular process. Figure is adapted 
from Linder P and Jankowsky E, Nat. Rev. Mol. Cell Biol. (2011).18 
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Figure 1.2. Human DEAD-box proteins functions in RNA metabolism and disease. 
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Figure 1.3. Literature DEAD-box protein inhibitors. 
 
A. Several natural products have been identified as eIF4A inhibitors, including elisabatin 
A and allolaurinterol, which are ATP-competitive, and pateamine A, hippuristanol, and 
silvestrol, which target allosteric sites. B. Literature DDX3 inhibitors are based on a 
variety of scaffolds (rhodanines, triazines, and ring-expanded nucleosides) and are 
poorly validated. C. Recently published eIF4A3 inhibitors (indole-2-carboxylic acids and 
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1,4-diacylpiperazines) and Brr2 inhibitors (4,6-dihydropyrido[4,3-d]pyrimidine-
2,7(1H,3H)-diones identified by Takeda Pharmaceuticals. 
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Abstract 
Proper maintenance of RNA structure and dynamics is essential to maintain cellular 
health. Multiple families of RNA chaperones exist in cells to modulate RNA structure, 
RNA-protein complexes, and RNA granules.  The largest of these families is the DEAD-
box proteins, named after their catalytic Asp-Glu-Ala-Asp motif. The human DEAD-box 
protein DDX3 is implicated in diverse biological processes including translation initiation 
and is mutated in numerous cancers. Like many DEAD-box proteins, DDX3 is essential 
to cellular health and exhibits dosage sensitivity, such that both decreases and 
increases in protein levels can be lethal. Therefore, chemical inhibition would be an 
ideal tool to probe the function of DDX3. However, most DEAD-box protein active sites 
are extremely similar, complicating the design of specific inhibitors. Here, we show that 
a chemical genetic approach best characterized in protein kinases, known as analog-
sensitive chemical inhibition, is viable for DDX3 and possibly other DEAD-box proteins. 
We present an expanded active site mutant that is tolerated in vitro and in vivo, and is 
sensitive to chemical inhibition by a novel bulky inhibitor. Our results highlight a course 
towards analog sensitive chemical inhibition of DDX3 and potentially the entire DEAD-
box protein family.  
 
Introduction  
RNA is a highly dynamic macromolecule and can form numerous intra- and inter-
molecular structures, which influence function. Like proteins, RNA molecules have 
chaperones that remodel structures to ensure proper function. RNA chaperones can be 
ATP-dependent like DEAD-box proteins,18 or ATP-independent like cold shock domain 
proteins and heteronuclear ribonucleoproteins (hnRNPs).16 In humans, there are 36 
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DEAD-box proteins which function in every step of RNA biology. For example, 18 
DEAD-box proteins have been implicated in ribosome assembly, six in splicing, six in 
translation, and others in numerous other functions.18 DEAD-box proteins also associate 
with non-membrane-bound, microscopically visible puncta in cells known as RNA 
granules,136 137 which are thought to arise from phase separation caused by multivalent 
weak interactions.138-140 Remarkably, loss of function of the C. elegans DEAD-box 
protein CGH-1 (human DDX6) causes germ line granules to form square, crystalline 
structures in vivo.141 Therefore, DEAD-box proteins can function both on individual 
RNA:protein complexes (RNPs), or function as molecular dispersants to promote fluidity 
of RNA granules.  
 
The human DEAD-box protein DDX3 (encoded by DDX3X) and its yeast ortholog DED1 
have been implicated in numerous cellular functions, but most consistently in 
remodeling RNA and RNPs during translation initiation.77,137,142-145 DDX3 and Ded1p 
also associate with two related types of RNA granules known as stress granules and P-
bodies,136,137 and introduction of catalytically deficient Ded1p increases granule size,137 
suggesting they may have a role in determining the size of RNA granules by modulating 
weak interactions. Frequent mutations of DDX3X are found in numerous human 
malignancies including medulloblastoma,65-68 diverse blood cancers,69-72 head and neck 
squamous cell carcinoma,73,74 lung cancer,127 and more. However, cellular studies are 
complicated by the fact that DDX3 and DED1 are essential genes, limiting the 
perturbations that can be made. Moreover, the poor time resolution of knockdown and 
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transfection experiments complicates assignment of direct and indirect targets of DDX3 
in cells.  
 
DDX3, like all DEAD-box proteins, couples ATP binding to conformational changes that 
create a binding surface selective for single stranded RNA.18,146 ATP hydrolysis then 
destabilizes this conformation and promotes product release.28 Conversion to the ATP-
bound closed state involves creation of a composite active site involving residues on 
both the N-terminal DEAD and C-terminal HELICc domains. Therefore, interfering with 
ATP binding or hydrolysis will prevent RNA and RNP remodeling by DEAD-box 
proteins.   
 
Chemical inhibitors are extremely powerful tools to study function in cells due to their 
high temporal resolution.  However, it is difficult to develop specific inhibitors to protein 
families with many highly related members, like DEAD-box proteins. In protein kinases, 
mutation of a “gatekeeper” residue to a smaller alanine or glycine uniquely sensitizes 
the mutant protein to bulky active site inhibitors which are otherwise inactive against the 
majority of the kinome.147 This approach allows for high affinity and specific inhibition of 
individual protein kinases by introducing a single point mutation, and has been widely 
used to generate analog sensitive inhibitors147 and artificial substrates.148 A similar 
approach has been used to generate synthetic substrates or inhibitors for myosin and 
kinesin.149,150 
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Here, we present proof-of-principle experiments demonstrating analog sensitive 
inhibition of the DEAD-box protein DDX3. We engineer a binding pocket near the ATP 
binding site by point mutation while retaining in vitro function and complementation of 
the essential yeast gene DED1. The expanded active site mutant is sensitized to 
pyrazolopyramidine-related compounds in vitro, including GXJ1-76. In yeast, treatment 
with GXJ1-76 is lethal in cells harboring expanded active site mutants, but this is due to 
synthetic interactions with temperature sensitivity rather than specific inhibition. We 
therefore performed a general screen of existing analog-sensitive inhibitors and find a 
new series of compounds that also demonstrate more potent analog sensitive inhibition 
in vitro. Taken together, our results demonstrate that analog sensitive inhibition of 
DEAD-box proteins is possible, and highlight two scaffolds that could be used to design 
high affinity inhibitors. 
 
Results 
Targeting a hydrophobic cluster for expanded active site mutation 
Analog sensitive inhibition of proteins requires generation of an expanded active site to 
accommodate bulky groups on the inhibitor. We examined the ATP binding site of 
DDX3 and found that the N6 position of adenosine points towards a cluster of four 
hydrophobic residues on the DEAD domain (Figure 2.1A).151 As N6 on adenosine is the 
position modified in many preexisting bulky kinase inhibitors and adenosine receptor 
agonists, we targeted this hydrophobic cluster for mutation. We then examined the 
conservation of this region in diverse human DEAD-box proteins and found high 
conservation at most positions but some variability (Figure 2.1B). Expanding this 
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analysis to DEAD-box proteins from Saccharomyces cerevisiae and Escherichia coli 
shows that all four positions are tolerant of substitutions, suggesting some structural 
plasticity in this region (Figure 2.1C). Therefore, there is a hydrophobic cluster adjacent 
to the ATP binding site that is conserved but also shows limited variability, suggesting it 
may be tolerant to mutation. 
 
Expanded active site mutants of DDX3 are functional 
We generated point mutants of three positions of the hydrophobic cluster in DDX3 
(Figure 2.1A) and expressed and purified them from E. coli. All three variants eluted 
from a gel filtration column normally, suggesting no major disturbance in folding (Figure 
2.2A). We used a shortened construct of DDX3 lacking the N- and C-terminal tails that 
has superior biochemical behavior and is highly active in vitro (DDX3 residues 132-
607).152 As F182 abuts the ATP binding pocket, we tested the ability of the mutant 
protein to bind to the nucleotide adenosine monophosphate (AMP). We used AMP 
rather than ATP to directly test the binding affinity of nucleotide to the DEAD domain 
without avidity effects from the HELICc domain caused by ATP-dependent 
conformational changes.18 Both wild-type and the most severe mutation, F182A, have 
similar affinity to AMP (Figure 2.2B),152 indicating that nucleotide binding is not affected 
by this mutation. The observation that the I195A and I211A point mutants exhibit less 
severe defects in duplex unwinding than F182A (Figure 2.2C) and yeast growth (Figure 
2.2D) suggests that they also bind nucleotide with similar affinity to wild-type DDX3, but 
we have not tested this directly.  
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We next functionally characterized the mutant proteins with expanded active sites. First, 
we tested the activity of the mutant proteins in RNA duplex unwinding assays153 and 
found that all mutants had reduced activity to varying degrees (Figure 2.2C). As a 
further test, we determined the ability of the mutant alleles to complement the essential 
yeast gene DED1 in vivo, and found that all three alleles are sufficient for growth at 
normal temperature, despite the in vitro defects (Figure 2.2D). However, the I157A 
(DDX3 I195A) and F144A (F182A) variants exhibit cold and heat sensitivity, respectively 
(Figure 2.2D). It is surprising that these mutations are tolerated in yeast given their large 
kinetic defects in vitro (Figure 2.2C). It is possible that the effect of the mutations on 
Ded1 is not the same as that on DDX3, or that the yeast gene DBP1, which is a high-
copy suppressor of DED1,154 is compensating for partially functional Ded1p. In sum, 
mutation of the active site hydrophobic cluster is tolerated in vitro and in vivo, 
demonstrating it is possible to create an expanded active site in a DEAD-box protein. 
 
Adenosine monophosphate but not published DDX3 inhibitors retards RNA 
duplex unwinding 
We started to search for a viable scaffold for engineering bulky active-site inhibitors of 
DDX3 by surveying published inhibitors. To verify that our duplex unwinding assay was 
able to measure inhibition of DDX3 we titrated AMP into the reaction, which binds with 
low micromolar affinity (Figure 2.2B) and inhibits the enzyme.152 We observed endpoint 
depression of duplex unwinding with only a two-fold effect on the rate with an apparent 
KI of ~30 μM (Figure 2.3A-B). We then tested a series of published inhibitors including 
one rhodanine derivative,120 two triazine derivatives,120 the ring-expanded nucleoside 
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RK-33,127 ketorolac salt,155 and kaempferol-3-O-b-D-glucopyranoside.121 Both ketorolac 
salt and Maga compound 4b showed two-fold effects on the rate of duplex unwinding 
but no change to the endpoint of the reaction (Figure 2.3C-D). As ATP hydrolysis is 
required for product release but not duplex unwinding,156 it is possible that endpoint 
depression (Figure 2.3B) is a signature of active-site inhibition while rate depression 
reflects noncompetitive inhibition by, for example, interacting with the duplex RNA 
substrate (Figure 2.3D). Alternatively, as Ded1p exhibits both ATP-dependent duplex 
unwinding and ATP-independent strand annealing activities,30 it may be that ATP-
competitive inhibition causes endpoint depression by altering the balance between 
unwinding and annealing. It remains possible that these inhibitors interact with the 
noncatalytic extensions that have been removed from DDX3132-607, or that they interact 
with a composite bimolecular surface that only exists in cells. As we were unable to 
observe strong inhibition with any of the tested compounds, we sought alternatives to 
screen for analog sensitive inhibitors of DDX3.  
  
Analog sensitive inhibition of DDX3 
We surveyed diverse compounds in an attempt to find analog sensitive inhibitors of our 
expanded active site versions of DDX3. Focus was placed on the F182A mutation as it 
generates the largest pocket for a bulky inhibitor. We assembled a panel of nine 
adenosine receptor agonists, three AAA+-ATPase inhibitors or related 
quinazolinones,134 and ~30 bulky kinase inhibitors and tested these using duplex 
unwinding. Kinase inhibitors were included because these have been shown to exhibit 
cross-reactivity with DEAD-box proteins.157,158 We found no inhibitory activity of any of 
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the adenosine receptor analogs and weak activity for the AAA+-ATPase DBeQ (data not 
shown). In addition, the large majority of the kinase inhibitors tested showed no effect. 
However, we found reproducible inhibition of duplex unwinding of only the mutant allele 
upon addition of the compound GXJ1-76 (Figure 2.4A-B). The concentration 
dependence of GXJ1-76 treatment is not linear (Figure 2.4B), possibly due to solubility 
issues at these concentrations. Notably, GXJ1-76 causes endpoint depression with only 
small changes on the rate (Figure 2.4C) as seen for AMP (Figure 2.3A-B), suggesting it 
is targeting the active site. GXJ1-76 shows a dose-dependent decrease in the ATPase 
activity of DDX3 with modest selectivity for the mutant allele (Figure 2.4D).  
 
We then tested the ability of GXJ1-76 to inhibit Ded1p in yeast where the sole copy of 
DED1 has been replaced by the expanded active site allele F144A (DDX3 F182A; 
Figure 2.2D).  Yeast harboring a wild-type allele of DED1 are minimally affected by 
treatment with 100 μM GXJ1-76 but ded1-F144A yeast grow considerably slower in the 
presence of GXJ1-76 (Figure 2.5A). As the ded1-F144A strain exhibits temperature 
sensitivity, we also tested inhibition in an unrelated temperature sensitive strain 
harboring mutations in the MCM3 replicative helicase159 to ensure that the growth defect 
was specific to GXJ1-76 interacting with Ded1p (Figure 2.5B). However, GXJ1-76 
treatment also severely inhibited growth of the mcm3-1 strain (Figure 5C), suggesting 
that the growth inhibition observed is due to off-target effects. In sum, expanded active 
site versions of DDX3 are preferentially inhibited by GXJ1-76 in vitro, but low potency 
and off-target effects in cells preclude use of this compound as is.  
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Bulky kinase inhibitor screen identifies anilinoquinazolines as lead scaffold 
The biochemical inhibition of the mutant allele of DDX3 by GXJ1-76 (Figure 2.4) 
suggests that kinase inhibitor scaffolds may provide a promising lead for the 
development of analog-sensitive DEAD-box helicase inhibitors. We therefore performed 
a more general screen of thirty-one bulky analog-sensitive kinase inhibitors. From this 
screen we hoped to identify a scaffold or bulky group that had increased potency 
against analog-sensitive mutants and retained selectivity over the wild-type allele. The 
screen included mostly pyrazolopyrimidine-based molecules with various substitutions 
at both the 3- and N1-positions. A number of the N1-substitutions had potential 
hydrogen bond donors or acceptors that we hoped might form favorable interactions 
within the binding pocket to increase potency compared to GXJ1-76. The screen also 
included alternate inhibitor scaffolds beyond the pyrazolopyrimidine including 
pyrimidine-, and anilinoquinazoline-based inhibitors which we hoped would have 
different inherent affinity for the DEAD-box helicase ATP-binding site. From this screen, 
we identified AQZ01, a 6,7-dimethoxyanilinoquinazoline, as the most potent inhibitor of 
the F182A mutant (Figure 2.6).  
 
Structure-activity relationship of AQZ01 yields compound 1, a selective analog-
sensitive DEAD-box helicase inhibitor 
Using screening hit AQZ01 as a starting point, we synthesized a series of molecules 
with increased steric bulk off the aniline of AQZ01 (Figure 2.7A). Interestingly, we found 
a strong preference for planar aromatic substitutions, as meta-bromo, isopropyl, or tert-
butyl anilines exhibit little activity against the F182A mutant. The position of the planar 
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fused aromatic ring is also important, as the 1-aminonaphthalene compound (AQZ04) 
was much more potent than the 2-aminonaphthalene compound (AQZ05). The most 
promising derivative of this series, AQZ06, contains a 4-aminoindole at this position and 
retained the selectivity of AQZ01 against wild-type DDX3, but increased potency against 
the F182A mutant substantially (Figure 2.7B).   
 
Assuming the 4-aminoindole of AQZ06 points into the pocket created by mutation of 
F182 of the hydrophobic cluster, we reasoned that changing the substitution of the 6- 
and 7-positions of AQZ06 could increase potency by making favorable interactions with 
the phosphate-binding P-loop of the helicase ATP-binding site. We therefore focused on 
placing hydrogen-bond donors/acceptors at the 6- and 7-positions of the 
anilinoquinazoline scaffold. Although we explored a series of molecules with formal 
negative charges at these positions (data not shown), we did not find a substitution that 
dramatically increased potency. Our most potent compound (1) shows a biochemical 
IC50 of ~100µM in an ATPase assay (Figure 2.7C). However, we did not observe 
inhibition of duplex unwinding by compound 1 (Figure 2.7D-E), which may be because 
DDX3 is superstoichiometric to RNA in this assay while substoichiometric in the ATPase 
assay. We did not test AQZ06 or compound 1 against Ded1p in yeast because the low 
on-target potency of these compounds suggest they may cause off-target effects like 
GXJ1-76, and anilinoquinazoline derivatives are pumped from yeast by efflux pumps160 
(K.M.S. unpublished observations). Thus, we used chemical derivatization to increase 
the potency of AQZ01 against the F182A mutant of DDX3 greater than 10-fold while 
maintaining selectivity against wild-type DDX3. 
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Discussion 
We have demonstrated a strategy for analog sensitive inhibition of the DEAD-box 
protein DDX3. By generating expanded active site mutations (Figures 2.1 and 2.2) we 
sensitized DDX3 to inhibition by bulky kinase inhibitors (Figure 2.4). Furthermore, 
treatment with the analog sensitive inhibitor GXJ1-76 is sufficient to block yeast growth 
when yeast contain the expanded active site allele F144A, however a MCM3 mutant 
strain (mcm3-1) is also inhibited by this compound suggesting the effect may be due to 
off-target interactions (Figure 2.5). We then found that anilinoquinazolines show 
selective biochemical inhibition of DDX3 F182A (Figure 2.6) and made a series of 
derivatives to generate compound 1, which selectively inhibits the mutant enzyme while 
sparing the wild-type (Figure 2.7). 
 
We targeted a hydrophobic cluster adjacent to the ATP binding site for mutation to 
generate the expanded active site alleles. This region is broadly conserved in DEAD-
box proteins in humans and other organisms (Figure 2.1B-C), suggesting it may be 
possible to apply this strategy to other DEAD-box proteins besides DDX3. Our data on 
DDX3 already suggests a promising strategy to probe DDX3 function.  However, prior to 
use in cells the affinity of the compound needs to be improved to avoid nonspecific 
toxicity (Figure 2.5).   
 
While using a kinase inhibitor scaffold as the starting point for our analog-senstive 
DEAD-box helicase inhibitor immediately presents the problem of off-target toxicity 
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towards cellular kinases, all the bulky inhibitors tested are remarkably inactive against 
most wild-type kinases. We hoped that by changing inhibitor scaffolds from the very 
promiscuous pyrazolopyrimidine to the more selective anilinoquinazoline we would 
additionally reduce this off-target toxicity. However, anilinoquinazolines have poor 
solubility and pharmacokinetic properties. Future work optimizing the scaffold with these 
considerations in mind could yield viable analog sensitive inhibitors of DDX3.  
 
An additional challenge is the low potency of all tested chemical scaffolds for DDX3. 
While initial work generating an analog-sensitive kinase inhibitor used PP1, a 
nanomolar inhibitor of Src, as a starting point,161 simple pyrazolopyrimidines and 
anilinoquinazolines are millimolar binders of DDX3. This is likely due to the fact that 
kinase inhibitors rely heavily on ‘hinge’ hydrogen bonding interactions for potency, and 
these contacts are not present in DEAD-box proteins. Making favorable interactions with 
the essential glutamine of the DEAD-box helicase Q-motif could provide a substantial 
jump in potency.25 Finding substituents that interact favorably with the helicase P-loop 
could also produce a similar potency boost. Since the majority of the affinity of AMP for 
the helicase active site is derived from the phosphate and not the adenosine,152 it is 
possible that potent P-loop binders will provide the most promising path forward. We 
expect that additional rational design of compounds described within this work, along 
with additional screening for more potent leads, is a promising path towards developing 
a potent chemical inhibitor of DDX3 and DEAD-box proteins in general. 
 
Materials and Methods 
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Muiltiple sequence alignments. Sequences for all DEAD-box proteins from Homo 
sapiens, Escherichia coli, and Saccharomyces cerevisiae were retrieved from the NCBI 
and were aligned using MUSCLE.162 A separate MUSCLE alignment of only human 
DEAD-box proteins was used to generate Figure 2.1B. Alignments were visualized 
using Jalview.163  
 
Recombinant protein purification. The codon optimized coding sequence for human 
DDX3X residues 132-607 fused to a 6xHis-MBP tag was expressed in E. coli BL21-Star 
cells. Induction was performed by addition of 1 mM IPTG for 18 hours at 16°C. Cell 
pellets were lysed by sonication, clarified by centrifugation at ~30,000 g, and purified by 
nickel chromatography including a 1M NaCl wash to remove bound nucleic acids. The 
His-MBP tag was cleaved using tobacco etch virus protease during dialysis into 200 mM 
NaCl, 10% glycerol, 20 mM HEPES pH 7, and 0.5 mM TCEP. The sample was then 
purified using heparin affinity chromatography, eluted at 400 mM NaCl, 10% glycerol, 20 
mM HEPES pH 7, and 0.5 mM TCEP, and applied to a Superdex 75 gel filtration 
column equilibrated in 500 mM NaCl, 10% glycerol, 20 mM HEPES pH 7.5 and 0.5 mM 
TCEP. Fractions were then concentrated to roughly 30 μM and supplemented with 20% 
glycerol and flash frozen in liquid nitrogen. 
 
RNA duplex unwinding. Duplex unwinding assays were performed as described153 
with 2 mM ATP (Figure 2.2), 0.1 mM ATP (Figure 2.3, 2.7) or 0.5 mM ATP (Figure 2.4) 
and 1 μM protein.  The sequences of the RNA duplex strands are 5′–
AGCACCGUAAAGACGC–3′ and 5′–
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GCGUCUUUACGGUGCUUAAAACAAAACAAAACAAAACAAAA–3′, and the short RNA 
strand was 5′ radiolabeled with 32P. Unlabeled “chase” RNA was not included. For 
experiments with inhibitors, protein, RNA and inhibitor were pre-incubated in helicase 
reaction buffer for five minutes and the reaction was initiated with ATP.  All inhibitors 
were stored in DMSO and DMSO concentrations were matched between all 
experiments, which never exceeded 5%.  
 
Coupled ATPase assays. Assays were performed using ADP-Quest (DiscoveRx) 
according to manufacturer’s instructions with 1µM enzyme, 10µM dsRNA and 100µM 
ATP-gold (DiscoveRx) in 20mM Tris pH 7.5, 200mM NaCl, 1mM MgCl2, and 0.01% 
Triton X-100. The sequences of the RNA duplex strands are the same as those used in 
the duplex unwinding assay. All experimental results are reported as the average of 
three replicates with error bars representing the standard deviation of results, except for 
Figure 2.6, which was completed without replicates. 
 
Yeast experiments. A strain of S. cerevisiae containing a deletion of the DED1 locus 
complemented by a URA3 marked plasmid harboring DED1 was described 
previously.137  Mutants were generated by site-directed mutagenesis in a plasmid 
containing DED1 marked with HIS3, which was then transformed into yeast and 
counterselected using 5-fluoroorotic acid on His- complete synthetic media. All strains 
were verified by plasmid purification and dideoxy sequencing. Strains were grown using 
YPD media following verification. Growth experiments in Figure 2.2D and 2.5B are 
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tenfold dilutions from OD ~1; continuous growth experiments in Figure 2.5 are by OD595 
measurement at 30°C in a Tecan Infinite F200 plate reader with 2mm orbital shaking.  
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Figure 2.1: Targeting a hydrophobic cluster adjacent to the ATP binding pocket of 
DDX3 for mutation.  
 
A. A structural view of the ATP binding pocket in human DDX3 bound to AMP (PDB 
2I4I). AMP is in purple, DDX3 is in blue and the hydrophobic cluster residues are in 
orange.  B and C. Sequence alignments of eight human DEAD-box proteins (B) or 
seven DEAD-box proteins from various organisms (C) showing overall conservation but 
some plasticity of the hydrophobic cluster residues. Core conserved motifs of DEAD-
box proteins are indicated. 
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Figure 2.2: Hydrophobic cluster mutants of DDX3 support function in vitro and in vivo.  
 
A. The indicated mutants of DDX3 purify normally as shown by their elution from a 
Superdex 75 gel filtration column.  The indicated smaller peak to the left is uncleaved 
protein attached to the His-MBP tag. B. DDX3132-607 wild-type and F182A bind AMP 
identically based on isothermal titration calorimetry. Error is standard error of the fit 
parameter. C. The hydrophobic cluster mutants are able to unwind RNA duplexes in 
vitro but at slower rates than wild-type DDX3132-607. Error is S.D (left) and standard error 
of the fit parameter (right). D. Yeast with hydrophobic cluster mutants in the sole copy of 
DED1 grow normally at 30°C but some exhibit cold (I157A) or heat (F144A) sensitivity.  
Yeast DED1 F144, I157, and V173 correspond to DDX3 F182, I195 and I211, 
respectively. Spots represent a tenfold dilution series from OD 1. 
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Figure 2.3: Adenosine monophosphate, but not putative DDX3 inhibitors, retards 
duplex unwinding in vitro.  
 
A and B. RNA duplex unwinding with AMP exerts concentration-dependent inhibition 
(A) and depresses the reaction endpoint but not rate (B). C and D. Duplex unwinding 
with seven published inhibitors of DDX3 (C) and fitted parameters (D) does not change 
the reaction endpoint and decreases the rate by at most two-fold. Error is S.D (A,B); 
standard error of the fit parameter (C,D). 
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Figure 2.4: Analog sensitive inhibition of DDX3.  
 
A. The structure of the initial lead compound GXJ1-76, which is a pyrazolopyrimidine-
based inhibitor. B. Treatment of wild-type DDX3132-607 with GXJ1-76 does not affect 
duplex unwinding (left), but treatment of DDX3132-607 F182A causes a reduction in the 
duplex unwinding endpoint in a concentration dependent manner (right). Error is S.D. C. 
The relative unwinding rate and endpoint compared to the rate and endpoint with no 
compound as a function of GXJ1-76 concentration. Error is propagated error of the fit 
parameter. D. GXJ1-76 shows modest selectivity towards DDX3132-607 F182A in ATP 
hydrolysis.  Error is S.D. 
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Figure 2.5: Expanded active site alleles of DED1 and other temperature sensitive yeast 
strains are inhibited by GXJ1-76.  
 
A. A yeast strain harboring the expanded site allele ded1-F144A as the sole copy of 
DED1 is inhibited by GXJ1-76. Continuous growth with OD595 measurements is plotted. 
B. Tenfold serial dilutions of DED1, ded1-F144A and mcm3-1 yeast strains from OD 1 
indicating similar growth at 30°C and temperature sensitivity at 37°C. C. Growth of the 
mcm3-1 strain is also inhibited by GXJ1-76, indicating that the results in (A) likely result 
from off-target effects. 
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Figure 2.6: Screen for analog-sensitive DEAD-box helicase inhibitors identifies 
anilinoquinazoline scaffold.  
 
The activity of 31 existing analog-sensitive kinase inhibitors against wild-type and 
F182A DDX3132-607 was screened by an ATPase assay at 1 mM concentration. The 
structure of AQZ01, the most promising lead from this screen, is shown.    
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Figure 2.7: Chemical derivatization of AQZ01 yields compound 1.  
 
A. A series of molecules were synthesized to contain bulky groups off the aniline of 
AQZ01. B. These analogs show stronger inhibition of DDX3132-607 F182A by a 4-
aminoindole (AQZ06) off the 6,7-dimethoxyanilinoquinazoline scaffold in an ATPase 
assay at 125 µM concentration. Error is S.D. C. Derivatization of the 6- and 7-positions 
of AQZ06 yielded compound 1, which shows selective inhibition of F182A-mutant, but 
not wild-type, DDX3132-607 in an ATPase assay. Error is S.D. D and E. RNA duplex 
unwinding rates are identical for wild-type and F182A DDX3 when treated with 
compound 1. Note that DDX3 is substoichiometric in the ATPase assays (B,C) but 
superstoichiometric in the duplex unwinding assays (D,E). 
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Chemical Synthesis 
Materials obtained commercially were reagent grade and were used without further 
purification.  Reactions were monitored by thin layer chromatography (TLC) and/or 
mass spectroscopy (LC-MS) using a Waters Acquity UPLC/ESI-TQD with an Acquity 
UPLC. 1H NMR spectra were obtained on a Brucker 400 spectrometer at 400 MHz. 
Synthesis of GXJ1-76 
1-(tert-butyl)-3-(m-tolyloxy)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (GXJ1-76). To a 
solution of 3-bromo-1-(tert-butyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine (50mg, 
0.186mmol), cesium carbonate (121.2mg, 0.372mmol), and pyridine (3.07µL, 
0.038mmol) in DMF (0.9mL) under Ar(g) was added m-cresol (23.3µL, 0.223mmol) and 
copper (I) iodide (3.62mg, 0.019mmol). The reaction was heated to 140ºC for 24hrs, 
filtered, then added to 20mL water and extracted with DCM. The combined organic 
layers were dried with sodium sulfate, filtered and concentrated. The resulting oil was 
purified by reverse phase HPLC (5-95% acetonitrile/water) to yield pure GXJ1-76 
(1.9mg, 3.4% yield). 1H NMR (400MHz, DMSO-d6) d 8.17 (1H, s), 7.28 (1H, t, J=7.85 
Hz), 7.17 (1H, s), 7.13 (1H, d, J=8.16 Hz), 6.98 (1H, d, J=7.43 Hz), 2.32 (3H, s), 1.65 
(9H, s). 
General procedure for the synthesis of AQZ01-AQZ06 
In an oven-dried and argon-cooled disposable scintillation vial, 4-chloro-6,7-
dimethoxyquinazoline was dissolved in isopropanol. The appropriate substituted aniline 
was then added and the reaction mixture was heated at reflux for at least 2 hours. The 
reaction mixture was then cooled and the resulting solid collected by Büchner filtration 
and washed with ice-cold isopropanol to yield the pure compound. 
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6,7-dimethoxy-N-phenylquinazolin-4-amine (AQZ01). 1H NMR (400MHz, DMSO-d6) 
d 11.31 (1H, br s), 8.82 (1H, s), 8.28 (1H, s), 7.69 (2H, d, J=7.55 Hz), 7.50 (2H, t, 
J=7.85 Hz), 7.35 (1H, s), 4.03 (3H, s), 4.01 (3H, s). 
N-(3-isopropylphenyl)-6,7-dimethoxyquinazolin-4-amine (AQZ02). 1H NMR 
(400MHz, DMSO-d6) d 11.28 (1H, br s), 8.81 (1H, s), 8.27 (1H, s), 7.52 (1H, dd, J=1.28 
Hz, J=3.59 Hz), 7.41 (1H, t, J=7.85 Hz), 7.35 (1H, s), 7.22 (1H, d, J=7.67 Hz), 4.02 (3H, 
s), 4.01 (3H, s), 1.53 (1H, s), 1.27 (3H, s), 1.25 (3H, s). 
N-(3-(tert-butyl)phenyl)-6,7-dimethoxyquinazolin-4-amine (AQZ03). 1H NMR 
(400MHz, DMSO-d6) d 11.25 (1H, br s), 8.81 (1H, s), 8.25 (1H, s), 7.64 (1H, t, J=1.83 
Hz), 7.53 (1H, m), 7.43 (1H, t, J=7.79 Hz), 7.34 (1H, s), 4.02 (3H, s), 4.01 (3H, s). 1.34 
(9H, s). 
6,7-dimethoxy-N-(naphthalene-1-yl)quinazolin-4-amine (AQZ04). 1H NMR (400MHz, 
DMSO-d6) d 11.67 (1H, br s), 8.65 (1H, s), 8.40 (1H, s), 8.05 (2H, m), 7.90 (1H, d, 
J=8.40 Hz), 7.62 (3H, m), 7.36 (1H, s), 4.04 (3H, s), 4.03 (3H, s). 
6,7-dimethoxy-N-(naphthalene-2-yl)quinazolin-4-amine (AQZ05). 1H NMR (400MHz, 
DMSO-d6) d 11.58 (1H, br s), 8.86 (1H, s), 8.40 (1H, s), 8.23 (1H, s), 8.03 (1H, d, J=8.89 
Hz), 7.97 (2H, t, J=8.64 Hz), 7.87 (1H, dd, J=1.95 Hz, J=8.77 Hz), 7.57 (1H, m), 7.38 
(1H, s), 4.05 (3H, s), 4.02 (3H, s). 
N-(1H-indol-4-yl)-6,7-dimethoxyquinazolin-4-amine (AQZ06). 1H NMR (400MHz, 
DMSO-d6) d 11.36 (1H, br s), 8.68 (1H, s), 8.27 (1H, s), 7.46 (1H, d, J=8.04 Hz), 7.39 
(1H, m), 7.34 (1H, s), 7.20 (1H, t, J=7.79 Hz), 7.13 (1H, d, J=7.06 Hz), 6.32 (1H, s), 4.02 
(6H, s). 
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N-(3-bromophenyl)-6,7-dimethoxyquinazolin-4-amine (PD153035). 1H NMR 
(400MHz, DMSO-d6) d 11.36 (1H, br s), 8.89 (1H, s), 8.32 (1H, s), 8.03 (1H, s), 7.78 
(1H, d, J=7.85 Hz), 7.46 (1H, t, J=7.97 Hz), 7.35 (1H, s), 4.03 (3H, s), 4.01 (3H, s). 
Synthesis of 1 
 
Scheme 1. Conditions: (a) formamidine acetate, EtOH, reflux, (b) acetic anhydride, 
Et3N, DMAP, DCM, reflux, (c) POCl3, DIPEA, DCM, reflux, (d) 4-aminoindole, IPA, relux. 
 
6-hydroxy-4-quinazolone (2). To a solution of 5-hydroxyanthranilic acid (500mg, 
3.26mmol) in ethanol (20mL) was added formamidine acetate (510mg, 4.90mmol). The 
reaction was heated under reflux until completed, as monitored by LCMS. The ethanol 
was then removed by rotary evaporation and the solid product was filtered from water 
as a grey solid (462.3mg, 85.7% yield). 1H NMR (400MHz, DMSO-d6) d 7.90 (1H, s), 
7.54 (1H, d, J=8.77 Hz), 7.41 (1H, d, J=2.80 Hz), 7.26 (1H, dd, J=2.92 Hz, J=8.77 Hz). 
MS (ESI) m/z 163.76 (100%, 164.73 (20%) [M + H]+. 
6-acetyl-4-quinazolone (3). To a solution of compound 2 (162mg, 1mmol) and 
triethylamine (28µL, 0.2mmol) in dichloromethane (6.15mL) at 0ºC was added 
dimethylaminopyridine (3.7mg, 0.03mmol). Acetic anhydride (283µL, 3.0mmol) was then 
 47 
added dropwise. The reaction was then warmed to room temperature and monitored by 
TLC until completed. The reaction was concentrated by rotary evaporation and the 
resulting solid was purified by silica chromatography using a methanol/dichloromethane 
gradient (0-10% MeOH/DCM) to yield pure 3 as a white solid (143.9mg, 70.6% yield). 
1H NMR (400MHz, DMSO-d6) d 8.11 (1H, s), 7.83 (1H, d, J=2.43 Hz), 7.73 (1H, d, 8.77 
Hz), 7.60 (1H, dd, J=2.68 Hz, J=8.77 Hz). MS (ESI) m/z 204.77 (100%), 205.41 (60%), 
206.06 (100%), 206.71 (35%) [M + H]+. 
6-acetyl-4-chloroquinazoline (4). To a solution of compound 3 (100mg, 0.49mmol) in 
dichloromethane (3.5mL) at 0ºC was added diisopropylethylamine (214µL, 1.23mmol). 
Phosphorus (V) oxychloride (54µL, 0.59mmol) was then added dropwise. The reaction 
was allowed to warm to room temperature then heated to 45ºC under reflux. After 
~24hours, the reaction was added to 25mL saturated sodium bicarbonate and extracted 
with DCM. The combined organic layers were dried with Na2SO4, filtered, and 
concentrated.  The resulting oil was dissolved in 50% ethyl acetate/hexanes and 
purified by silica chromatography (20-50% EtOAc/hexanes) to yield pure 4 as a white 
solid (58.6mg, 53.9% yield). 1H NMR (400MHz, DMSO-d6) d 9.13 (1H, s), 8.19 (1H, d, 
J=9.13 Hz), 8.06 (1H, dd, J=0.43 Hz, J=2.50 Hz), 7.97 (1H, dd, J=2.50 Hz, J=9.07 Hz), 
2.38 (3H, s). MS (ESI) m/z 222.78 (65%), 223.73 (90%), 225.34 (100%) [M + H]+. 
4-((1H-indol-4-yl)amino)quinazolin-6-yl acetate (1). 4-aminoindole (25.9mg, 
0.196mmol) was added to a solution of compound 4 (21.8mg, 0.098mmol) in methanol 
(2mL) and the resulting solution was heated to 48ºC for 1hr. The solution was allowed to 
cool to room temperature and then concentrated in vacuo. The resulting oil was 
dissolved in 5% MeOH/DCM and purified by silica chromatography (2-5% MeOH/DCM) 
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to yield pure compound 1 as a pale yellow solid (5.1mg, 16.4% yield). 1H NMR 
(400MHz, DMSO-d6) d 11.17 (1H, s), 9.84 (1H, s), 8.42 (1H, s), 7.82 (1H, d, J=8.52 Hz), 
7.66 (1H, d, J=8.77 Hz), 7.31 (1H, s), 7.17 (2H, m), 6.34 (1H, s), 2.38 (3H, s). MS (ESI) 
m/z 318.48 (90%), 320.95 (100%), 321.94 (15%) [M + H]+. 
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Chapter 3 
 
 
Chemical genetic inhibition of DEAD-box proteins using covalent 
complementarity 
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Abstract 
DEAD-box proteins are an essential class of enzymes involved in all stages of RNA 
metabolism. The study of DEAD-box proteins is challenging in a native setting since 
they are structurally similar, often essential, and display dosage sensitivity. 
Pharmacological inhibition would be an ideal tool to probe the function of these 
enzymes. In this work, we describe a chemical genetic strategy for the specific 
inactivation of individual DEAD-box proteins with small molecule inhibitors using 
covalent complementarity. We identify a residue of low conservation within the P-loop of 
the nucleotide binding site of DEAD-box proteins and show that it can be mutated to 
cysteine without a substantial loss of enzyme function to generate electrophile-sensitive 
mutants. We then present a series of small molecules that rapidly and specifically bind 
and inhibit electrophile-sensitive DEAD-box proteins with high selectivity over the wild-
type enzyme. Thus, this approach can be used to systematically generate small 
molecule-sensitive alleles of DEAD-box proteins, allowing for pharmacological inhibition 
and functional characterization of members of this enzyme family. 
 
Introduction 
Small molecule inhibitors are powerful tools for the study of cellular enzymatic 
processes due to their rapid onset of inhibition, which prevents cellular compensation, 
and their ability to be administered at varying doses, allowing for partial as well as 
complete loss-of-function phenotypes. As compared to the ATP-binding site of kinases, 
the development of small molecules targeting the nucleotide-binding pocket of ATPases 
has proven challenging. ATP-competitive inhibitors of the AAA+ ATPase p97/VCP and 
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structurally-related family members have been discovered,134,164 although a 
generalizable small molecule scaffold with high affinity for the ATPase nucleotide-
binding pocket has not yet been identified. This is likely due to the reliance on 
electrostatic interactions for high affinity binding with its native substrate (ATP). Even if 
a suitable uncharged pharmacophore of the tri- or di-phosphate could be identified, the 
high conservation of this site across greater than 400 human proteins would make 
identifying a selective inhibitor of a single member of the family a significant 
challenge.23,24 As such, it is difficult to develop potent small molecule inhibitors of most 
ATPases, including the DEAD-box proteins. 
 
DEAD-box proteins are the largest family of enzymatic RNA chaperones in humans.17 
Named for their conserved Walker B motif consisting of adjacent aspartate-glutamate-
alanine-aspartate (D-E-A-D) residues, DEAD-box proteins are required for all stages of 
RNA metabolism including transcription, processing and splicing, export, translation and 
decay.18,22,165 DEAD-box proteins bind nucleotides via the canonical Walker A and B 
motifs and the family-specific Q-motif that recognizes the adenine of ATP and makes 
the DEAD-box proteins ATP-specific.23-25 ATP binding and hydrolysis drives 
nonprocessive unwinding of RNA substrates by local strand separation.27,28 Yet despite 
the successful biochemical and structural characterization of this essential family of 
enzymes, our understanding of the specific functions and substrate specificity of DEAD-
box proteins remains poorly understood.18  
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Owing to their roles in essential cellular processes, DEAD-box proteins are often 
misregulated in human disease and have been identified as potential pharmaceutical 
targets in cancer and viral and bacterial infection.35,132 However, specific chemical 
targeting of a single member of the DEAD-box family is challenging. Several natural 
product inhibitors of eIF4A have been identified, including hippuristanol and 
silvestrol109,111 and Takeda Pharmaceuticals recently published synthetic small 
molecules targeting eIF4AIII and Brr2.129,166 However, these compounds all rely on 
targeting cryptic allosteric pockets for their specific inhibition and as such they are highly 
selective yet are unlikely to be good structural starting points for discovery of inhibitors 
for other members of the DEAD-box family. 
 
Although genetic and biochemical methods have been invaluable in the advancement of 
our understanding of DEAD-box proteins, they are fundamentally limited. Genetic 
knockout and loss of function mutants require extensive selection and verification167,168 
during which time cellular compensation may obscure the primary role of the protein 
being studied. Gene knockout studies of structurally similar enzymes such as DEAD-
box proteins may additionally be subject to compensation by partially redundant family 
members.154,169 The use of temperature-sensitive mutants in S. cerevisiae partially 
solves these problems,170 although temperature-sensitive mutant enzyme inactivation 
often occurs though poorly understood mechanisms and temperature changes may 
alter temperature-sensitive processes such as RNA homeostasis. Pharmacologically 
controllable fusion proteins would be a potential avenue to acutely regulate DEAD-box 
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protein function,171 although the multiprotein complexes in which these proteins function 
may complicate fusion protein design. 
 
A potential solution to these challenges is to utilize the tools of chemical genetics. 
Previous chemical genetic approaches achieved specificity to the ATPases myosin-1b 
and kinesin through analog-sensitive alleles generated by space-creating mutations 
adjacent to the N6-position of ATP.149,150 As further evidence for the importance of 
charged small molecules for targeting the ATPase nucleotide-binding pocket, both 
studies developed nucleotide di- and triphosphate-based inhibitors, and thus were 
limited by the inherent affinity of nucleotides for this pocket. This class of small 
molecules is additionally challenging to modify to develop cell-active compounds.172 
Recently we reported an effort to identify analog-sensitive mutants of the DEAD-box 
protein DDX3.133  We identified a space creating mutation generated through mutation 
of a conserved aromatic residue in the adenine-binding pocket which showed a one 
hundred-fold reduction in biochemical activity.  Yeast expressing this mutant in DDX3-
homolog Ded1 displayed a temperature-sensitive phenotype, suggesting that increasing 
the size of the ATP pocket leads to a hypomorphic allele.  We therefore turned to 
another strategy for imparting drug sensitivity into the ATP binding pocket of DEAD-box 
proteins.  
 
Cysteine is the most nucleophilic of the twenty natural amino acids and is the second 
least common amino acid, after tryptophan. Additionally, cysteine-reactive small 
molecules are clinically approved and stable in vivo.173 These properties provide an 
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ideal scenario for introduction of a cysteine into the binding pocket of a DEAD-box 
protein and targeting it for irreversible inhibition. Non-native cysteines have previously 
allowed for specific chemical inhibition of challenging targets,174 and kinases expressing 
non-endogenous cysteines have been targeted in an ‘electrophile-sensitive’ (ES) 
chemical genetic approach,175-177 analogous to the ‘analog-sensitive’ approach (Figure 
3.1A). This approach may be especially beneficial in DEAD-box proteins because of the 
difficulty in generating space-creating mutations in the ATPase active site that do not 
adversely affect enzyme function.133 In fact, a previous study found that sensitivity to the 
semi-selective cysteine-targeting small molecule N-ethylmaleimide could be transferred 
to other ATPases through mutation of an active-site residue to cysteine.178,179 
 
In this work, we describe a method for the inhibition of specific DEAD-box proteins using 
covalent complementarity. We identify a site of low conservation in the P-loop of DEAD-
box proteins that can be mutated to cysteine without a substantial reduction in enzyme 
activity. We then develop a series of electrophile-containing small molecules that target 
this cysteine and specifically inhibit electrophile-sensitive, but not wild-type DEAD-box 
proteins.  Analysis of the drug bound complex in DDX3 reveals that the formation of a 
covalent bond between the engineered cysteine and the electrophilic inhibitor retains 
the adenine base interactions but requires a reorientation of the P-loop.  Taken 
together, these results demonstrate that chemical genetic inhibition of the DEAD-box 
protein family is possible through targeting the ATP-binding site, and identify novel small 
molecules for the biochemical inhibition of these enzymes. 
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Results 
Low conservation residue of the P-loop as a site for electrophile-sensitive 
mutation 
The nucleotide-binding pocket of DEAD-box proteins, and ATPases in general, is highly 
conserved and recalcitrant to mutation.24 In order to identify a chemically targetable and 
functionally silent mutation in the ATP-binding pocket, a structural alignment of all 
human DEAD-box proteins was performed. We identified the third residue of the P-
loop/Walker A-motif (Figure 3.1B, red arrow) to be of lower conservation than 
surrounding nearly invariant residues. This residue lies approximately 5-6Å from the a- 
and b-phosphates of ATP and forms a hydrogen bond with a single phosphate oxygen 
(Figure 3.1B). Although no human DEAD-box proteins natively express a cysteine at 
this position, several members of the structurally related DExH-box protein family do, 
and cysteine is the third most common amino acid at this position across all human 
RNA helicases (Supplementary Figure 1A-C). We hypothesized that DEAD-box proteins 
could tolerate mutation of this position to cysteine to create an electrophile-sensitive 
helicase mutant. 
 
Electrophile-sensitive DEAD-box proteins are functional 
To test if introduction of a cysteine residue in the ATP pocket (the putative ES-mutant) 
was tolerated in DEAD-box proteins, we expressed and purified wild-type and ES-
versions of human DDX3 (residues 132-607).180  Since the ES-mutation (S228C in 
DDX3) lies within the ATP-binding pocket, we first tested if DDX3ES retained RNA-
dependent ATPase activity. Indeed, both DDX3WT and DDX3ES hydrolyzed ATP in the 
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presence of duplex RNA (Figure 3.2A), although DDX3ES shows a three-fold reduction 
in activity compared to the wild-type (Figure 3.2B). 
 
DEAD-box proteins hydrolyze ATP to remodel RNA and RNA-protein complexes.18  To 
test if ES mutants retained this function, we utilized an RNA duplex unwinding assay 
that monitors the separation of a 32P-labeled 12-mer RNA oligonucleotide from a non-
labeled 32-mer.153 Electrophile-sensitive DDX3 retains ATP-dependent RNA-unwinding 
activity, although the rate of unwinding is three-fold lower than wild-type (Figure 3.2C-
D). A similar reduction in RNA unwinding activity is observed in the electrophile-
sensitive version of closely related yeast Ded1 (Supplementary Figure 3.1D-E). In a 
third example, the ES mutant of yeast Dbp2 shows no reduction in RNA unwinding 
activity (Supplementary Figure 3.1F), suggesting a differential effect of this mutation 
across the DEAD-box family. These results indicate that three DEAD-box proteins 
expressing a non-natural cysteine residue in the nucleotide-binding pocket are 
biochemically functional. 
 
To assess whether electrophile-sensitive mutants of four different DEAD-box proteins 
(Ded1, Fal1, Dbp2, Dbp5) are able to substitute for their WT counterpart in vivo, we 
determined their ability to rescue the loss of essential DEAD-box protein genes DED1, 
FAL1, DBP2, and DBP5 in S. cerevisiae.143,145,181-184 Yeast expressing electrophile-
sensitive versions of these DEAD-box proteins under endogenous promoters on 
extrachromosomal centromeric plasmids showed normal growth at permissive and 
restrictive temperatures (Figure 3.2E), in contrast to previous analog-sensitive mutants 
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(Supplementary Figure 3.1G). Taken together, these results demonstrate that 
electrophile-sensitive DEAD-box proteins are functional biochemically and in vivo. 
 
Synthesis of electrophile-sensitive DEAD-box helicase inhibitors from AMP 
To our knowledge there are currently no high-affinity ATP-competitive inhibitors of any 
RNA helicase. This limitation hindered our previous efforts to develop a chemical 
genetic method for the inhibition of the DEAD-box proteins using an analog-sensitive 
strategy.133 Without a good drug-like starting point, we turned to nucleotide mimetics. 
Previous work identified adenosine-5’-monophosphate (AMP) as the minimal 
component of ATP required for DEAD-box helicase binding, since AMP is able to 
decrease RNA duplex unwinding by the DEAD-box protein Ded1 while adenosine is 
not.152 This work also found that AMP shows increased potency of inhibition of a subset 
of DEAD-box proteins as compared to ADP. These data illustrate the importance of the 
phosphate-P-loop electrostatic interactions for ligand-binding. Therefore, we sought to 
develop novel high-affinity chemical probes by preserving these interactions while 
correctly positioning an electrophile for reaction with the engineered cysteine residue.  
 
The simplest molecule with both of these characteristics is AMP-acrylate (Figure 3.3A), 
which appends a cysteine-reactive Michael acceptor from the phosphate of AMP 
through a phosphoester linkage. To test whether these electrophiles bind covalently to 
DDX3, we first constructed a truncated mutant (residues 132-406) with improved 
characteristics for mass spectrometry, which allows for direct monitoring of the 
formation of a covalent adduct. Treating this optimized form of DDX3ES with AMP-
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acrylate showed complete adduct formation within five minutes at 5µM, while no 
detectable binding to DDX3WT was observed after five hours of incubation (Figure 3.3B). 
This modification is robust and rapid down to equimolar concentrations of AMP-acrylate 
and protein (Supplementary Figure 3.2A). AMP-acrylate derivatives (AMP-methacrylate 
and AMP-crotonate) and AMP-acrylamide (Figure 3A) displayed reduced rates of 
reactivity against DDX3ES according to their expected reduced cysteine reactivity 
(Figure 3.3B).185 We also appended an electrophile to the acyclic AMP-analog PMEA 
(adefovir)186 to yield adefovir-acrylate (Supplementary Figure 3.2B).  Adefovir-acrylate 
displayed only slightly reduced kinetics of labeling compared to AMP-acrylate 
(Supplementary Figure 3.2C), showing acyclic nucleotide analogs are also capable of 
labeling electrophile-sensitive DEAD-box proteins. Thus, the high rate of reactivity of 
AMP-acrylates against electrophile-sensitive DDX3 suggests that the nucleophile-
electrophile pair are properly oriented within the ATP-binding site, and the sparing of 
wild-type DDX3 shows that this reactivity is dependent on the presence of the 
engineered cysteine. 
 
AMP-acrylates undergo two-step reaction with electrophile-sensitive DEAD-box 
proteins 
Although AMP-acrylates rapidly and irreversibly labeled DDX3ES in five minutes, 
inspection of this reaction after longer periods of time surprisingly showed a loss of the 
full mass adduct (+ 401 Da) and the formation of a new adduct of + 54 Da 
(Supplementary Figure 3.2D-E). This adduct is not observed with AMP-acrylamide (data 
not shown). Carboxylic acids can be activated for nucleophilic attack in biological 
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systems through formation of an acyl-phosphate and acyl-phosphates are 
chemoselective reagents for acylation of basic amines,187 including the catalytic lysine 
of kinases.188,189  We hypothesized that the + 54 Da adduct is the result of addition of an 
active site nucleophile (for example K230 in DDX3) into the acyl-phosphate bond of 
AMP-acrylate and subsequent elimination of AMP (Supplementary Figure 3.2F). The 
phosphoramidate P-N bond is not labile under physiological conditions, consistent with 
the finding that the second step does not occur with AMP-acrylamide. Indeed, mutation 
of K230 in DDX3ES reduced the rate of formation of this +54 Da state (Supplementary 
Figure 3.2E). That this mutation did not fully abrogate the formation of this + 54 Da 
adduct suggests that other nucleophilic residues in the nucleotide-binding site may 
additionally contribute to this reaction.  
 
AMP-acrylate maintains normal nucleotide-protein interactions with electrophile-
sensitive DEAD-box proteins 
Nucleotide binding to the DEAD-box protein active site requires numerous interactions 
that stabilize a specific enzyme conformation. To test if AMP-acrylates maintain these 
interactions upon covalent modification of electrophile-sensitive enzymes, we used 
differential scanning fluorimetry (DSF) to assess protein stabilization after compound 
binding.190 Saturating concentrations of AMP stabilizes DDX3WT and DDX3ES to the 
same extent (Figure 3.3C-D), again showing the electrophile-sensitive mutation does 
not significantly disrupt nucleotide-binding. However, only DDX3ES is stabilized by AMP-
acrylate (Figure 3.3C-D). This confirms we have developed a chemical probe with 
specific reactivity to electrophile-sensitive DEAD-box proteins. That the magnitude of 
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stabilization by AMP-acrylate is as large as the stabilization by saturating concentrations 
of AMP suggests that compound binding has preserved native protein-ligand 
interactions. 
 
A 3.0Å crystal structure of DDX3ES bound to AMP-acrylamide 
To better understand the binding of AMP-acrylates to electrophile-sensitive DEAD-box 
proteins, we solved the crystal structure of DDX3 (132-607) S228C bound to AMP-
acrylamide to 3.0Å (Supplementary Table 3.1). The overall protein structure is highly 
similar to the previously published structure of DDX3 bound to AMP,180 with a root mean 
squared deviation of 1.265Å (Figure 3.4A), as expected from its similar thermal stability 
(Figure 3.3C-D). AMP-acrylamide can be fit unambiguously to its density and clearly 
binds cysteine-228 through a covalent bond (Figure 3.4B). The adenine of AMP-
acrylamide maintains several hydrogen-bonding interactions with the Q-motif of DDX3 
including interactions with glutamine-207 and the backbone of arginine-202, as well as 
pi-stacking with tyrosine-200 (Figure 3.4B). The covalent linkage significantly re-orders 
the P-loop into a conformation that to our knowledge has not previously been observed 
in nucleotide-bound structures of DEAD-box proteins. This results in a 9.4Å shift in the 
sidechain of T226 as compared to AMP-bound DDX3 (Figure 3.4C). In addition, the 
phosphoramidate of AMP-acrylamide is also displaced more than 3Å out of the 
phosphate-binding pocket as compared to the phosphate of AMP so that only the 5’-
oxygen hydrogen bonds with the P-loop backbone, whereas the phosphate of AMP 
typically makes numerous electrostatic interactions (Figure 3.4D). 
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AMP-acrylate specifically inhibits duplex unwinding by electrophile-sensitive 
DEAD-box proteins 
In addition to specifically binding to electrophile-sensitive DEAD-box proteins, we asked 
whether AMP-acrylate binding inhibits DEAD-box protein function. Previously, 
compounds were identified that reduced DDX3 ATPase activity in a mutant selective 
manner, but did not inhibit its duplex unwinding activity.133 This is likely due to the large 
stoichiometric excess of enzyme required for the single-turnover nature of the duplex 
unwinding assay while the ATPase assay utilized high substrate-enzyme ratios. 
Therefore, AMP-acrylates were tested for their ability to inhibit duplex unwinding by 
wild-type and electrophile-sensitive DEAD-box proteins.  
 
While AMP-acrylate shows no appreciable inhibition of wild-type DDX3 (Figure 3.5A), 
the duplex unwinding activity of DDX3ES is significantly reduced (Figure 3.5B). This 
inhibition is dose-dependent (Figure 3.5C-D) down to equimolar ratios of probe-enzyme, 
consistent with our previous findings that equimolar amounts of AMP-acrylate 
stoichiometrically bind to DDX3ES (Figure 3.3). Surprisingly, AMP-acrylate reduces both 
the endpoint (Figure 3.5E) and the rate (initial velocity, Figure 3.5F) of duplex unwinding 
by DDX3ES, in contrast to AMP which largely showed endpoint depression of duplex 
unwinding by DDX3WT 133. To confirm that these results are not confined to one ES 
mutant DEAD-box protein, we also show that duplex unwinding by electrophile-sensitive 
Dbp2 (S161C) is reduced by AMP-acrylate, while Dbp2WT is unaffected (Supplementary 
Figure 3.3A-B). These results demonstrate that AMP-acrylates are a novel chemical tool 
for the inhibition of biochemical activity of electrophile-sensitive DEAD-box proteins. 
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Discussion 
We have developed a strategy for the chemical genetic inhibition of DEAD-box proteins 
through covalent complementarity. After identifying a residue of low conservation in the 
P-loop of all DEAD-box proteins (Figure 3.1), we generated ‘electrophile-sensitive’ 
DEAD-box proteins with near wild-type biochemical activity and the ability to 
complement loss of essential alleles in yeast (Figure 3.2). We then developed a series 
of AMP-acrylates that rapidly and specifically bind and inhibit these electrophile-
sensitive DEAD-box proteins (Figures 3.3 and 3.5). 
 
To our knowledge, the structure of AMP-acrylamide bound to DDX3ES is the first crystal 
structure of a DEAD-box protein in complex with a small molecule inhibitor. The 
significant flattening of the P-loop observed in this structure is likely due to the torsion 
placed on this flexible loop by the tethered small molecule as it moves to maintain 
hydrogen bonds within the Q-motif. Interestingly, this distortion of the P-loop breaks the 
electrostatic interactions between the phosphate and the P-loop backbone, which are 
typically thought to drive nucleotide affinity. Since covalent compounds are 
hypothesized to undergo rapid reversible binding prior to covalent bond formation, we 
hypothesize that the initial binding event of AMP-acrylates by electrophile-sensitive 
DEAD-box proteins is driven by normal electrostatic interactions between the phosphate 
and P-loop and that covalent bond formation disrupts the positioning of the protein and 
small molecule to the final position observed in the crystal structure. This phenomenon 
was also observed with covalent inhibitors of Src kinase which lost hinge hydrogen 
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bonding contacts upon covalent bond formation.191 We cannot, however, rule out the 
possibility that this is an artifact of the rigidity of the amide bond of AMP-acrylamide and 
not representative of AMP-acrylates as a whole. This could explain the reduced rate of 
covalent modification observed by AMP-acrylamide as compared to AMP-acrylates 
(Figure 3.3B). Nonetheless, we expect the reordering of the P-loop observed upon 
binding of this compound to strongly antagonize the closed (active) conformation of 
DDX3. 
 
We anticipate significant potential utility for these probes in cell-free systems in which 
DEAD-box proteins are often studied, including assays of spliceosomal assembly and 
function,192-194 ribosome biogenesis,195,196 and translation.197-200 The current AMP-
acrylate inhibitors are likely unable to cross the plasma membrane and thus cannot be 
used in whole-cell systems. These problems can be addressed through various pro-
drug strategies developed for monophosphate- and phosphonate-containing nucleotide-
reverse transcriptase inhibitors201,202 or through development of more ‘drug-like’ 
phosphate-mimics. Acyclic derivatives of AMP-acrylate, like adefovir-acrylate 
(Supplementary Figure 2B-C), could additionally provide a path for improving the 
pharmacological properties of electrophile-sensitive DEAD-box protein inhibitors. 
Continued screening for small molecules that bind the DEAD-box protein nucleotide-
binding site may yield novel chemotypes with improved pharmacological properties that 
can be modified into electrophile-sensitive inhibitors. AMP-acrylates could be used as 
occupancy probes to aid in the identification of nucleotide-competitive compounds.203  
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AMP-acrylates developed in this work are notable because of their extremely fast 
binding to electrophile-sensitive DEAD-box proteins and their selectivity for electrophile-
sensitive over wild-type enzymes (Figure 3.3B). The rapid kinetics of binding and 
inhibition allows for little or no pretreatment of compounds, thus mitigating off-target 
effects. These effects can be additionally ruled out through the use of wild-type controls, 
which appear to be completely spared from inhibition at doses of AMP-acrylate up to 
50µM (Figure 3.5A). Although previous studies have identified AMP as an inhibitor of 
DEAD-box proteins at doses as low as 10µM,133 we hypothesize that AMP-acrylates 
have reduced reversible affinity for the nucleotide-binding site of DEAD-box proteins 
because of the added electrophilic moiety and reduced formal charge. That no reactivity 
was observed between AMP-acrylates and wild-type enzymes additionally suggests that 
the cysteine reaction is required for addition into the phosphoanhydride bond 
(Supplementary Figure 3.2D-F). This is likely due to the fast kinetics of the cysteine 
reaction and slow kinetics of addition into the phosphoanhydride, which is only 
accessible upon covalent tethering of the compound into the active site. Therefore, 
AMP-acrylates show improved affinity for electrophile-sensitive DEAD-box proteins due 
to covalent complementarity and reduced binding to wild-type enzymes. These 
characteristics make these probes ideal for the study of complex biological processes 
with multiple ATPases in which DEAD-box proteins often function.  
 
While no DEAD-box proteins natively express a P-loop cysteine, RIG-I, a closely related 
protein of the RLR family of RNA helicases,204 and several DExH-box proteins express 
endogenous cysteines at this position. This raises the intriguing possibility that the 
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chemical tools developed in this work could function as native chemical inhibitors of 
these enzymes. Additionally, since DExH-box proteins exhibit unselective nucleotide 
base binding and do not contain a Q-motif,205 changing the nucleotide base of AMP-
acrylates may yield compounds with heightened specificity for natively electrophile-
sensitive DExH-box proteins. The different orientation of the nucleotide base relative to 
the triphosphates in DExH-box proteins may also result in altered binding by acyclic 
AMP derivatives such as adefovir-acrylate. 
 
Although our work establishes a chemical genetic strategy in DEAD-box proteins only, 
the high conservation of the P-loop and nucleotide-binding site suggests that this 
strategy may work in other RNA helicases and ATPases in general.  In fact, all other 
families of ATPases (AAA+, ABC transporters, etc.) contain family members with native 
cysteines at this position (Supplementary Figure 3.1A). This implies that the overall 
ATPase fold can accept the electrophile-sensitive mutation and suggests that the 
strategy developed in this work may have implications outside the DEAD-box protein 
family.  The presence of related enzymes with native cysteines at this position also 
suggests that the AMP-acrylate may react with proteins outside of the RNA-helicase 
family.  Other modifications to AMP-acrylate such as the acyclic adefovir-acrylate may 
obviate these other activities. Although AMP-acrylates likely have utility beyond DEAD-
box proteins, we expect that novel probes will be required for the specific inhibition of 
the diverse ATPase families. This will allow for the specific chemical inhibition of nearly 
five hundred human enzymes, encompassing nearly every biological process. 
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Materials and Methods 
Multiple sequence alignment. Sequences for all human DEAD-box proteins were 
obtained from NCBI. All visualizations were generated by WebLogo 
(weblogo.berkeley.edu).206 
 
Recombinant protein purification. DDX3 (132-406) and DDX3 (132-607) were 
expressed and purified as previously described.133 Full-length Ded1 and Dbp2 were 
expressed as 6xHis-SUMO fusion proteins in E. coli BL21 (DE3) cells. Cultures were 
grown to OD ~0.8 then protein expression was induced with 0.5mM IPTG at 16ºC 
overnight. Cells were lysed by microfluidizer, clarified at 20,000 x g for 25min, and 
purified by nickel chromatography including a 1M NaCl wash to remove bound nucleic 
acids. Eluted protein was incubated with SUMO protease and dialyzed into 25mM Tris 
pH 7.5, 300mM NaCl, 0.5mM TCEP overnight at 4ºC. The sample was then purified by 
heparin chromatography and eluted at ~700mM NaCl, 25mM Tris pH 7.5, 0.5mM TCEP. 
Fractions containing pure protein, as analyzed by coomassie staining, were 
concentrated to at least 50µM, supplemented with 10% glycerol, and snap frozen in 
liquid nitrogen. 
 
Coupled ATPase assays. Assays were performed as previously described.133 All 
experimental results are reported as the average of three replicates with error bars 
representing the standard deviation of the results.  
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RNA duplex unwinding assays. RNA duplex unwinding assays were performed as 
previously described153 using 1nM duplex RNA, 2mM ATP/MgCl2, and 1µM DDX3 (132-
607), 0.5µM Ded1 or 0.5µM Dbp2. Reaction buffer contained 20mM HEPES pH 7.5, 
100mM NaCl, 0.5mM MgCl2, 1mM TCEP, 0.01% (v/v) NP-40, and 5% glycerol. The 
sequences of the RNA duplex strands are 5’-GCUUUACGGUGC-3’ and 5’-
GAACAACAACAACAACCAUGGCACCGUAAAGC-3’. For experiments that included 
chemical inhibitors, RNA, protein and inhibitors were pre-incubated in reaction buffer for 
5min prior to addition of ATP-Mg. Results were quantified using ImageJ (NIH) 207. All 
experimental results are reported as the average of three replicates with error bars 
representing the standard error of the results. 
 
Yeast genetics. For a complete list of yeast strains and plasmids used in this work, see 
Supplementary Tables 3.2 and 3.3. A strain of S. cerevisiae containing a deletion of the 
DED1 locus complemented by URA3-marked plasmid containing DED1 was previously 
described.137 Heterodiploid strains containing single locus knockouts of FAL1, DBP2, or 
DBP5 were purchased from Dharmacon (GE Life Sciences). Strains were transformed 
with URA3-marked plasmids containing the genetic locus of the DEAD-box protein of 
interest and selected for on Ura- synthetic media. Strains were then sporulated by 
carbon starvation (1% potassium acetate, 0.1% yeast extract, 0.05% dextrose) for 5 
days, released from their asci by lyticase treatment (Sigma-Aldrich) and dispersed by 
sonication.167 Haploid strains containing KanMX-cassette knockouts of FAL1, DBP2, or 
DBP5 at the genetic locus complemented with URA3-marked plasmids containing 
FAL1, DBP2 or DBP5 were selected on geneticin and Ura- synthetic complete media. 
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Strains were confirmed to be unable to grow on 5-FOA synthetic complete media, then 
verified by plasmid isolation followed by sequencing. Mating type was determined by 
complementation with MATa (his2-) and MATalpha (his2-) tester strains (gift from David 
Morgan, UCSF) on Ura- His- synthetic complete media. Electrophile-sensitive mutants 
were generated by site-directed mutagenesis in a HIS3-marked plasmid, transformed 
into yeast and counterselected using 5-FOA and His- synthetic complete media. Strains 
were verified by plasmid isolation followed by sequencing and subsequently grown in 
YPD media. Growth experiments are 10-fold dilutions from cultures grown to OD ~1. 
 
Mass spectroscopy assay. DDX3 (132-406) WT or S228C (250nM unless otherwise 
noted) or DDX3 (132-607) (500nM) in 10mM Tris pH 7.5, 100mM NaCl and 1mM MgCl2 
was incubated with compounds at 4ºC. The extent of modification at various time points 
was determined by whole protein mass spectrometry using a Waters Acquity UPLC/G2-
XF QTOF. Reported data points are single-replicates from three independent 
experiments (Figure 3.3B, Supplementary Figure 3.2E) or means of three independent 
experiments with error bars representing the standard error (Supplementary Figure 2A-
C). Curves are fit using Prism (GraphPad). 
 
Differential scanning fluorimetry. DSF was performed as described190 using 4µM 
DDX3 (132-406) in a reaction buffer containing 20mM HEPES pH 7.5, 150mM NaCl, 
and 5mM MgCl2. Reaction mixtures were incubated for 5min prior to the start of the 
assay. Results are the average of three independent experiments with error bars 
representing the standard error of the mean. Curves are fit using Prism (GraphPad). 
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X-ray crystallography. Purified DDX3ES (132-607) was incubated with 100µM AMP-
acrylamide at 4ºC until completely labeled, as judged by LC-MS.  Protein was then 
applied to a Superdex 200 gel filtration column equilibrated in 20mM HEPES pH 7.5, 
500mM NaCl, 10% (v/v) glycerol, and 0.5mM TCEP and fractions containing pure 
protein were flash frozen in liquid nitrogen for storage. Conditions for crystallography 
were previously described.180 Data was collected at Beamline 8.2.2 of the Advanced 
Light Source (LBNL, Berkeley, CA). Data were indexed and integrated using iMosflm,208 
scaled using Scala,209 phased using molecular replacement with PHASER210 using 
Protein Data Bank (PDB) 5e7j as a search model, and refined and built using 
PHENIX211 and Coot.212 Structures were visualized with PyMOL.213 Atomic coordinates 
and structure factors for the reported crystal structure have been deposited with the 
Protein Data Bank under accession number 6CZ5. 
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Figure 3.1. Development of an ‘electrophile-sensitive’ mutation in DEAD-box proteins.  
 
A. Analog-sensitive (AS) chemical genetic strategies rely on space-creating mutations 
and bulky inhibitors, while electrophile-sensitive (ES) strategies rely on cysteine-
electrophile covalent complementarity. B. Conserved nucleotide binding site of DEAD-
box proteins including the P-loop/Walker A (yellow), DEAD-box/Walker B (orange) and 
Q-motif (white) with conservation across all human DEAD-box proteins (inserts) and the 
site of electrophile-sensitive mutation identified (red arrow; PDB 2HXY).  
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Figure 3.2. Electrophile-sensitive DEAD-box proteins retain biochemical and cellular 
function.  
 
A. RNA-dependent ATPase activity of DDX3WT and DDX3ES (S228C) at four 
concentrations of ATP. B. Comparison of the observed rate of RNA-dependent ATP 
hydrolysis by DDX3WT and DDX3ES. C. Representative RNA duplex unwinding assay 
comparing the activity of DDX3WT and DDX3ES. D. Quantification of the fraction of RNA 
duplex unwound by DDX3WT and DDX3ES. E. Serial dilutions of log-phase cultures of 
budding yeast strains expressing wild-type or electrophile-sensitive DEAD-box proteins 
grown at permissive (30ºC) or restrictive (20ºC, 37ºC) temperatures. 
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Figure 3.3. AMP-acrylate and derivatives potently and irreversibly bind electrophile-
sensitive DEAD-box proteins.  
 
A. Structures of AMP-acrylate and derivatives used in this study. B. Percent 
modification of DDX3 (132-406) WT and ES (S228C) incubated with 5µM AMP-acrylate 
and derivatives at 4ºC. C. Differential scanning fluorimetry curves of DDX3 (132-406) 
WT and ES in the presence of AMP or 5µM, 10µM, or 20µM AMP-acrylate. D. 
Experimentally determined melting temperatures (Tm) of DSF curves from (C) with 
significant differences from DMSO in bold (t-test, p<0.001).  
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Figure 3.4. Crystal structure of AMP-acrylamide bound to electrophile-sensitive DDX3.  
 
A. Overall structure of AMP-acrylamide bound to DDX3ES (grey) aligned to AMP-bound 
DDX3 (green, PDB 5E7J). B. AMP-acrylamide bound to the nucleotide binding site of 
DDX3 with conserved hydrogen bonding interactions (black lines) with Y200, R202, and 
Q207. AMP-acrylamide 2mFo-DFc difference map is shown (black mesh, 1.5s). C. 
Alignment of AMP-acrylamide- (grey) and AMP-bound (green) structures of DDX3 
shows flattening of the P-loop in AMP-acrylamide-bound structure including an 9.4Å 
shift in T226. D. Comparison of the coordination of the phosphoramidate of AMP-
acrylamide (grey) to the coordination of the phosphate of AMP (green) by DDX3 (PDB 
5E7J) (dashed lines are predicted hydrogen bonds). 
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Figure 3.5. AMP-acrylates inhibit electrophile-sensitive DEAD-box proteins.  
 
A and B. RNA duplex unwinding by DDX3WT (A) and DDX3ES (S228C) (B) in the 
presence of 50µM and 12.5µM AMP-acrylate. C and D. RNA duplex unwinding by 
DDX3ES in the presence of serial dilutions of AMP-acrylate starting at 50µM (C) with 
quantification of three independent experiments (D). E and F. Effect of AMP-acrylate of 
the endpoint (E) and rate (F) of RNA duplex unwinding by DDX3ES.  
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Supplementary Figure 3.1. Development of an ‘electrophile-sensitive’ mutation in 
DEAD-box proteins.  
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A. Identification of human ATPases from diverse enzyme families that natively express 
a P-loop cysteine. B. Structural alignment of the P-loop of all human RNA helicases. C. 
Alignment of the P-loop of all human DEAD-box proteins to identify position of 
electrophile-sensitive mutation (red arrow). D. Representative RNA duplex unwinding 
assay comparing the activity of Ded1WT and Ded1ES (S190C). E. Quantification of the 
fraction of RNA duplex unwound by Ded1WT and Ded1ES. F. Representative RNA duplex 
unwinding assay comparing the activity of Dbp2WT and Dbp2ES (S161C). G. Serial 
dilutions of log-phase cultures of budding yeast strains expressing wild-type, 
electrophile-sensitive (S190C), or analog-sensitive (F144A) Ded1 grown at permissive 
(30ºC) or restrictive (37ºC) temperatures. 
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Supplementary Figure 3.2. AMP-acrylates undergo two-step reaction with electrophile-
sensitive DEAD-box proteins.  
 
A. Percent modification of 125nM DDX3ES (S228C) by various concentrations of AMP-
acrylate at 4ºC. B. Structure of Adefovir-acrylate. C. Comparison of the rate of 
modification of 250nM DDX3ES by 1µM AMP-acrylate and 1µM Adefovir-acrylate at 4ºC. 
D. Whole-protein mass spectrometry of DDX3ES with DMSO or 5µM AMP-acrylate at 
4ºC showing formation of +401 Da adduct after 5min and +54 Da adduct after 300min. 
E. Quantification of the percentage of DDX3ES and DDX3ES K230M with +54 Da adduct 
over time. F. Proposed mechanism for the two-step reaction of DDX3ES with AMP-
acrylates. The electrophile-sensitive mutation (C228 in DDX3) undergoes a Michael-
addition into the electrophilic beta-carbon of the acrylate of AMP-acrylate (first-step). 
AMP is then eliminated from this adduct by addition of a nucleophilic amino acid such 
as lysine (K230 in DDX3; second-step) or arginine to form the final product.  
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Supplementary Figure 3.3. AMP-acrylates inhibit electrophile-sensitive DEAD-box 
proteins.  
 
A. RNA duplex unwinding by Dbp2 WT in the presence of 50µM and 12.5µM AMP-
acrylate. B. RNA duplex unwinding by electrophile-sensitive Dbp2 (S161C) in the 
presence of serial dilutions of AMP-acrylate starting at 200µM. 
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Supplementary Table 3.1. Data collection and refinement statistics. 
 DDX3 (132-607) – AMP-acrylamide 
Data collection  
Space group P 21 21 21 
Cell dimensions    
    a, b, c (Å) 53.96, 101.09, 105.69 
    α, β, γ (°)  90, 90, 90 
Resolution (Å) 73.05-3.00 (3.16-3.00)a 
Rmerge, Rmeas, and Rpim 0.121 (1.089), 0.135 (1.201), 0.057 (0.500) 
I/σ(I) 8.5 (1.6) 
CC1/2 0.996 (0.766) 
Completeness (%) 100.0 (100.0) 
Redundancy 5.4 (5.6) 
  
Refinement  
Resolution (Å) 73.05-3.00 
No. reflections 12100 
Rwork / Rfree 0.2219/0.2667 
No. atoms  
    Protein 3378 
    Ligand/ion (specify/describe) 27 
    Water 0 
B factors  
    Protein 87.39 
    Ligand/ion 107.20 
R.m.s. deviations  
    Bond lengths (Å) 0.002 
    Bond angles (°) 0.50 
a Values in parentheses are for highest-resolution shell. 
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Supplementary Table 3.2: Yeast strains used in this study. 
Strain Genotype Source 
Ded1 WT MATa his3∆1 leu2∆0 met15∆0 ura3∆0 
ded1::KanMX pKJB001 
Hilliker A et al. (2011)137 
HA-Ded1 WT MATa his3∆1 leu2∆0 met15∆0 ura3∆0 
ded1::KanMX pKJB002 
This study 
HA-Ded1 S190C MATa his3∆1 leu2∆0 met15∆0 ura3∆0 
ded1::KanMX pKJB003 
This study 
Fal1 HetDip MATa/MATalpha his3∆1/his3∆1 
leu2∆0/leu2∆0 MET15/met15∆0 
LYS2/lys2D0 ura3∆0/ura3∆0 
FAL1/fal1::KanMX 
GE Dharmacon (Clone 
ID: 23960) 
Fal1 WT MATalpha his3∆1 leu2∆0 ura3∆0 
fal1::KanMX pKJB004 
This study 
HA-Fal1 WT MATalpha his3∆1 leu2∆0 ura3∆0 
fal1::KanMX pKJB005 
This study 
HA-Fal1 T71C MATalpha his3∆1 leu2∆0 ura3∆0 
fal1::KanMX pKJB006 
This study 
Dbp2 HetDip MATa/MATalpha his3∆1/his3∆1 
leu2∆0/leu2∆0 MET15/met15∆0 
LYS2/lys2D0 ura3∆0/ura3∆0 
DBP2/dbp2::KanMX 
GE Dharmacon (Clone 
ID: 27822) 
Dbp2 WT MATa his3∆1 leu2∆0 ura3∆0 
dbp2::KanMX pKJB007 
This study 
HA-Dbp2 WT MATa his3∆1 leu2∆0 ura3∆0 
dbp2::KanMX pKJB008 
This study 
HA-Dbp2 S161C MATa his3∆1 leu2∆0 ura3∆0 
dbp2::KanMX pKJB009 
This study 
Dbp5 HetDip MATa/MATalpha his3∆1/his3∆1 
leu2∆0/leu2∆0 MET15/met15∆0 
LYS2/lys2D0 ura3∆0/ura3∆0 
DBP5/dbp5::KanMX 
GE Dharmacon (Clone 
ID: 21822) 
Dbp5 WT MATalpha his3∆1 leu2∆0 ura3∆0 
dbp5::KanMX pKJB010 
This study 
HA-Dbp5 WT MATalpha his3∆1 leu2∆0 ura3∆0 
dbp5::KanMX pKJB011 
This study 
HA-Dbp5 T142C MATalpha his3∆1 leu2∆0 ura3∆0 
dbp5::KanMX pKJB011 
This study 
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Supplementary Table 3.3: Plasmids used in this study. 
Plasmid Description Vector Insert Source 
pKJB001 Ded1 WT pRS416 
(URA3/CEN) 
DED1 (-106 to +2727) Hilliker A 
et al. 
(2011) 
pKJB002 HA-Ded1 
WT 
pRS413 
(HIS3/CEN) 
DED1 (-106 to +2727)/N-
terminal HA-tag 
This study 
pKJB003 HA-Ded1 
S190C 
pRS413 
(HIS3/CEN) 
DED1 S190C (-106 to 
+2727)/N-terminal HA-tag 
This study 
pKJB004 Fal1 WT pRS416 
(URA3/CEN) 
FAL1 (-607 to +1826) This study 
pKJB005 HA-Fal1 WT pRS413 
(HIS3/CEN) 
FAL1 (-607 to +1826)/N-
terminal HA-tag 
This study 
pKJB006 HA-Fal1 
T71C 
pRS413 
(HIS3/CEN) 
FAL1 T71C (-607 to +1826)/N-
terminal HA-tag 
This study 
pKJB007 Dbp2 WT pRS416 
(URA3/CEN) 
DBP2 (-757 to +4107; Dintron) This study 
pKJB008 HA-Dbp2 
WT 
pRS413 
(HIS3/CEN) 
DBP2 (-757 to +4107; 
Dintron)/N-terminal HA-tag 
This study 
pKJB009 HA-Dbp2 
S161C 
pRS413 
(HIS3/CEN) 
DBP2 S161C (-757 to +4107; 
Dintron)/N-terminal HA-tag 
This study 
pKJB010 Dbp5 WT pRS416 
(URA3/CEN) 
DBP5 (-1029 to +2462) This study 
pKJB011 HA-Dbp5 
WT 
pRS413 
(HIS3/CEN) 
DBP5 (-1029 to +2462)/N-
terminal HA-tag 
This study 
pKJB012 HA-Dbp5 
T142C 
pRS413 
(HIS3/CEN) 
DBP5 T142C (-1029 to 
+2462)/N-terminal HA-tag 
This study 
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Chemical Synthesis 
Materials obtained commercially were reagent grade and were used without further 
purification. Reactions were monitored by thin layer chromatography (TLC) and/or mass 
spectrometry (LC-MS) using a Waters Acquity UPLC/ESI-G2 XS QTOF. All NMR 
spectra were obtained on a Brucker 400 spectrometer. 
 
Synthesis of intermediate 1 
 
Acrylic anhydride (intermediate 1). Acrylic acid (Sigma-Aldrich, 205.7µL, 3.0mmol, 
1.0eq) was added to a 20mL scintillation vial under Ar(g), followed by tetrahydrofuran 
(5mL) and triethylamine (418.1µL, 3.0mmol, 1.0eq). The reaction mixture was chilled to 
0ºC and acryloyl chloride (242.4µL, 3.0mmol, 1.0eq) in tetrahydrofuran (1mL) was 
added dropwise. The reaction was allowed to warm to room temperature and stirred 
overnight. The reaction was filtered, evaporated to dryness, then dissolved in ethyl 
acetate (30mL) and extracted with a solution of saturated sodium bicarbonate. The 
organic fraction was dried with sodium sulfate, filtered, evaporated to dryness and the 
resulting oil was used without further purification. 
 
General procedure for the synthesis of AMP-acrylate, AMP-crotonate, and AMP-
methacrylate 
 83 
 
In a 4mL scintillation vial, adenosine 5’-monophosphate sodium salt (Sigma, 25mg, 
0.0720mmol) was dissolved in DMSO (1mL) and triethylamine (100µL,0.720mmol, 
10eq) with sonication and stirring. In a separate vial, the appropriate symmetric acrylic 
anhydride (0.0792mmol, 1.1eq) was dissolved in DMSO (100µL) and added slowly to 
the reaction vial. After 30min, the reaction was quenched by addition of 1% formic acid 
(1mL) and purified by reverse phase HPLC (0-30% acetonitrile/water) to yield the pure 
compound.   
 
acrylic (((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-
yl)methyl phosphoric) anhydride (AMP-acrylate). White solid, 20.6mg, 71.2% yield. 
1H NMR (400MHz, D2O) d 8.48 (s, 1H), 8.33 (s, 1H), 6.31 (dd, J = 14.6, 3.5 Hz, 1H), 
6.08 (d, J = 5.2 Hz, 1H), 6.01 – 5.89 (m, 2H), 4.74 (t, J= 5.2 Hz, 1H), 4.45 (t, J = 4.5 Hz, 
1H), 4.31 (s, 1H), 4.20 (tq, J = 9.8, 6.4, 4.5 Hz, 2H). 31P NMR (162MHz, D2O) d -7.32. 
13C NMR (100MHz, D2O) d 163.57 (d, J = 8.2 Hz), 150.49, 148.44, 145.49, 142.17, 
134.56, 127.25 (d, J = 7.5 Hz), 118.58, 88.00, 83.91 (d, J = 8.7 Hz), 74.23, 70.22, 65.59 
(d, J = 5.7 Hz). [M+H]+ m/z calculated 402.0809 (100%), 403.0843 (14%), observed 
402.0800 (100%), 403.0861 (12%). 
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(((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-
yl)methyl phosphoric) (E)-but-2-enoic anhydride (AMP-crotonate). White solid, 
13.66mg, 44.8% yield. 1H NMR (400MHz, D2O) d 8.48 (s, 1H), 8.33 (s, 1H), 6.93 (m, 
1H), 6.07 (d, J = 5.3 Hz, 1H), 5.63 (dt, J = 15.5, 1.9 Hz, 1H), 4.75 (t, J = 5.2 Hz, 1H), 
4.45 (m, 1H), 4.31 (d, J = 2.9 Hz, 1H), 4.17 (pt, J = 5.6, 2.4 Hz, 2H), 1.74 (dd, J = 6.9, 
1.6 Hz, 3H). 31P NMR (162MHz, D2O) d -7.27. 13C NMR (100MHz, D2O) d 163.80 (d, J = 
8.2 Hz), 150.67, 150.36, 148.43, 145.36, 142.28, 121.00 (d, J = 7.4 Hz), 118.53, 88.01, 
84.00 (d, J = 8.5 Hz), 74.17, 70.26, 65.53 (d, J = 5.8 Hz), 17.52. [M+H]+ m/z calculated 
416.0966 (100%), 417.0999 (15%), observed 416.0961 (100%), 417.0987 (12%). 
 
(((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-
yl)methyl phosphoric) methacrylic anhydride (AMP-methacrylate). White solid, 
10.0mg, 32.9% yield. 1H NMR (400MHz, D2O) d 8.46 (s, 1H), 8.32 (s, 1H), 6.07 (d, J = 
5.3 Hz, 1H), 5.95 (s, 1H), 5.59 (s, 1H), 4.77 (t, J = 5.2 Hz, 1H), 4.46 (m, 1H), 4.30 (m, 
1H), 4.19 (ttt, J = 8.4, 5.6, 2.5 Hz, 2H), 1.69 (s, 3H). 31P NMR (162MHz, D2O) d -7.16. 
13C NMR (100MHz, D2O) d 164.73 (d, J = 8.7 Hz), 150.85, 148.51, 146.02, 142.06, 
135.28 (d, J = 6.6 Hz), 128.86, 118.61, 87.97, 83.96 (d, J = 8.5 Hz), 74.04, 70.28, 65.65 
(d, J = 5.9 Hz), 16.99. [M+H]+ m/z calculated 416.0966 (100%), 417.0999 (15%), 
observed 416.0961 (100%), 417.0987 (10%). 
 
Synthesis of Intermediate 2 
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((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-
yl)methyl hydrogen phosphoramidate (intermediate 2). The protocol for the 
synthesis of this intermediate was previously described214. Adenosine 5’-
monophosphate sodium salt (Sigma, 1041.7mg, 3.0mmol) was dissolved in ammonium 
hydroxide (2N, 7.5mL) and formamide (5mL). To this solution, a suspension of N,N-
dicyclohexylcarbodiimide (DCC, 3095mg, 15.0mmol, 5eq) in tert-butanol (20mL) was 
added and the resulting two-phase reaction was heated to 80ºC. After 2-3hr, the 
solution becomes homogenous and after an additional 7hrs, the reaction is allowed to 
cool overnight. Unreacted DCC was removed by filtration and washed with water and 
the resulting solution was evaporated under reduced pressure to remove volatiles. The 
resulting solution was extracted with diethyl ether, then the aqueous layer was 
evaporated to dryness. Acetone was added to the resulting oil and the ammonium salt 
of the product was isolated by filtration (white gummy solid; 884.3mg, 81.8% yield). 
 
Synthesis of AMP-acrylamide 
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((2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-
yl)methyl hydrogen acryloylphosphoramidate (AMP-acrylamide). In a 4mL 
intermediate 2 (50mg, 0.138mmol) was dissolved in DMSO (1mL) and triethylamine 
(48µL, 0.344mmol, 2.5eq) with sonication and stirring. In a separate vial, intermediate 1 
(19.1mg, 0.151mmol, 1.1eq) was dissolved in DMSO (100µL) and added slowly to the 
reaction vial. After 30min, the reaction was quenched by addition of 1% formic acid 
(1mL) and purified by reverse phase HPLC (0-30% acetonitrile/water) to yield the pure 
compound (white solid, 4.93mg, 8.5% yield). 1H NMR (400MHz, D2O) d 8.46 (s, 1H), 
8.24 (s, 1H), 6.09 (d, J = 1.7 Hz, 1H), 6.05 (d, J = 5.4 Hz, 1H), 5.65 (d, J = 10.4 Hz, 1H), 
4.73 (d, J = 5.3 Hz, 1H), 4.44-4.37 (m, 1H), 4.29 (d, J = 2.6 Hz, 1H), 4.09 (tddt, J = 11.7, 
9.3, 5.8, 3.0 Hz, 2H). 31P NMR (162MHz, D2O) d -4.69. 13C NMR (100MHz, D2O) 
d 169.48, 153.02, 149.14, 148.70, 141.09, 129.98, 129.20, 118.59, 87.52, 83.91 (d, J = 
9.0 Hz), 74.19, 70.37, 64.83 (d, J = 5.3 Hz). [M+H]+ m/z calculated 401.0969 (100%), 
402.1003 (14%), observed 401.0957 (100%), 402.1006 (11%). 
 
Synthesis of Adefovir-acrylate 
 
acrylic ((2-(6-amino-9H-purin-9-yl)ethoxy)methyl)phosphonic anhydride (Adefovir-
acrylate). In a 4mL scintillation vial, 9-[2-(Phosphonomethoxy)ethyl]adenine (PMEA, 
Adefovir) (AK Scientific, 20mg, 0.0732mmol) was dissolved in DMSO (1mL) and 
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triethylamine (102µL,0.732mmol, 10eq) with sonication and stirring. In a separate vial, 
intermediate 1 (10.2mg, 0.0805mmol, 1.1eq) was dissolved in DMSO (100µL) and 
added slowly to the reaction vial. After 2hr, the reaction was quenched by addition of 
1% formic acid (1mL) and purified by reverse phase HPLC (0-25% acetonitrile/water) to 
yield the pure compound (white solid, 18.4mg, 72% yield).  1H NMR (400MHz, DMSO-
d6 + Et3N) d 8.16 (s, 1H), 8.12 (s, 1H), 7.16 (s, 2H), 6.21 (dd, J = 17.2, 1.9 Hz, 1H), 
6.12-6.04 (m, 1H), 5.86 (dd, J = 10.1, 1.9 Hz, 1H), 4.27 (t, J = 5.2 Hz, 2H), 3.85 (t, J = 
5.2 Hz, 2H), 3.60 (d, J = 8.1 Hz, 2H). 31P NMR (162MHz, DMSO-d6 + Et3N) d 9.67 
(t, J = 8.0 Hz). 13C NMR (100MHz, DMSO-d6 + Et3N) d 163.24 (d, J = 7.8 Hz), 156.35, 
152.73, 149.92, 141.66, 131.84, 130.66 (d, J = 3.7 Hz), 118.97, 70.09 (d, J = 9.2 Hz), 
68.36 (d, J = 154.7 Hz), 43.01. [M+H]+ m/z calculated 328.0805 (100%), 329.0839 
(12%), observed 328.0799 (100%), 329.0854 (13%). 
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Chapter 4 
 
 
Developing reversible chemical inhibitors of DDX3 
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Introduction 
Owing to the success in the elucidation of novel biology using potent cell-active small 
molecule inhibitors of eIF4A,116,118,215 we sought to elaborate on our chemical genetic 
inhibitors of DEAD-box proteins and develop potent, cell-active ATP-competitive 
inhibitors of DDX3. We hope to distinguish these small molecules from other published 
DDX3 inhibitors that show limited efficacy in our hands133 through rigorous biochemical 
characterization.  
 
As discussed in chapter 2, our analog-sensitive strategy for the inhibition of DEAD-box 
proteins was unsuccessful because of poorly tolerated mutations and the low potency of 
analog-sensitive inhibitors.133 We hypothesized that our difficulty in developing more 
potent inhibitors stemmed from a lack of potent ATP-competitive small molecules that 
target DEAD-box proteins. In contrast to kinases, for which chemical genetic strategies 
started with nanomolar binders that lacked specificity, our most potent screening hit was 
a millimolar binder that was optimized to bind ~10-fold more potently.133 Our 
electrophile-sensitive chemical genetic strategy yielded potent and selective inhibitors of 
electrophile-sensitive DEAD-box proteins. However, these nucleotide-based small 
molecule inhibitors are not cell-permeable in their current form, and the 
phosphate/phosphonate moiety that limits their ability to transit across cell membranes 
is essential for binding activity.152 Therefore, additional screening for novel chemical 
scaffolds with drug-like properties and high affinity for the ATP-binding site of DEAD-box 
proteins was required. 
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The AAA+ ATPase superfamily (ATPases associated with various cellular activities) are 
a diverse set of cellular enzymes required in numerous cellular processes including 
proteolysis, DNA replication and recombination, and protein disaggregation.216 AAA+ 
ATPases typically exist in homo- or heterohexameric complexes, and utilize ATP 
hydrolysis to drive cellular processes, typically as a subunit of large cellular complexes 
termed molecular machines.217 AAA+ ATPases contain an ATP-binding site that is 
structurally related to other ATPases, including the DEAD-box proteins,23,218 although it 
does not rely on a Q-motif for nucleotide base recognition.25 Therefore, ATP-competitive 
small molecule inhibitors of AAA+ ATPases may maintain some affinity for the 
nucleotide-binding site of DEAD-box proteins. 
 
As with other ATPases, most chemical inhibitors of AAA+ ATPases are natural products 
that target an allosteric site.219,220 However, a few chemical inhibitors are ATP-
competitive, including the small electrophile N-ethylmaleimide (NEM) that targets the 
ATP-binding site of the N-ethylmaleimide-sensitive factor (NSF).178 N2,N4-
dibenzylquinazoline-2,4-diamine (DBeQ, Figure 4.1A) was additionally identified as an 
ATP-competitive inhibitor of p97/VCP, a AAA+ ATPase required in the ubiquitin-
proteasome system.134 Derivatives of DBeQ inhibit the ATPase activity of p97 with a Ki 
of less than 25nM and have advanced to clinical trials in multiple myeloma.135 An 
additional screening effort from Genentech identified a covalent, ATP-competitive 
inhibitor of p97 based on a saccharin scaffold.164 
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In this study, we tested a series of DBeQ-derivatives for their efficacy as DDX3 
inhibitors. We find that N4-(5-phenyl-1H-pyrazol-3-yl)quinazoline-2,4-diamines inhibit the 
RNA duplex unwinding activity of DDX3 at low micromolar doses, with dramatic SAR 
with substitution of the phenyl ring and robust SAR with substitution of the N2-position of 
the 2,4-diaminoquinazoline. We then identify TC347 as the most potent compound, and 
determine it is an ATP-competitive inhibitor of DDX3 WT. 
 
Results 
Small molecule screen identifies DBeQ-derivatives that inhibit the RNA duplex 
unwinding activity of DDX3 WT 
DDX3, like other DEAD-box proteins, is capable of separating short RNA duplexes by 
local strand separation utilizing ATP hydrolysis.153 A series of small molecule derivatives 
of DBeQ were synthesized to expand around the benzyl substituents at the N2- and N4-
positions, and these compounds were tested for their capability to inhibit the ATP-
dependent RNA duplex unwinding activity of DDX3 WT at 100µM in 2mM ATP (Figure 
4.1B-C). The screen identified several derivatives that potently reduced the unwinding 
activity of DDX3, including TC329 and TC123R, although the chemical structure of 
several hit compounds raised the possibility of an aggregator phenotype.221 Therefore, 
future experiments were conducted with 0.01% Triton X-100 to discourage compound 
aggregation.222 These results indicate that derivatives of the p97/VCP inhibitor DBeQ 
inhibit the duplex unwinding activity of DDX3. 
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Structure-activity relationship of DBeQ-derivatives identifies N-(5-phenyl-1H-
pyrazol-3-yl)quinazoline-4-amines as lead scaffold 
Based on the results of the screen performed in Figure 4.1, we selected structurally 
related derivatives of TC329 and TC123R and analyzed their activity as inhibitors of 
DDX3 over a full RNA duplex unwinding time course (Figure 4.2A-B). Within the set of 
TC329-derivatives, we found a strong preference for a 2-aminomethypyrrolidine 
substitution at the 2-position of the quinazoline (Figure 4.2A), while other substitutions 
showed little activity at 50µM. Within the set of TC123R-derivatives, we observed 
increased potency of phenyl-substituted pyrazoles at the N4-position of the 2,4-
diaminoquinazolines, as TC327 and TC391 reduced the duplex unwinding activity of 
DDX3 by greater than 75% (Figure 4.2B). We then tested TC327 and TC391 at three 
lower doses and found that TC327 is the most potent, inhibiting the endpoint RNA 
duplex unwinding activity of DDX3 by >50% at 12.5µM (Figure 4.2C-D). Therefore, 
derivatives of DBeQ show structure-activity relationships against DDX3 and display 
dose-dependent inhibition of its duplex unwinding activity. 
 
Structure-activity relationship of N4-(5-phenyl-1H-pyrazol-3-yl)quinazoline-2,4-
diamines identifies TC347 as most potent inhibitor of DDX3 
To further elaborate on the N4-(5-phenyl-1H-pyrazol-3-yl)quinazoline-2,4-diamine 
scaffold, we tested a set of compounds structurally related to TC327 and TC391. From 
this set, we first identified that substitution to the phenyl ring of N4-(5-phenyl-1H-pyrazol-
3-yl)quinazoline-2,4-diamines shows dramatic SAR (Figure 4.3A-B). Whereas TC326 
shows a similar potency to TC391 (Figure 4.2D), pyridine or furan derivatives show 
 93 
markedly reduced potency (Figure 4.3A). Compound pairs TC386/TC387 and 
TC450/TC453 showed similarly dramatic results with small chemical perturbations 
(Figure 4.3B), although the dramatic potency of TC453 may be due to an aggregator 
phenotype, as naphthalene-based compounds are notoriously aggregation prone.221 
 
A series of eight small molecule derivatives of TC391 varying in N2-position substitution 
were also tested (Figure 4.3C, insert). In contrast to above, these structural changes 
result in more modest perturbations in activity (Figure 4.3C). The most promising of 
these compounds were TC347 (and its racemate TC337) and TC348, both of which 
contain potential hydrogen bond donors in a 3-(aminomethyl)pyrrolidine and 4-
hydroxyazetidine, respectively. Compounds with aromatic or other saturated 
heterocycles at this position show more modest potency. Therefore, placement of a 
hydrogen bond donor off the N2-position of N4-(5-phenyl-1H-pyrazol-3-yl)quinazoline-
2,4-diamines yields inhibitors of DDX3 with low micromolar potency. 
 
TC347 is an ATP competitive inhibitor 
Since substituted aromatic small molecules can be either allosteric or ATP-competitive 
inhibitors of p97/VCP,135,164 we sought to understand the nature of the binding of TC347 
to DDX3. We performed a three-point dose response of TC347 (Figure 4.4A) at varying 
concentrations of ATP (50µM-10mM) and found that TC347 displays ATP-competitive 
binding (Figure 4.4B-C). Visually, this can be seen by the decreased efficacy of TC347 
at all doses at 10mM ATP as compared to 200µM ATP (Figure 4.4B) as well as by a 
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Lineweaver-Burk plot, which shows increasing doses of TC347 have the same y-
intercept on a double-reciprocal plot (Figure 4.4C).  
 
In a complementary approach, we also monitored the binding of AMP-acrylamide 
(Figure 3.3A-B) to DDX3ES (S228C) in the presence of TC347 or inactive analog TC355 
(Figure 4.4A). We observed that TC347 competes with AMP-acrylamide binding to 
C228 of DDX3ES down to doses as low as 12.5µM, indicating they bind to the same or 
similar sites on DDX3, while TC355 shows little competition up to 50µM (Figure 4.4D-E). 
Since the binding position of AMP-acrylamide has been characterized by mutational 
studies and crystallography to be the ATP-binding site of DDX3 (Figure 3.3B, 3.4), this 
indicates that TC347 is an ATP-competitive DDX3 inhibitor. 
 
Moving towards more drug-like irreversible inhibitors of DDX3ES  
Based on the potency of TC347, we hypothesized that it binds DDX3 with a Ki ~ 10µM, 
which makes it a tighter binder than AMP (Figure 2.3A). Therefore, proper placement of 
an electrophile off the TC347 scaffold may produce an electrophile-sensitive DEAD-box 
protein inhibitor with improved drug-like properties to complement the electrophile-
sensitive mutation discussed in Chapter 3. Based on previous results that the C8 of the 
quinazoline ring points towards the P-loop of AAA+ ATPases (data not shown), we 
synthesized KBELN2-55 and KBELN2-74B to point an electrophile towards that position 
(Figure 4.5A). KBELN2-74A was synthesized during this process as a side-product.  
Upon incubation of these compounds with DDX3ES, only KBELN2-74A showed 
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evidence of a covalent adduct between the protein and the small molecule (Figure 
4.5A), indicating our initial hypothesis of the binding pose of TC347 was incorrect. 
 
Previous screening efforts to identify a drug-like electrophile-sensitive DEAD-box 
protein inhibitor uncovered KB3-101 as a semi-potent binder of DDX3ES (data not 
shown). We hypothesized that the positioning of the electrophile in KBELN2-74A may 
indicate that substitution of the C2-position of the quinazoline of KB3-101 may yield 
more potent binders to DDX3ES. To test this, we synthesized a series of KB3-101-
derivatives with substitutions at the C2-position similar to TC347 and TC348 (Figure 
4.5B). Although the 4-hydroxyazetidine-derivative of KB3-101 (KBELN4-53) displayed 
an increased rate of labeling to DDX3ES, these results were not dramatic, and other 
derivatives showed decreased potency compared to the parent compound (Figure 
4.5C). This indicates that further chemical derivatization is necessary to convert TC347 
into a high-affinity electrophile-sensitive DEAD-box protein inhibitor. 
 
Discussion 
We have identified that derivatives of DBeQ, an inhibitor of the AAA+ ATPase p97/VCP, 
inhibit the duplex unwinding activity of DDX3 WT (Figure 4.1). A screen of DBeQ-
derivatives found a preference for N4-(5-phenyl-1H-pyrazol-3-yl)quinazoline-2,4-
diamines and a hydrogen bond donor off the N2-position (Figure 4.2 and 4.3). The most 
potent of these compounds, TC347, shows ATP-competitive inhibition of DDX3 and 
competes with AMP-acrylamide binding to DDX3ES, indicating it binds in the nucleotide-
binding site of DDX3 (Figure 4.4). 
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To our knowledge, this is the first report of an ATP-competitive inhibitor of DDX3, and 
the third report of an ATP-competitive inhibitor of any DEAD-box protein, after the 
recent publications of natural products elisabatin A and allolaurinterol (Figure 1.3A) 
targeting eIF4A and indole-2-carboxylic acids targeting eIF4A3.103,128 In contrast to 
these studies, the small molecules identified in this work show activity at low micromolar 
doses in a stringent RNA duplex unwinding assay, as opposed to an ATPase assay. 
Owing to the large enzyme:RNA substrate ratio used in the duplex unwinding assay, as 
well as the high concentration of ATP, we feel compound activity in this assay is more 
indicative of activity in cellular assays since small molecules must have high 
occupancy/potency to show inhibition in this setting.133  
 
Despite the promising biochemical data, movement towards more complex biochemical 
and cellular studies with these compounds will be complicated by the incomplete picture 
of their activity on other cellular ATPases. From previous work testing DBeQ-derivatives 
against other human AAA+ ATPases, we know that they show varying selectivity 
towards this family (data not shown). It is therefore likely that the compounds identified 
in this work also target a subset of AAA+ ATPases at equal or greater potency than 
DEAD-box proteins. Owing to the hypothesized difference in the binding mode of these 
compounds between DEAD-box proteins and AAA+ ATPases, there are likely chemical 
modifications that can be made to TC347 to antagonize binding to AAA+ ATPases while 
preserving activity in the DEAD-box family. A structural understanding of the binding of 
TC347 to DDX3 will aid in these studies. 
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To combat this assumed lack of selectivity, one could generate TC347-resistant alleles 
of DEAD-box proteins and leverage these mutants to determine the ‘background signal’ 
of other ATPases in a focused biochemical question. Structural studies with TC347 will 
aid in this process, although the invariant nature of the DEAD-box protein nucleotide-
binding site may complicate these efforts.25 Additionally, appending an electrophile off 
these novel binders that specifically targets the engineered cysteine of electrophile-
sensitive DEAD-box proteins would immediately provide a huge boost in potency 
towards the target, and potentially antagonize binding to non-cysteine-containing 
ATPases. Our initial efforts towards this goal were unsuccessful (Figure 4.5), although 
structural studies on TC347 may provide insight to allow for proper electrophile 
placement. 
 
An exciting possibility from these results is the idea that all ATPases, not just p97/VCP 
and NSF, can be targeted with ATP-competitive small molecules. Although we 
anticipate the identification of selective small molecules against the greater than 400 
human ATPases will pose a significant challenge, the generation of non-selective but 
potent chemical inhibitors may provide the first step towards this goal. Further synthesis 
and characterization of the small molecules described in this work is a first step towards 
an understanding of ATP-competitive DEAD-box protein inhibitors. 
 
Materials and Methods 
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Recombinant protein purification. DDX3 (132-406) and DDX3 (132-607) were 
expressed and purified as previously described.133 
 
RNA duplex unwinding assays. RNA duplex unwinding assays were performed as 
previously described153 using 1nM duplex RNA, 2mM ATP/MgCl2, and 1µM DDX3 (132-
607). Reaction buffer contained 20mM HEPES pH 7.5, 100mM NaCl, 0.5mM MgCl2, 
1mM TCEP, 0.01% (v/v) Triton X-100, and 5% glycerol. The sequences of the RNA 
duplex strands are 5’-GCUUUACGGUGC-3’ and 5’-
GAACAACAACAACAACCAUGGCACCGUAAAGC-3’. RNA, protein and inhibitors were 
pre-incubated in reaction buffer for 5min prior to addition of ATP-Mg. Results were 
quantified using ImageJ (NIH).207 
 
Mass spectroscopy assay. DDX3 D1 (132-406) S228C (250nM) or DDX3 D1D2 (132-
607) S228C (500nM) in 10mM Tris pH 7.5, 100mM NaCl and 1mM MgCl2 was 
incubated with compounds at the indicated doses at room temperature. For competition 
experiments, compounds were pre-incubated with the protein in reaction buffer for 2min, 
followed by addition of 10µM AMP-acrylamide. The extent of modification at various 
time points was determined by whole protein mass spectrometry using a Waters Acquity 
UPLC/G2-XF QTOF. Reported data points are single-replicates. Curves are fit using 
Prism (GraphPad). 
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Figure 4.1. Screen of DBeQ-derivatives identifies small molecule inhibitors of DDX3. 
 
A. Structure of p97/VCP inhibitor DBeQ. B and C. Single dose (100µM) screen of select 
AAA+ ATPase-inhibitors based on DBeQ against DDX3 WT (B), quantified in (C) with 
lines corresponding to standard deviations from the DMSO control (Z=1 – one standard 
deviation, Z=2 – two standard deviations). 
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Figure 4.2. Structure-activity relationship (SAR) of DBeQ-derivatives and DDX3. 
 
A. The effect of methylthiazole derivatives of DBeQ on the RNA-duplex unwinding 
activity DDX3 WT, with structures in insert. B. The effect of substituted pyrazole 
derivatives of DBeQ on the RNA-duplex unwinding activity DDX3 WT, with structures in 
insert. C and D. TC327 (C) and TC391 (D) inhibit the RNA duplex unwinding activity of 
DDX3 WT in a dose responsive manner. 
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Figure 4.3. Structure-activity relationship (SAR) of TC327/TC391-derivatives and 
DDX3. 
 
A and B. Substitutions at the phenyl ring of N4-(5-phenyl-1H-pyrazol-3-yl)quinazoline-
2,4-diamines dramatically alter inhibition of the RNA duplex unwinding activity of DDX3 
WT. C. Substitutions at the 2-position of N4-(5-(4-chlorophenyl)-1H-pyrazol-3-
yl)quinazoline-2,4-diamines show robust SAR against DDX3 WT and yield TC347 and 
TC348 as lead compounds. 
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Figure 4.4. TC347 is an ATP-competitive DDX3 WT inhibitor. 
 
A. Chemical structures of TC347 and control compound TC355. B. Monitoring the 
duplex unwinding activity of DDX3 WT in the presence of a dose response of TC347 
(50µM, 12.5µM, 3.13µM) at varying doses of ATP (0.2mM, 2mM, 10mM). C. 
Lineweaver-Burk plot of the effect of ATP concentration on the duplex unwinding activity 
of DDX3 WT. D and E. Competition of labeling of DDX3ES (S228C) by AMP-acrylamide 
in the presence of doses of TC347 (D) or TC355 (E). 
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Figure 4.5. Moving towards more drug-like irreversible inhibitors of DDX3ES. 
 
A. KBELN2-74A, but not derivatives with an altered position of the electrophile, labels 
DDX3ES. B. Derivatives of KB3-101 with substituents at the C2-position of the 
quinazoline ring. C. Derivatives of KB3-101 with substitutions at the C2-position of the 
quinazoline ring show variable rates of labeling of domain 1 only (D1) of DDX3ES and 
the full helicase domain (D1D2) of DDX3ES. 
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Chapter 5 
 
 
Analyzing CDK4 complexes to expand the efficacy of clinical CDK4/6 inhibitors 
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Introduction 
The cell cycle is an evolutionarily conserved process across all eukaryotic cells by 
which DNA replication and cell division occurs.223 The cell cycle consists of two gap 
phases, G1 and G2, S-phase, and M-phase; cells outside of the cell cycle, typically 
quiescent or resting cells, are maintained G0. Interphase encompasses G1, S-phase and 
G2; cellular components are duplicated during G1, DNA replication occurs during S-
phase, and additional protein synthesis occurs and replicated DNA is error-checked 
during G2. The stages of mitosis and cytokinesis occur during M-phase (Figure 5.1A).224 
These coordinated events are tightly regulated by extracellular ligands and intracellular 
signaling whereby information from environmental cues and nutrient levels is integrated 
into a binary decision of whether a cell has the proper resources for division.225 As such, 
in states of rapid unrestrained proliferation such as cancer, there are fundamental 
alterations in the genetic and signaling control of the cell cycle.225 
 
Cyclins and cyclin-dependent kinases (CDKs) are intimately involved in the regulation of 
the cell cycle.226 Cyclins, as their name suggests, are a class of protein that are 
synthesized and destroyed during different stages of the cell cycle. D-type cyclins are 
abundant during G1, E-type cyclins during the G1/S-phase transition, A-type cyclins 
during S-phase to the G2/M boundary, and B-type cyclins from early G2 until 
cytokinesis.223 Cyclins function as obligate allosteric activators of cyclin-dependent 
kinases, which are serine/threonine kinases that phosphorylate cell cycle proteins to 
maintain the unidirectional nature of the cell cycle.223 CDK4 and CDK6 associate with D-
type cyclins during G1, CDK2 with E- and A-type cyclins during G1/S-phase and S-
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phase/G2, respectively, and CDK1 associates with A- and B-type cyclins during G2/M 
(Figure 5.1A).226 Interestingly, CDK1 is the only essential CDK in mammalian cells.227 
 
The dysregulation of CDK activity is commonly observed in hyperproliferative disorders 
such as cancer.227 This is often through loss of negative regulators of cell cycle 
progression, including loss of CDKN2A, which encodes p16INK4A, a small protein 
inhibitor of CDK4/6, or loss of CDKN1A or CDKN1B, which encode p21Cip1 and p27Kip1, 
respectively, small protein inhibitors of CDK4/6 and CDK2.227 The tumor suppressor 
retinoblastoma protein (Rb), the major downstream target of cyclin D-CDK4/6 and a 
negative regulator of the E2F family of transcription factors (Figure 5.1B), is also 
commonly mutated or deleted in cancer.227 Overexpression and amplification of D- and 
E-type cyclins is also observed.228 
 
Owing to their central role in cell cycle progression, small molecule inhibitors targeting 
CDKs are highly sought after as anti-cancer therapeutics.229 Flavopiridol, a 
polyhydroxylated flavonoid and the first identified pan-CDK inhibitor, was discovered in 
1992 as a potent inhibitor of cancer cell growth in vitro.230 More selective inhibitors of 
many cell cycle CDKs have been developed and advanced into clinical trials, although 
there has been limited clinical success.227,229 More recently, several selective CDK4/6 
inhibitors (palbociclib, ribociclib, and abemaciclib from Pfizer, Novartis/Astex, and Eli-
Lily, respectively) were clinically approved for the treatment of ER-positive breast 
cancer (Figure 5.1C).231  However, these compounds are only approved as co-therapies 
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with ER-antagonists or aromatase inhibitors,232-234 and despite being low nanomolar 
biochemical inhibitors of CDK4/6, have shown limited efficacy as monotherapies.235 
 
To better understand the lack of efficacy of CDK4/6 inhibitors as monotherapy, we 
confirmed that the most selective clinically approved CDK4/6 inhibitor, ribociclib, shows 
limited efficacy as a monotherapy in breast and non-breast cell culture cells. We then 
identify that only a portion of cellular CDK4 is competent to bind an irreversible kinase 
active-site probe and that this fraction of CDK4 varies across different cell types. 
Cellular fractionation studies revealed CDK4 exists in several high molecular weight 
complexes within the cell, and these high molecular weight complexes appear to shield 
CDK4 from small molecule inhibitors. Lastly, we find that knockdown of Cyclin D1 
improves the efficacy of ribociclib in cell culture, and synthesize a novel ribociclib analog 
that disrupts the CDK4-cyclin D1 complex leading to cyclin D1 degradation. 
 
Results 
Ribociclib shows limited efficacy as a monotherapy in cell culture 
To confirm clinical observations of low efficacy of CDK4/6 inhibitors as monotherapy,235 
we tested ribociclib in two breast cancer cell lines, MCF7 and BT549, and three KRas 
G12C cell lines, H23, H358, and MIA PaCa-2. In all cell lines, ribociclib showed limited 
efficacy, with IC50s greater than 10µM after three days of culture (Figure 5.1D). 
Notably, CDK4/6 inhibitors display increased efficacy over longer assay times (Pfizer 
reported treatments up to five days for cellular assays),236 possibly suggesting high on-
target potency but limited target accessibility. Ribociclib was especially ineffective in 
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BT549 cell lines, as previously reported.237 This matches clinical data since BT549 cells 
are Rb-null, and therefore should not be dependent on CDK4/6 activity for cell cycle 
progression. 
 
Kinase active site probe, XO44, partially labels CDK4 in MCF7, but not BT549, 
cells 
To better understand the limited efficacy of ribociclib in these cell lines, we tested the 
hypothesis that low ribociclib activity was due to poor target accessibility, as previously 
suggested for palbociclib.237 To test this, we utilized a cell-active kinase active site 
probe (XO44), that forms a covalent bond with the conserved catalytic lysine of protein 
kinases.238 We added XO44 to proliferating MCF7 cells, used click chemistry to attach 
TAMRA-N3, and observed the proportion of CDK4 bound by XO44 by gel shift (Figure 
5.2A). A kinase that is unlabeled by XO44 will run at its expected molecular weight, a 
kinase fully labeled by XO44 will display a full gel shift, and a kinase partially labeled by 
XO44 will run as a double band.  
 
We observed that CDK4 is partially labeled by XO44 in MCF7 cells (Figure 5.2B). This 
labeling is competed by a non-clickable version of XO44 (KL-E2-94), the non-specific 
kinase inhibitor staurosporine, and ribociclib (Figure 5.2B). This demonstrates that a 
portion of CDK4 within MCF7 cells is incapable of binding small molecule inhibitors 
related to XO44, and that the population of CDK4 bound by ribociclib includes the entire 
portion bound by XO44. In contrast, we observed no gel shift in CDK4 after similar 
treatment of BT549 cells with XO44, while a complete gel shift was seen in Aurora B 
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(Figure 5.2C). This indicates that the entirety of CDK4 within BT549 cells exists in a 
state that is inaccessible to small molecule inhibitors. To confirm the partial labeling of 
CDK4 in MCF7 cells was not a result of the dose of XO44, we treated MCF7 cells with 
increasing doses of XO44. We observed that XO44-labeling of CDK4 saturates at ~50% 
of total at single-digit micromolar doses, whereas XO44-labeling of CDK2 saturates at 
~90% (Figure 5.2D). Therefore, using a kinase active site probe, we determined that 
half of the CDK4 in MCF7, and all of the CDK4 in BT549 cells, exists in a state that is 
incompetent of binding small molecule inhibitors. 
 
CDK4 complexes vary across cell lines 
Owing to its central role in initiating cell cycle progression, CDK4 activity is tightly 
regulated through numerous interacting partners. Hsp90 and its kinase-specific co-
chaperone Cdc37 are required for the initial folding of most human kinases.239 As a 
strong client of Hsp90, CDK4 is unstable as a monomer, and thus protein co-factors are 
thought to be required for the displacement of CDK4 from the chaperone system.240 D-
type cyclins have been hypothesized to perform this function, and ATP-competitive 
inhibitors, including palbociclib and ribociclib, can also antagonize the CDK4-Cdc37 
interaction.241 Additionally, CDK4 forms tight interactions with small protein inhibitors of 
the INK4 family, including p16INK4A and p18INK4C,242,243 and Cip/Kip family, including 
p21Cip1 and p27Kip1.244,245 It has been reported that the CDK4-Cyclin D-p27Kip1 complex 
contains the catalytically active CDK4.246 
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To observe the native complexes in which CDK4 exists in MCF7 and BT549 cells, 
protein lysates from these cell lines were subjected to native gel filtration to separate 
cellular complexes by size.246 The fractionated lysates were then analyzed by western 
blotting (Figure 5.3A). We observed that in MCF7 cell lysates, CDK4 is found in a 
~500kDa complex with Hsp90 and Cdc37, in a ~200kDa complex with Cyclin D1 and 
p27Kip1, and in a ~60kDa complex with INK4 family members (Figure 5.3B). As 
previously reported, no CDK4-Cyclin D dimers are observed,246 suggesting this complex 
may not exist without additional cofactors. In contrast, in BT549 cell lysates CDK4 is 
found entirely in a ~60kDa complex with INK4 family members. Since BT549 cells are 
Rb-null, this indicates that the cell can sense its lost requirement for CDK4/6 in cell 
cycle progression, and inactivates CDK4 with INK4 proteins. CDK2 additionally shows 
altered complex formation between these cell lines – it is located predominantly as a 
monomer and in a >200kDa complex in MCF7 cell lysates, while it appears to exist as a 
monomer, in ~60kDa complexes, and in ~150kDa complexes in BT549 lysates (Figure 
5.3B). Therefore, CDK2 and CDK4 are dynamically distributed into high-molecular 
weight complexes that differ between MCF7 and BT549s cells. 
 
CDK4 complexes are resistant to active site probe binding 
To determine which CDK4 and CDK2 complexes are capable of binding small molecule 
active-site inhibitors, we treated cells with XO44 and subjected these lysates to gel 
filtration chromatography and then performed the click reaction on individual fractions 
(Figure 5.3C). We observed that after XO44 treatment, CDK4 is no longer localized into 
~500kDa complexes with Hsp90/Cdc37, likely because ATP-competitive inhibitors 
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antagonize the CDK4-Cdc37 interaction.241 Instead, CDK4 is localized predominantly in 
~200kDa complexes, ~60kDa complexes, and as a monomer. Only the monomeric 
CDK4 displays a gel shift, indicating that CDK4-cyclinD-p27Kip1 complexes are 
insensitive to active site inhibitors (Figure 5.3C). XO44 displays a similar labeling 
pattern of CDK2 – high molecular weight complexes are insensitive while monomeric 
CDK2 is fully labeled. These results indicate that active site inhibitors mature CDK4 
from Hsp90/Cdc37-bound complexes and stabilize a small molecule-bound monomer. 
Additionally, we found that the CDK4-cyclin D-p27Kip1 complex is resistant to small 
molecule binding, and therefore may represent a signaling competent, but active site 
inhibitor-resistant, state of CDK4. 
 
Knockdown of cyclin D1 improves efficacy of ribociclib in cell culture 
If the CDK4-cyclin D-p27Kip1 complex is active in the presence of CDK4 active-site 
inhibitors, we hypothesized that reducing cyclin D protein levels would decrease the 
abundance of this complex and sensitize cells to CDK4/6 inhibitors. Therefore, we used 
siRNA to knockdown cyclin D1 or CDK4 in NIH3T3 cells and tested for increased 
cellular sensitivity to ribociclib. We observed that NIH3T3 cells show increased 
sensitivity to ribociclib in combination with cyclin D1 knockdown in both cell growth 
(Figure 5.4A), cell cycle arrest (Figure 5.4B), and apoptosis (Figure 5.4C). A western 
blot analysis of cellular signaling also showed increased p-Rb sensitivity to ribociclib in 
combination with cyclin D1 knockdown (Figure 5.4D). Knockdown of CDK4 had little 
effect on NIH3T3 cell sensitivity to ribociclib (Figure 5.4A-D). These results indicate that 
knockdown of cyclin D1 levels increase cellular sensitivity to ribociclib, and suggests 
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that targeting cyclin D1 for degradation may have additive effects with CDK4 active site 
inhibitors. 
 
Synthesis of type II analogs of ribociclib 
Our research group has previously had success developing kinase active-site inhibitors 
to antagonize kinase protein-protein interactions. Briefly, one of these small molecules 
stabilized an inactive aC-helix-out conformation of Aurora A to disrupt its stabilization of 
Myc-N and target it for degradation.247 We hypothesized that similar ‘type II’ inhibitors of 
CDK4 may disrupt its interaction with cyclin D, altering its incorporation into high 
molecular weight complexes and potentially leading to its degradation.248 Therefore we 
generated a series of twenty-nine derivatives of ribociclib (named CDK4i) with various 
type II kinase inhibitor elements (Figure 5.5A).249  
 
Ribociclib analogs disrupt the CDK4-cyclin D1 interaction and promote cyclin D1 
degradation in cells 
To screen these small molecules for their capability to disrupt the CDK4-cyclin D 
interaction, we generated a reversible fluorogenic reporter of this interaction using split 
UnaG.250 This technology allows for the direct monitoring of the CDK4-cyclin D1 
interaction in cells using live imaging (Figure 5.5B). While ribociclib treatment does not 
affect the CDK4-cyclin D1 interaction, we found that several CDK4i were capable of 
disrupting this complex after two hours at 10µM (Figure 5.5C-D). The most robust 
decrease in fluorescence was observed with CDK4i-8 and CDK4i-16, which are 
structurally related. To confirm these results are not an artifact of the fluorogenic 
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reporter assay, we tested these compounds in NIH3T3 cells and found that both 
compounds induce a marked decrease in cyclin D1, but not cyclin E, after 24 hours 
(Figure 5.5E). These results demonstrate that active site inhibitors of CDK4 can be 
expanded to induced cyclin D1 degradation through increased steric bulk pointing 
towards the aC-helix. 
 
Discussion 
We have demonstrated that the active-site inhibitor of CDK4/6, ribociclib, shows limited 
efficacy as a monotherapy in cell culture (Figure 5.1). We determined that only a portion 
of CDK4 is accessible to bind an active site probe, XO44, and that this fraction is 
different in MCF7 and BT549 cell lines, in a manner that is consistent with their genetic 
background (Figure 5.2). Using lysate fractionation, we found that CDK4 exists in high 
molecular weight complexes, and that CDK4 in complex with cyclin D and p27Kip1 is 
incapable of binding XO44 (Figure 5.3). We then used siRNA knockdown of cyclin D1 to 
show that reducing cyclin D protein levels increases cellular sensitivity to ribociclib 
(Figure 5.4), and developed novel chemical derivatives of ribociclib that disrupt the 
CDK4-cyclin D interaction and promote cyclin D1 degradation in cells (Figure 5.5). 
 
Our results using a kinase active-site probe and the fractionation of cell lysates have 
helped uncover which CDK4 complexes are capable of binding active-site inhibitors. 
The increase in monomeric CDK4 and loss of Hsp90-Cdc37-bound CDK4 after XO44 
treatment confirm previous biochemical and cellular studies indicating a release of 
kinases from the chaperone system upon small molecule binding.241,251 That this hand-
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off is complete after the short timescale of this experiment (30 minutes), indicates that 
the Hsp90-Cdc37-CDK4 complex exists in a rapidly-exchanging equilibrium. In contrast, 
no labeling of cyclin D-p27Kip1-bound CDK4 is observed and the abundance of this 
complex shows little, if any, change, suggesting this complex exists in a slowly-
exchanging equilibrium and that CDK4 in this complex is incapable of binding active-site 
inhibitors. The complete lack of XO44 binding by CDK4 in BT549 cells indicates that the 
CDK4-INK4 complex is also recalcitrant to active-site binders and that this complex also 
exists in a slowly-exchanging equilibrium. Therefore, our results indicate that the only 
fraction of CDK4 capable of binding small molecule active-site inhibitors in cells is in 
Hsp90-Cdc37-bound complexes.  
 
Since all experiments using XO44 relied on an observed gel shift of the target kinase 
(CDK4 or CDK2), it is possible that differential PTMs on CDK2 or CDK4 may influence 
its gel shift, leading to a false negative conclusion regarding XO44-binding. To control 
for this potential confounder, we plan to immunoprecipitate CDK4 from fractionated 
lysates and directly test for XO44 labeling by TAMRA fluorescence. This type of 
experiment – immunoprecipitation of CDK4 from fractionated lysates – will also directly 
confirm that proteins that co-elute with CDK4 by gel filtration are directly bound. 
 
Remaining questions from these results surround the dynamics of these complexes, i.e. 
on what timescale does CDK4 exchange from one complex to another or is a CDK4 
molecule stuck within a single one of these complexes for its cellular lifetime? A model 
proposed by Hallett and colleagues241 suggests that after initial CDK4 folding within the 
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chaperone system, CDK4 is transiently released as a monomer and is quickly bound 
and stabilized by small molecule inhibitors or by protein cofactors such as cyclin D, 
p27Kip1 or INK4 family members. The chaperone system has therefore been proposed to 
provide an additional layer of regulation of client proteins, since the relative abundance 
of protein cofactors will influence the equilibrium state of these complexes.239 We clearly 
observe this, as siRNA-knockdown of cyclin D1, which one would anticipate 
antagonizes the CDK4-cyclin D-p27Kip1 complex and thus shifts the CDK4 equilibrium 
towards a Hsp90-Cdc37-bound state, increases the efficacy of ribociclib. Tumors with 
low Cip/Kip-family expression might therefore be expected to exhibit sensitivity to 
CDK4/6 inhibitors. 
 
An additional outstanding question regarding CDK4-interacting proteins involves the 
role of the Hsp70-family, which were previous demonstrated to bind CDK4-cyclin D-
p27KIP1 complexes in vitro and in vivo.252 Our results replicate those of Diehl and 
colleagues, as CDK4-cyclin D-p27KIP1 complexes run with at an observed molecular 
weight of ~150-200kDa by gel filtration chromatography (Figure 5.3C), suggesting there 
are additional members of this protein complex. If Hsp70s indeed assist in the initial 
folding of D-type cyclins and assembly of the CDK4-cyclin D-p27KIP1 complex as 
hypothesized, this would add an additional level of complexity to the regulation of CDK4 
by associated proteins, and may suggest that CDK4/6 inhibitors will demonstrate 
efficacy as co-therapy with Hsp70 inhibitors. 
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Why are CDK4/6 inhibitors ineffective as monotherapy but effective in the clinic in 
combination with aromatase inhibitors and other estrogen receptor antagonists? 
Mitogenic and hormone receptor signaling upregulate cyclin D1 transcription to promote 
cell cycle progression.228 Small molecules that antagonize cyclin D1 transcription by 
targeting mitogenic or hormone receptor signaling reduce cyclin D1 levels. Similar to our 
results using siRNA-knockdown of cyclin D1, this sensitizes cells to CDK4/6 inhibition, 
possibly by reducing active, but inhibitor resistant CDK4-cyclin D-p27Kip1 complexes. 
This explains why other inhibitors of mitogenic signaling also show promise as co-
therapies with CDK4/6 inhibitors.253 
 
However, a single agent that exhibits these characteristics (active-site inhibitor of CDK4 
and decrease cyclin D levels) would be ideal. Our newly developed CDK4i compounds 
were designed to stabilize a conformation of CDK4 that should disrupt the CDK4-cyclin 
D interaction through outward movement of the kinase aC-helix. Further 
characterization is needed, but we anticipate CDK4i are also incapable of binding to 
CDK4-cyclin D-p27Kip1 and CDK4-INK4 complexes and therefore remain dependent on 
targeting a transient monomeric state of CDK4/6 for activity. These compounds may 
distinguish themselves from existing clinical CDK4/6 inhibitors indirectly, first through 
the degradation of cyclin D, leading to reduced CDK4-cyclin D-p27Kip1 complexes and 
the transitioning of CDK4 to the chaperone system where it is more accessible to small 
molecule binding. Additional screening for small molecule scaffolds with high affinity for 
the CDK4-cyclin D-p27Kip1 trimer may provide an additional path towards improving 
CDK4/6 inhibitor efficacy. Thus, through chemical screening of inhibitor-resistant 
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complexes, and rational design of molecules with novel chemical characteristics, we 
may be able to develop state-specific CDK4 inhibitors to expand their therapeutic 
efficacy in the clinic. 
 
Materials and Methods 
Cell culture. All cells were maintained in Dulbecco’s modified eagle medium (DMEM) 
supplemented with 10% fetal bovine serum and 1% pen/strep and grown in a 37ºC 
incubator at 5% CO2. For western blotting, ~500,000 cells were plated in 6-well plates at 
full serum for 24hr, then treated with compounds in the same media for an additional 
24hrs. For viability assays, cells were plated at 1,000 cells/well in a 96-well plate for 
24hrs, then compounds were added along with fresh media.  
 
Cell viability assay. Cell viability assays were performed using CellTiter-Glo (Promega) 
according to the manufacturer’s instructions, except 1/5 of the recommended 
luminescent reagent was used. 
 
XO44-labeling experiments. XO44 labeling experiments were performed as described 
using 2µM XO44 for 30min.238 Click reactions were incubated at room temperature for 
1hr. 
 
Gel filtration assay. Gel filtration assays on crude cell lysates were performed as 
previously described.246 Briefly, ~25 million cells are lysed in lysis buffer (50mM Tris pH 
7.5, 150mM NaCl, 1% NP-40, 10% glycerol, 1mM EDTA) plus complete protease 
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inhibitor cocktail (Roche) on ice for 20min. Lysates are then clarified by centrifugation at 
18,000 x g for 15min, incubated with DNaseI (1 unit/mg lysate) for 20min on ice, and 
clarified again. Samples are then diluted to 10mg/mL and 5mg is loaded on a 
Superdex200 column pre-equilibrated in 50mM HEPES pH 7.5, 150mM NaCl, 1% NP-
40, 10% glycerol. The column is run for 1.25CV at 0.35mL/min and 0.5mL fractions are 
collected starting at 5mL. 
 
Split UnaG assay. HEK293T cells were transfected using calcium phosphate with 
pCDNA3.1-CDK4-cUnaG-T2A-nUnaG-CCND1 and pCDNA3.1-mIFP-H2B-T2A-
mCherry.  
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Figure 5.1. Clinical CDK4/6 inhibitors show limited efficacy as monotherapy. 
 
A. The cell cycle is tightly controlled by Cyclin-CDK complexes, including the CDK4/6-
Cyclin D (G1 phase), CDK2-Cyclin E (G1/S transition), CDK2-Cyclin A (S and G2 
phases), and CDK1-Cyclin B (G2/M phases). B. CDK4/6-Cyclin D complexes integrate 
mitogenic and antiproliferative signals to initiate cell cycle progression through the 
phosphorylation of retinoblastoma protein (Rb). C. Chemical structures of clinically 
approved CDK4/6 inhibitors. D. Decreased viability of breast cancer cell lines (MCF7, 
BT549) and KRas G12C cancer cell lines (H23, H358, MIA PaCa-2) in response to 
ribociclib. 
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Figure 5.2. CDK4 is partially labeled by XO44 in MCF7, but not BT549, cells. 
 
A. Scheme for XO44 labeling of cellular kinases and the separation of XO44-labeled 
and unlabeled kinases by western blotting. B and C. Western blot of CDK4 from MCF7 
(B) or BT549 cells (C) treated with 2µM XO44 after pre-treatment with KL-E2-94, 
staurosporine, or ribociclib. D. Western blot of CDK4 and CDK2 from MCF7 cells 
treated with increasing concentrations of XO44 for 30min. 
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Figure 5.3. CDK4 complexes vary across cell lines and influence small molecule 
accessibility.  
 
A. Scheme for the fractionation of cell lysates followed by western blotting to 
understand CDK high-molecular weight complexes. B. Fractionation of MCF7 and 
BT549 cell lysates shows CDK4 and CDK2 exist in differential high-molecular weight 
complexes. C. Fractionation of MCF7 cells treated with 2µM XO44 for 30min. 
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Figure 5.4. Knockdown of cyclin D1 improves efficacy of ribociclib in cell culture. 
 
A. Relative growth of NIH3T3 cells in response to three doses of ribociclib in the 
presence of siRNA control (scramble) or siRNA targeting Cyclin D1 or CDK4. B. 
Changes in cell cycle after ribociclib treatment in the presence of siRNA control 
(scramble) or siRNA targeting Cyclin D1 or CDK4. C. Induction of apoptosis, as 
measured by annexin V staining, after ribociclib treatment in the presence of siRNA 
control (scramble) or siRNA targeting Cyclin D1 or CDK4. D. Cell signaling after 
ribociclib treatment in the presence of siRNA control (scramble) or siRNA targeting 
Cyclin D1 or CDK4.  
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Figure 5.5. Ribociclib analogs disrupt CDK4-cyclin D1 interaction and promote cyclin 
D1 degradation in cells. 
 
A. Chemical structure of ribociclib and CDK4i analogs. B. Fluorogenic assay of the 
CDK4-Cyclin D1 protein-protein interaction using split UnaG. C. Screen of CDK4i 
(10µM, 2hr) activity in the disruption of the CDK4-Cyclin D1 complex. D. Representative 
images showing the CDK4-Cyclin D1 interaction in the presence of ribociclib or CDK4i-8 
after 0hr and 2hr. E. Western blot of NIH3T3 cells treated for 24hr with ribociclib or 
increasing doses of CDK4i-8 and CDK4i-16. 
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Chemical Synthesis 
Materials obtained commercially were reagent grade and were used without further 
purification. Reactions were monitored by thin layer chromatography (TLC) and/or mass 
spectrometry (LCMS) using a Waters Acquity UPLC/ESI-TQD (low-res.) or Waters 
Acquity UPLC/ESI-G2 XS QTOF (high-res.). All NMR spectra were obtained on a 
Brucker 400 spectrometer. 
 
Scheme 1 
 
 
5-bromo-2-chloro-N-cylopentylpyrimidin-4-amine (1). To a solution of 5-bromo-2,4-
dichloropyrimidine (3g, 13.17mmol) in 1,4-dioxane (25mL) was added triethylamine 
(2.75mL, 19.75mmol, 1.5eq) followed by cyclopentylamine (1.69mL, 17.12mmol, 1.3eq) 
and the reaction was stirred at RT. After completion, the reaction mixture was 
evaporated to dryness under reduced pressure and the resulting solid was dissolved in 
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EtOAc/brine and the organic layer was isolated, dried with Na2SO4 and evaporated to 
dryness under reduced pressure. The resulting oil was purified by silica chromatography 
(0-25% EtOAc/hexanes) to yield the product as a yellow/white solid (3341mg, 91.7% 
yield). 1H NMR (400MHz, CDCl3) δ 8.11 (s, 1H), 5.46 (d, J = 7.5 Hz, 1H), 4.43 (h, J = 
7.0 Hz, 1H), 2.21 – 2.08 (m, 2H), 1.85 – 1.60 (m, 4H), 1.56 – 1.41 (m, 2H). 
 
2-chloro-N-cyclopentyl-5-(3,3-diethoxyprop-1-yn-yl)pyrimidin-4-amine (2). To a 
35mL microwave vial charged with anhydrous THF (18mL) under Ar(g) was added 
intermediate 1 (1.5g, 5.42mmol). This solution was purged of oxygen with Ar(g) and 
[1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with 
dichloromethane (221.46mg, 0.2700mmol, 0.05eq) was added, and the solution was 
purged again. Triethylamine (1889.92uL, 13.56mmol, 2.5eq) and 3,3-diethoxyprop-1-
yne (1943.98uL, 13.56mmol, 2.5eq) were added slowly. The reaction was heated to 
140ºC for 1hr in microwave reactor, then cooled, filtered through celite, and evaporated 
to dryness under reduced pressure. The resulting oil was purified by silica 
chromatography (0-25% EtOAc/hexanes) to yield the pure product as a brown oil 
(657mg, 37.4%). 1H NMR (400MHz, CDCl3) δ 8.11 (s, 1H), 5.58 (d, J = 7.5 Hz, 1H), 
5.52 (s, 1H), 4.45 (h, J = 7.0 Hz, 1H), 3.80 (dq, J = 9.5, 7.1 Hz, 2H), 3.68 (dq, J = 9.4, 
7.0 Hz, 2H), 2.20 – 2.07 (m, 2H), 1.72 (dddd, J = 28.8, 14.4, 7.1, 4.1 Hz, 4H), 1.48 (dq, 
J = 12.3, 5.9 Hz, 2H), 1.30 (t, J = 7.1 Hz, 7H). LCMS (TOF) m/z calculated 322.1328 
(M-H)–, found 322.1356. 
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2-chloro-7-cyclopentyl-6-(diethoxymethyl)-7H-pyrrolo[2,3-d]pyrimidine (3). To a 
solution of intermediate 2 (657mg, 2.03mmol) in THF (1mL) was added 
tetrabutylammonium fluoride (1M solution in THF; 8.12mL, 8.12mmol, 4eq) and the 
resulting solution was heated to 40ºC for 40min. The reaction was cooled, evaporated to 
dryness under reduced pressure, and purified by silica chromatography (0-20% 
EtOAc/hexanes) to yield the pure product as a light brown oil (653.1mg, 99.4% yield). 
1H NMR (400MHz, CDCl3) δ 8.74 (s, 1H), 6.62 (d, J = 0.7 Hz, 1H), 5.67 (s, 1H), 5.00 (p, 
J = 8.7 Hz, 1H), 3.62 (dtt, J = 16.4, 9.4, 7.0 Hz, 5H), 2.46 (ddd, J = 17.0, 8.6, 4.4 Hz, 
2H), 2.22 – 2.10 (m, 2H), 2.10 – 1.95 (m, 2H), 1.72 (tt, J = 6.8, 2.9 Hz, 2H), 1.27 (t, J = 
7.1 Hz, 7H). LCMS (TOF) m/z calculated 324.1473 (M+H)+, found 324.1416. 
 
2-chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidine-6-carbaldehyde (4). 
Intermediate 3 (653.1mg, 2.02mmol) was dissolved in water (900µL) and acetic acid 
(7.2mL) and stirred overnight. The solution was added to saturated NaHCO3 and 
extracted with EtOAc. The combined organic layers were dried with Na2SO4, filtered, 
and concentrated under reduced pressure. The resulting oil was purified by silica 
chromatography to yield the pure product as a clear oil (433.1mg, 86.0% yield). 1H NMR 
(400MHz, CDCl3) δ 9.96 (s, 1H), 9.02 (s, 1H), 7.35 (s, 1H), 5.78 (p, J = 8.8 Hz, 1H), 
2.37 – 2.23 (m, 2H), 2.22 – 2.03 (m, 4H), 1.84 – 1.67 (m, 2H). LCMS (TOF) m/z 
calculated 250.0742 (M+H)+, found 250.0731. 
 
2-chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid (5). To a 
solution of intermediate 4 in DMF (2mL) and water (200µL) was added oxone (228.5mg, 
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1.5mmol, 2.5eq) and the resulting suspension was heated to 70ºC. Additional oxone 
was added as needed until the reaction was judged complete by LCMS. The reaction 
was cooled, dissolved in DCM and extracted with 1M NaOH. Hydrochloric acid (1M) 
was added to the combined aqueous layers until pH~1, and this solution was extracted 
with EtOAc to yield the pure product as a tan solid (111.8mg, 70.0% yield). 1H NMR 
(400 MHz, Acetone-d6) δ 9.05 (s, 1H), 7.48 (s, 1H), 5.91 (p, J = 8.7 Hz, 1H), 2.43 (ddd, 
J = 13.4, 9.8, 6.1 Hz, 2H), 2.17 – 2.02 (m, 4H), 1.74 (tq, J = 10.5, 4.9, 4.5 Hz, 2H). 
LCMS (TOF) m/z calculated 266.0691 (M+H)+, found 266.0718. 
 
General procedure for the synthesis of intermediates 6-20.  
To a solution of intermediate 4 (20mg, 0.080mmol) in 9:1 methanol:acetic acid was 
added the appropriate aromatic amine (0.200mmol, 2.5eq) and the resulting solution 
was stirred at RT for 4hr. Sodium cyanoborohydride (10mg, 0.160mmol, 2eq) was then 
added and the reaction was stirred at RT overnight. The reaction was added to 
saturated NaHCO3 and extracted with EtOAc. The combined organic layers were dried 
with Na2SO4, filtered, concentrated under reduced pressure, and purified by silica 
chromatography to yield intermediates 6-20. 
 
N-((2-chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)methyl)-3-
(trifluoromethyl)aniline (6). White solid (7.8mg, 27.7% yield). LCMS (TQD) m/z 
calculated 395.12 (M+H)+, found 395.11. 
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1-(4-(((2-chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-6-
yl)methyl)amino)phenyl)cyclopentane-1-carbonitrile (7). White solid (25.7mg, 76.4% 
yield). 1H NMR (400MHz, CDCl3) δ 8.68 (s, 1H), 7.34 – 7.29 (m, 2H), 6.75 – 6.63 (m, 
2H), 6.49 (s, 1H), 4.88 (p, J = 8.5 Hz, 1H), 4.51 (d, J = 5.3 Hz, 2H), 4.08 (t, J = 5.3 Hz, 
1H), 2.54 – 2.33 (m, 4H), 2.20 – 1.86 (m, 10H), 1.81 – 1.68 (m, 2H). LCMS (TOF) m/z 
calculated 420.1950 (M+H)+, found 420.1934. 
 
3-(tert-butyl)-N-((2-chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)methyl)-1-
methyl-1H-pyrazol-5-amine (8). White solid (21.3mg, 68.7% yield). 1H NMR (400MHz, 
CDCl3) δ 8.64 (s, 1H), 6.46 (s, 1H), 5.53 (s, 1H), 4.85 (p, J = 8.4 Hz, 1H), 4.39 (s, 2H), 
3.65 (s, 3H), 2.44 (dt, J = 14.7, 7.7 Hz, 2H), 2.21 – 2.00 (m, 4H), 1.80 – 1.65 (m, 2H), 
1.32 (s, 9H). LCMS (TOF) m/z calculated 387.2058 (M+H)+, found 387.2038. 
 
3-(tert-butyl)-N-((2-chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)methyl)-1-
(p-tolyl)-1H-pyrazol-5-amine (9). White solid (18.2mg, 49.1% yield). LCMS (TQD) m/z 
calculated 463.24 (M+H)+, found 463.22. 
 
N-((2-chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)methyl)-3-(4-methyl-1H-
imidazol-1yl)-5-(trifluoromethyl)aniline (10). White solid (11.3mg, 29.7% yield). 
LCMS (TQD) m/z calculated 475.16 (M+H)+, found 475.15. 
 
3-(tert-butyl)-N-((2-chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)methyl)-1-
isopropyl-1H-pyrazol-5-amine (11). White solid (27.9mg, 83.9% yield). 1H NMR 
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(400MHz, CDCl3) δ 8.67 (s, 1H), 6.48 (s, 1H), 5.53 (s, 1H), 4.89 (p, J = 8.6 Hz, 1H), 
4.39 (d, J = 6.0 Hz, 2H), 4.35 – 4.26 (m, 1H), 3.41 (t, J = 6.0 Hz, 1H), 2.45 (ddt, J = 
14.6, 8.5, 3.7 Hz, 2H), 2.22 – 2.01 (m, 6H), 1.80 – 1.65 (m, 2H), 1.44 (d, J = 6.7 Hz, 
6H), 1.31 (s, 9H). LCMS (TQD) m/z calculated 415.24 (M+H)+, found 415.29. 
 
1,3-di-tert-butyl-N-((2-chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-6-
yl)methyl)-1H-pyrazol-5-amine (12). White solid (19.0mg, 84.4% yield). 1H NMR 
(400MHz, CDCl3) δ 8.72 (s, 1H), 6.51 (s, 1H), 5.59 (s, 1H), 4.92 (p, J = 8.6 Hz, 1H), 4.36 
(d, J = 6.0 Hz, 2H), 3.48 – 3.43 (m, 1H), 2.56 – 2.40 (m, 2H), 2.22 – 2.02 (m, 4H), 1.81 – 
1.67 (m, 3H), 1.62 (s, 9H), 1.30 (s, 9H). LCMS (TOF) m/z calculated 429.2528 (M+H)+, 
found 429.2534. 
 
3-(tert-butyl)-N-((2-chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)methyl)-1-
isobutyl-1H-pyrazol-5-amine (13). White solid (16.3mg, 47.4% yield). 1H NMR 
(400MHz, CDCl3) δ 8.68 (s, 1H), 6.47 (s, 1H), 5.52 (s, 1H), 4.87 (p, J = 8.7 Hz, 1H), 4.39 
(d, J = 6.0 Hz, 2H), 3.71 (d, J = 7.5 Hz, 2H), 3.39 (t, J = 6.0 Hz, 1H), 2.46 (ddd, J = 12.2, 
6.1, 3.9 Hz, 2H), 2.20 – 2.02 (m, 5H), 1.81 – 1.66 (m, 2H), 1.31 (s, 9H), 0.90 (d, J = 6.7 
Hz, 6H). LCMS (TOF) m/z calculated 429.2528 (M+H)+, found 429.2534. 
 
3-(tert-butyl)-N-((2-chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)methyl)-1-
cyclopentyl-1H-pyrazol-5-amine (14). White solid (24.6mg, 69.6% yield). 1H NMR 
(400MHz, CDCl3) δ 8.68 (s, 1H), 6.48 (s, 1H), 5.53 (s, 1H), 4.89 (p, J = 8.6 Hz, 1H), 4.39 
(d, J = 6.3 Hz, 3H), 3.41 (t, J = 6.0 Hz, 1H), 2.44 (ddd, J = 12.4, 10.2, 4.8 Hz, 2H), 2.21 
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– 2.03 (m, 4H), 1.93 (dtd, J = 16.3, 13.6, 12.7, 6.9 Hz, 4H), 1.77 – 1.67 (m, 2H), 1.62 
(dd, J = 10.0, 5.8 Hz, 2H), 1.30 (s, 9H).  
 
3-(tert-butyl)-N-((2-chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)methyl)-1-
phenyl-1H-pyrazol-5-amine (15). White solid (6.8mg, 16.9% yield). 1H NMR (400MHz, 
CDCl3) δ 8.71 (s, 1H), 7.55 (dd, J = 8.4, 1.1 Hz, 2H), 7.50 – 7.40 (m, 2H), 7.36 – 7.27 
(m, 2H), 6.47 (s, 1H), 5.61 (s, 1H), 4.87 (p, J = 8.7 Hz, 1H), 4.43 (d, J = 5.8 Hz, 2H), 
3.84 (t, J = 5.8 Hz, 1H), 2.52 – 2.36 (m, 2H), 2.21 – 2.10 (m, 2H), 2.10 – 1.97 (m, 2H), 
1.74 (ddd, J = 10.8, 7.8, 4.6 Hz, 2H), 1.37 (s, 9H). LCMS (TQD) m/z calculated 449.22 
(M+H)+, found 449.26. 
 
1-(tert-butyl)-N-((2-chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)methyl)-3-
isopropyl-1H-pyrazol-5-amine (16). White solid (14.7mg, 44.2% yield). 1H NMR 
(400MHz, CDCl3) δ 8.73 (s, 1H), 6.51 (s, 1H), 5.56 (s, 1H), 4.91 (p, J = 8.6 Hz, 1H), 4.36 
(d, J = 5.9 Hz, 2H), 3.53 (t, J = 5.9 Hz, 1H), 2.91 (p, J = 6.9 Hz, 1H), 2.55 – 2.40 (m, 
2H), 2.10 (ddt, J = 22.9, 11.2, 7.9 Hz, 4H), 1.70 (tt, J = 15.4, 6.6 Hz, 2H), 1.62 (s, 9H), 
1.26 (d, J = 6.9 Hz, 6H). LCMS (TOF) m/z calculated 415.2371 (M+H)+, found 
415.2365. 
 
1-(tert-butyl)-N-((2-chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)methyl)-3-
cyclopentyl-1H-pyrazol-5-amine (17). White solid (17.7mg, 50.1% yield). 1H NMR 
(400MHz, CDCl3) δ 8.72 (s, 1H), 6.51 (s, 1H), 5.54 (s, 1H), 4.90 (p, J = 8.6 Hz, 1H), 4.36 
(d, J = 5.9 Hz, 2H), 3.54 (t, J = 5.9 Hz, 1H), 3.01 (p, J = 8.4 Hz, 1H), 2.54 – 2.40 (m, 
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2H), 2.20 – 1.98 (m, 6H), 1.83 – 1.57 (m, 17H). LCMS (TOF) m/z calculated 441.2528 
(M+H)+, found 441.2515. 
 
1-(tert-butyl)-N-((2-chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)methyl)-3-
phenyl-1H-pyrazol-5-amine (18). White solid (24.6mg, 68.4% yield). 1H NMR 
(400MHz, CDCl3) δ 8.72 (s, 1H), 7.81 (d, J = 7.3 Hz, 2H), 7.39 (t, J = 7.6 Hz, 2H), 7.29 
(d, J = 7.4 Hz, 1H), 6.54 (s, 1H), 6.04 (s, 1H), 4.93 (p, J = 8.5 Hz, 1H), 4.46 (d, J = 5.9 
Hz, 2H), 3.70 (t, J = 5.7 Hz, 1H), 2.47 (dt, J = 15.0, 8.3 Hz, 2H), 2.12 (dq, J = 18.7, 11.0, 
10.2 Hz, 4H), 1.71 (s, 11H). LCMS (TOF) m/z calculated 449.2215 (M+H)+, found 
449.2236. 
 
N-((2-chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)methyl-3-isopropyl-1-
methyl-1H-pyrazol-5-amine (19).  White solid (6.3mg, 60.9% yield). 1H NMR (400MHz, 
CDCl3) δ 8.70 (s, 1H), 6.50 (s, 1H), 5.49 (s, 1H), 4.86 (p, J = 8.6 Hz, 1H), 4.40 (d, J = 
5.3 Hz, 2H), 3.63 (s, 3H), 3.47 (d, J = 8.6 Hz, 1H), 2.91 (hept, J = 6.9 Hz, 1H), 2.54 – 
2.38 (m, 2H), 2.21 – 1.99 (m, 4H), 1.74 (ddt, J = 9.9, 7.0, 4.3 Hz, 2H), 1.27 (d, J = 6.9 
Hz, 6H). LCMS (TQD) m/z calculated 373.19 (M+H)+, found 373.17. 
 
N-((2-chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)methyl-1-methyl-1H-
pyrazol-5-amine (20). White solid (18.0mg, 67.9% yield). 1H NMR (400MHz, CDCl3) δ 
8.61 (s, 1H), 7.39 – 7.31 (m, 1H), 6.44 (s, 1H), 5.63 (d, J = 1.4 Hz, 1H), 4.85 (p, J = 8.6 
Hz, 1H), 4.41 (d, J = 5.8 Hz, 2H), 3.80 (t, J = 5.7 Hz, 1H), 3.71 (s, 3H), 2.44 (dq, J = 
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15.4, 7.8 Hz, 2H), 2.10 (dddd, J = 20.1, 15.3, 9.6, 5.1 Hz, 4H), 1.74 (dd, J = 12.8, 7.0 
Hz, 2H). LCMS (TOF) m/z calculated 331.1432 (M+H)+, found 331.1420. 
 
General procedure for the synthesis of intermediates (21-26).  
To a solution of intermediate 5 (15mg, 0.056mmol) in THF (1mL) under Ar(g) was 
added N,N-diisopropylethylamine (14.8µL, 0.0847mmol, 1.5eq) and HATU (25.8mg, 
0.0677mmol, 1.2eq) and the resulting solution was stirred at RT for 20min, then cooled 
on ice. The appropriate amine (0.0847, 1.5eq) was dissolved in THF (0.5mL) and added 
dropwise to the reaction vial. The reaction was allowed to warm to RT and stirred until 
complete by LCMS with mild heating (40ºC), as necessary. The reaction was added to 
brine and extract with EtOAc. The combined organic layers were dried with Na2SO4, 
filtered, and concentrated under reduced pressure. The resulting solid was purified by 
silica chromatography to yield intermediates 21-26. 
 
2-chloro-7-cyclopentyl-N-(3-(trifluoromethyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidine-
6-carboxamide (21). White solid (12.7mg, 55.0% yield). LCMS (TQD) m/z calculated 
409.10 (M+H)+, found 409.10. 
 
2-chloro-N-(4-(1-cyanocyclopentyl)phenyl)-7-cyclopentyl-7H-pyrrolo[2,3-
d]pyrimidine-6-carboxamide (22). White solid (9.8mg, 88.8% yield). 1H NMR 
(400MHz, CDCl3) δ 8.87 (s, 1H), 8.11 (s, 1H), 7.67 (d, J = 8.7 Hz, 2H), 7.57 – 7.44 (m, 
2H), 6.97 (s, 1H), 5.48 (p, J = 8.7 Hz, 1H), 2.57 – 2.39 (m, 4H), 2.20 – 1.91 (m, 10H), 
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1.72 (tt, J = 10.9, 5.2 Hz, 2H). LCMS (TOF) m/z calculated 434.1742 (M+H)+, found 
434.1735. 
 
N-(3-(tert-butyl)-1-methyl-1H-pyrazol-5-yl)-2-chloro-7-cyclopentyl-7H-pyrrolo[2,3-
d]pyrimidine-6-carboxamide (23). White solid (23.5mg, 79.8% yield). LCMS (TQD) 
m/z calculated 401.19 (M+H)+, found 401.22. 
 
2-chloro-N-(4-(1-cyanocyclobutyl)phenyl)-7-cyclopentyl-7H-pyrrolo[2,3-
d]pyrimidine-6-carboxamide (24). White solid (18.1mg, 76.4% yield). 1H NMR 
(400MHz, CDCl3) δ 8.83 (s, 1H), 8.27 (s, 1H), 7.74 – 7.66 (m, 2H), 7.48 – 7.41 (m, 2H), 
6.97 (s, 1H), 5.48 (p, J = 8.7 Hz, 1H), 2.93 – 2.80 (m, 2H), 2.71 – 2.56 (m, 2H), 2.45 
(tdd, J = 10.3, 8.5, 3.6 Hz, 2H), 2.11 (tqd, J = 14.8, 8.6, 7.6, 4.1 Hz, 5H), 1.79 – 1.64 (m, 
3H). LCMS (TOF) m/z calculated 420.1586 (M+H)+, found 420.1598. 
 
2-chloro-N-(4-(1-cyanocyclohexyl)phenyl)-7-cyclopentyl-7H-pyrrolo[2,3-
d]pyrimidine-6-carboxamide (25). White solid (9.3mg, 55.6% yield). 1H NMR 
(400MHz, CDCl3) δ 8.87 (s, 1H), 8.10 (s, 1H), 7.72 – 7.64 (m, 2H), 7.59 – 7.49 (m, 2H), 
6.97 (s, 1H), 5.48 (p, J = 8.7 Hz, 1H), 2.56 – 2.37 (m, 2H), 2.24 – 2.04 (m, 6H), 1.97 – 
1.60 (m, 10H).  
 
2-chloro-N-(4-(1-cyanopropan-2-yl)phenyl)-7-cyclopentyl-7H-pyrrolo[2,3-
d]pyrimidine-6-carboxamide (26). White solid (16.1mg, 69.9% yield). 1H NMR 
(400MHz, CDCl3) δ 8.87 (s, 1H), 8.07 (s, 1H), 7.74 – 7.64 (m, 2H), 7.57 – 7.46 (m, 2H), 
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6.97 (s, 1H), 5.49 (p, J = 8.7 Hz, 1H), 2.53 – 2.39 (m, 2H), 2.14 (qd, J = 9.9, 8.4, 5.5 Hz, 
4H), 1.76 – 1.66 (m, 2H). LCMS (TOF) m/z calculated 408.1586 (M+H)+, found 
408.1603. 
 
General procedure for the synthesis of intermediates 27-45.  
A solution of the appropriate intermediate 6-26, intermediate 60 (2eq), and cesium 
carbonate (4eq) in 1,4-dioxane (1.5mL) in a 10mL microwave vial was purged with 
Ar(g). Pd2(dba)3 (0.05eq), XANTPhos (0.05eq), and tBuXPhos Pd G3 (0.05eq) were 
then added and the resulting solution was purged with Ar(g). The reaction was heated 
to 140ºC for 45min in a microwave reactor, cooled, filtered through celite, and washed 
with EtOAc. The resulting filtrate was concentrated under reduced pressure and 
separated by silica chromatography to yield intermediates 27-45 that were carried 
forward without further purification or characterization. 
 
General procedure for the synthesis of CDK4i-## 
To a solution of intermediates 27-45 in DCM (2mL) was added trifluoroacetic acid 
(400µL) and the resulting solution was stirred until judged complete by LCMS (~1hr). 
This solution was added to saturated NaHCO3, extracted with DCM, dried with Na2SO4, 
filtered, and concentrated under reduced pressure. The resulting oil was purified by 
reverse-phase chromatography (0-70% MeCN/water) and lyophilized to yield the final 
product. 
 
CDK4i-1. LCMS (TQD) m/z calculated 389.21 (M+H)+, found 389.21. 
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CDK4i-2. LCMS (TQD) m/z calculated 407.23 (M+H)+, found 407.25. 
 
CDK4i-3. LCMS (TQD) m/z calculated 551.25 (M+H)+, found 551.26. 
 
CDK4i-4. LCMS (TQD) m/z calculated 537.27 (M+H)+, found 537.28. 
 
CDK4i-5. 1H NMR (400 MHz, DMSO-d6) δ 10.57 (s, 1H), 9.53 (s, 1H), 8.91 (s, 1H), 8.30 
(s, 1H), 8.17 (d, J = 9.1 Hz, 1H), 8.04 (d, J = 3.0 Hz, 1H), 7.86 – 7.73 (m, 2H), 7.55 – 
7.39 (m, 3H), 7.18 (s, 1H), 5.47 (p, J = 8.9 Hz, 1H), 3.17 (dd, J = 6.8, 3.4 Hz, 4H), 3.02 
(t, J = 5.0 Hz, 4H), 2.57 – 2.46 (m, 2H), 2.47 – 2.36 (m, 2H), 2.16 – 1.92 (m, 6H), 1.95 – 
1.82 (m, 4H), 1.77 – 1.56 (m, 2H). LCMS (TQD) m/z calculated 576.31 (M+H)+, found 
576.34. 
 
CDK4i-6. 1H NMR (400 MHz, DMSO-d6) δ 9.12 (s, 1H), 8.62 (s, 1H), 8.31 (br s, 1H), 
8.17 (d, J = 9.1 Hz, 1H), 7.99 (d, J = 3.0 Hz, 1H), 7.42 (dd, J = 9.2, 3.0 Hz, 1H), 7.24 – 
7.14 (m, 2H), 6.77 – 6.68 (m, 2H), 6.39 (s, 1H), 6.30 (t, J = 5.7 Hz, 1H), 4.76 (p, J = 8.8 
Hz, 1H), 4.43 (d, J = 5.0 Hz, 2H), 3.11 (dd, J = 6.6, 3.5 Hz, 4H), 2.98 (dd, J = 6.5, 3.6 
Hz, 4H), 2.51 (s, 2H), 2.38 – 2.25 (m, 2H), 1.99 (s, 6H), 1.90 – 1.76 (m, 4H), 1.76 – 1.59 
(m, 2H). LCMS (TQD) m/z calculated 562.34 (M+H)+, found 562.36. 
 
CDK4i-7. 1H NMR (400 MHz, DMSO-d6) δ 10.39 (br s, 1H), 9.48 (s, 1H), 8.91 (s, 1H), 
8.32 (s, 1H), 8.14 (d, J = 9.1 Hz, 1H), 8.01 (d, J = 3.0 Hz, 1H), 7.44 (dd, J = 9.1, 3.0 Hz, 
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1H), 7.24 (s, 1H), 6.18 (s, 1H), 5.50 (p, J = 9.0 Hz, 1H), 3.67 (s, 3H), 3.14 – 3.04 (m, 
4H), 2.92 (d, J = 4.9 Hz, 5H), 2.58 – 2.42 (m, 2H), 2.09 – 1.91 (m, 4H), 1.66 (s, 2H), 
1.24 (s, 9H). LCMS (TQD) m/z calculated 543.33 (M+H)+, found 543.36. 
 
CDK4i-8. 1H NMR (400 MHz, DMSO-d6) δ 9.16 (s, 1H), 8.66 (d, J = 2.9 Hz, 1H), 8.28 
(br s, 2H), 8.19 (d, J = 9.2 Hz, 1H), 8.01 (d, J = 3.0 Hz, 1H), 7.45 (dd, J = 9.1, 3.0 Hz, 
1H), 6.44 (s, 1H), 5.73 (s, 1H), 5.44 (s, 1H), 4.80 (p, J = 8.8 Hz, 1H), 4.34 – 4.24 (m, 
2H), 3.48 (s, 3H), 3.19 (dd, J = 6.7, 3.5 Hz, 4H), 3.11 – 3.02 (m, 4H), 2.60 – 2.45 (m, 
2H), 2.11 – 1.95 (m, 4H), 1.75 – 1.60 (m, 2H), 1.18 (s, 9H). LCMS (TOF) m/z calculated 
529.3510 (M+H)+, found 529.3511. 
 
CDK4i-9. 1H NMR (400 MHz, DMSO-d6) δ 9.07 (s, 1H), 8.64 (s, 1H), 8.31 (br s, 1H), 
8.16 (d, J = 9.1 Hz, 1H), 7.98 (d, J = 2.9 Hz, 1H), 7.49 – 7.37 (m, 3H), 7.31 – 7.21 (m, 
2H), 6.41 (s, 1H), 5.71 (d, J = 6.7 Hz, 2H), 4.83 (p, J = 8.9 Hz, 1H), 4.32 (d, J = 5.4 Hz, 
2H), 3.10 (dd, J = 6.5, 3.6 Hz, 4H), 2.96 (dd, J = 6.5, 3.6 Hz, 4H), 2.51 (d, J = 1.8 Hz, 
2H), 2.33 (s, 3H), 2.10 – 1.85 (m, 4H), 1.71 – 1.58 (m, 2H), 1.24 (s, 9H). LCMS (TQD) 
m/z calculated 605.38 (M+H)+, found 605.37. 
 
CDK4i-10. LCMS (TQD) m/z calculated 617.31 (M+H)+, found 617.31. 
 
CDK4i-16. 1H NMR (400 MHz, DMSO-d6) δ 9.09 (s, 1H), 8.65 (s, 1H), 8.20 – 8.12 (m, 
1H), 8.03 – 7.92 (m, 1H), 7.39 (dd, J = 9.1, 3.0 Hz, 1H), 6.42 (s, 1H), 5.64 (t, J = 5.5 Hz, 
1H), 5.43 (s, 1H), 4.82 (p, J = 8.8 Hz, 1H), 4.38 (p, J = 6.6 Hz, 1H), 4.29 (d, J = 5.5 Hz, 
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2H), 3.01 (dd, J = 6.3, 3.6 Hz, 4H), 2.85 (dd, J = 6.0, 3.6 Hz, 4H), 2.51 (s, 2H), 2.09 – 
1.92 (m, 4H), 1.66 (d, J = 5.3 Hz, 2H), 1.27 (d, J = 6.5 Hz, 6H), 1.19 (s, 9H). LCMS 
(TOF) m/z calculated 557.3823 (M+H)+, found 557.3821. 
 
CDK4i-17. 1H NMR (400 MHz, DMSO-d6) δ 9.12 (s, 1H), 8.65 (s, 1H), 8.33 (br s, 1H), 
8.17 (d, J = 9.1 Hz, 1H), 7.99 (d, J = 3.0 Hz, 1H), 7.42 (dd, J = 9.1, 3.0 Hz, 1H), 6.41 (s, 
1H), 5.58 (s, 1H), 5.14 (t, J = 5.4 Hz, 1H), 4.91 (p, J = 8.9 Hz, 1H), 4.28 (d, J = 5.4 Hz, 
2H), 3.11 (dd, J = 6.8, 3.4 Hz, 4H), 2.97 (t, J = 4.9 Hz, 4H), 2.60 – 2.47 (m, 2H), 2.12 – 
1.94 (m, 4H), 1.68 (d, J = 7.0 Hz, 2H), 1.53 (s, 9H), 1.18 (s, 9H). LCMS (TOF) m/z 
calculated 571.3980 (M+H)+, found 571.3997. 
 
CDK4i-18. 1H NMR (400 MHz, DMSO-d6) δ 9.10 (s, 1H), 8.65 (s, 1H), 8.16 (d, J = 9.1 
Hz, 1H), 7.97 (d, J = 3.0 Hz, 1H), 7.39 (dd, J = 9.2, 3.0 Hz, 1H), 6.42 (s, 1H), 5.66 (t, J = 
5.5 Hz, 1H), 5.43 (s, 1H), 4.81 (p, J = 8.9 Hz, 1H), 4.51 (p, J = 7.3 Hz, 1H), 4.29 (d, J = 
5.4 Hz, 2H), 3.01 (dd, J = 6.4, 3.6 Hz, 4H), 2.85 (dd, J = 6.1, 3.6 Hz, 4H), 2.61 – 2.43 
(m, 2H), 2.15 – 1.93 (m, 4H), 1.92 – 1.73 (m, 6H), 1.67 (t, J = 6.0 Hz, 2H), 1.54 (dq, J = 
9.9, 5.6, 4.5 Hz, 2H), 1.18 (s, 9H). LCMS (TOF) m/z calculated 583.3980 (M+H)+, found 
583.3994. 
 
CDK4i-19. 1H NMR (400 MHz, CDCl3) δ 8.61 (s, 1H), 8.34 (d, J = 9.1 Hz, 1H), 8.01 (d, J 
= 2.8 Hz, 1H), 7.67 (s, 1H), 7.55 (dd, J = 8.5, 1.1 Hz, 2H), 7.44 (t, J = 7.9 Hz, 2H), 7.34 
(dd, J = 9.1, 3.0 Hz, 1H), 6.32 (s, 1H), 5.64 (s, 1H), 4.75 (p, J = 8.9 Hz, 2H), 4.35 (d, J = 
5.7 Hz, 3H), 3.17 – 3.04 (m, 8H), 2.72 – 2.57 (m, 2H), 2.10 (d, J = 14.4 Hz, 2H), 1.98 (s, 
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2H), 1.82 – 1.71 (m, 2H), 1.39 (s, 9H). LCMS (TOF) m/z calculated 591.3667 (M+H)+, 
found 591.3656. 
 
CDK4i-21. 1H NMR (400 MHz, CDCl3) δ 8.78 (s, 1H), 8.37 (d, J = 9.1 Hz, 1H), 8.04 (d, J 
= 2.8 Hz, 1H), 7.92 (s, 1H), 7.84 (s, 1H), 7.66 (d, J = 8.8 Hz, 2H), 7.53 (d, J = 8.8 Hz, 
2H), 7.36 (dd, J = 9.1, 3.0 Hz, 1H), 6.89 (s, 1H), 5.52 (p, J = 8.8 Hz, 1H), 3.15 (dd, J = 
6.5, 3.0 Hz, 4H), 3.10 (dd, J = 6.4, 2.9 Hz, 4H), 2.75 – 2.59 (m, 2H), 2.24 – 2.03 (m, 
6H), 1.98 – 1.70 (m, 8H), 1.59 (d, 2H), 1.40 – 1.21 (m, 2H). LCMS (TOF) m/z calculated 
590.3350 (M+H)+, found 590.3358. 
 
CDK4i-22. 1H NMR (400 MHz, DMSO-d6) δ 10.58 (s, 1H), 9.58 (s, 1H), 8.92 (s, 1H), 
8.20 (d, J = 9.1 Hz, 1H), 8.07 (d, J = 2.5 Hz, 1H), 7.83 (d, J = 8.6 Hz, 2H), 7.51 (dd, J = 
9.1, 2.6 Hz, 1H), 7.46 (d, J = 8.5 Hz, 2H), 7.19 (s, 1H), 5.46 (q, J = 8.8 Hz, 1H), 3.35 – 
3.27 (m, 4H), 3.25 – 3.19 (m, 4H), 2.83 – 2.70 (m, 2H), 2.68 – 2.57 (m, 2H), 2.55 – 2.46 
(m, 2H), 2.37 – 2.20 (m, 1H), 2.13 – 1.93 (m, 5H), 1.78 – 1.58 (m, 2H). LCMS (TOF) 
m/z calculated 562.3037 (M+H)+, found 562.3024. 
 
CDK4i-23. 1H NMR (400 MHz, DMSO-d6) δ 10.59 (s, 1H), 9.43 (s, 1H), 8.90 (s, 1H), 
8.14 (d, J = 9.0 Hz, 1H), 7.99 (d, J = 3.0 Hz, 1H), 7.86 – 7.77 (m, 2H), 7.51 (d, J = 8.8 
Hz, 2H), 7.42 (dd, J = 9.2, 3.0 Hz, 1H), 7.19 (s, 1H), 5.47 (p, J = 8.9 Hz, 1H), 3.33 (s, 
6H), 3.04 (dd, J = 6.3, 3.6 Hz, 4H), 2.86 (dd, J = 6.1, 3.7 Hz, 4H), 2.58 – 2.42 (m, 2H), 
2.09 – 1.93 (m, 4H), 1.76 – 1.62 (m, 2H). LCMS (TOF) m/z calculated 550.3037 (M+H)+, 
found 550.3057. 
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CDK4i-24. 1H NMR (400 MHz, DMSO-d6) δ 9.09 (s, 1H), 8.65 (s, 1H), 8.16 (d, J = 9.0 
Hz, 1H), 7.97 (d, J = 3.0 Hz, 1H), 7.40 (dd, J = 9.1, 3.0 Hz, 1H), 6.42 (s, 1H), 5.67 (t, J = 
5.5 Hz, 1H), 5.41 (s, 1H), 4.80 (p, J = 8.9 Hz, 1H), 4.29 (d, J = 5.5 Hz, 2H), 3.64 (d, J = 
7.3 Hz, 2H), 3.02 (dd, J = 6.4, 3.7 Hz, 4H), 2.87 (t, J = 4.9 Hz, 4H), 2.14 – 1.93 (m, 6H), 
1.71 – 1.58 (m, 2H), 1.18 (s, 9H), 0.81 (d, J = 6.7 Hz, 6H). LCMS (TOF) m/z calculated 
571.3980 (M+H)+, found 571.3997. 
 
CDK4i-25. 1H NMR (400 MHz, DMSO-d6) δ 9.05 (s, 1H), 8.63 (s, 1H), 8.15 (d, J = 9.1 
Hz, 1H), 7.96 (d, J = 2.9 Hz, 1H), 7.73 – 7.66 (m, 2H), 7.39 (dd, J = 9.1, 3.0 Hz, 1H), 
7.34 (dd, J = 8.3, 7.1 Hz, 2H), 7.25 – 7.21 (m, 1H), 6.48 (s, 1H), 6.13 (s, 1H), 5.61 (t, J = 
5.3 Hz, 1H), 4.97 (p, J = 8.8 Hz, 1H), 4.41 (d, J = 5.2 Hz, 2H), 3.03 (dd, J = 6.3, 3.6 Hz, 
4H), 2.87 (dd, J = 6.3, 3.6 Hz, 4H), 2.14 – 1.93 (m, 6H), 1.76 – 1.64 (m, 2H), 1.62 (s, 
9H). LCMS (TOF) m/z calculated 591.3667 (M+H)+, found 591.3656. 
 
CDK4i-26. 1H NMR (400 MHz, DMSO-d6) δ 9.11 (s, 1H), 8.65 (s, 1H), 8.32 (br s, 1H), 
8.17 (d, J = 9.1 Hz, 1H), 7.99 (d, J = 2.9 Hz, 1H), 7.42 (dd, J = 9.1, 2.9 Hz, 1H), 6.39 (s, 
1H), 5.51 (s, 1H), 5.22 (t, J = 5.4 Hz, 1H), 4.91 (p, J = 8.8 Hz, 1H), 4.28 (d, J = 5.3 Hz, 
2H), 3.10 (d, J = 5.0 Hz, 4H), 2.98 (d, J = 5.2 Hz, 4H), 2.87 – 2.75 (m, 1H), 2.61 – 2.46 
(m, 2H), 2.11 – 1.92 (m, 4H), 1.92 – 1.79 (m, 2H), 1.75 – 1.59 (m, 4H), 1.61 – 1.47 (m, 
13H). LCMS (TOF) m/z calculated 583.3980 (M+H)+, found 583.3994. 
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CDK4i-27. 1H NMR (400 MHz, DMSO-d6) δ 9.09 (s, 1H), 8.64 (s, 1H), 8.34 (br s, 1H), 
8.17 (d, J = 9.1 Hz, 1H), 7.98 (d, J = 3.0 Hz, 1H), 7.41 (dd, J = 9.1, 3.0 Hz, 1H), 6.40 (s, 
1H), 5.53 (s, 1H), 5.21 (t, J = 5.4 Hz, 1H), 4.91 (p, J = 8.9 Hz, 1H), 4.28 (d, J = 5.4 Hz, 
2H), 3.08 (d, J = 5.3 Hz, 4H), 2.94 (d, J = 5.3 Hz, 4H), 2.69 (p, J = 6.9 Hz, 1H), 2.60 – 
2.43 (m, 2H), 2.12 – 1.92 (m, 4H), 1.76 – 1.60 (m, 2H), 1.53 (s, 9H), 1.12 (d, J = 6.9 Hz, 
6H). LCMS (TOF) m/z calculated 557.3923 (M+H)+, found 557.3821. 
 
CDK4i-28. 1H NMR (400 MHz, Chloroform-d) δ 8.65 (s, 1H), 8.39 (d, J = 9.2 Hz, 1H), 
8.03 (d, J = 2.9 Hz, 1H), 7.39 – 7.32 (m, 1H), 6.38 (s, 1H), 5.52 (s, 1H), 4.74 (p, J = 8.9 
Hz, 1H), 4.33 (s, 2H), 3.61 (s, 3H), 3.26 (s, 8H), 2.92 (p, J = 6.9 Hz, 1H), 2.71 – 2.59 (m, 
2H), 2.07 (m, 4H), 1.82 – 1.68 (m, 2H), 1.29 (d, J = 6.9 Hz, 6H). LCMS (TOF) m/z 
calculated 515.3354 (M+H)+, found 515.3303. 
 
CDK4i-29. 1H NMR (400 MHz, Chloroform-d) δ 8.65 (s, 1H), 8.41 (d, J = 9.1 Hz, 1H), 
8.02 (d, J = 2.9 Hz, 1H), 7.39 – 7.34 (m, 2H), 6.40 (s, 1H), 5.67 (d, J = 2.0 Hz, 1H), 4.74 
(p, J = 8.9 Hz, 1H), 4.36 (s, 2H), 3.68 (s, 3H), 3.40 – 3.27 (m, 9H), 2.73 – 2.55 (m, 3H), 
2.19 – 1.99 (m, 4H), 1.84 – 1.67 (m, 2H). LCMS (TOF) m/z calculated 473.2884 (M+H)+, 
found 473.2808. 
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Scheme 2 
 
2-(3-(2-chloro-4-(cyclopentylamino)pyrimidin-5-yl)prop-2-yn-1-yl)isoindoline-1,3-
dione (46). To a 35mL microwave vial charged anhydrous THF (20mL) under Ar(g) was 
added intermediate 1 (1080mg, 3.91mmol) followed by [1,1′-Bis(diphenylphosphino) 
ferrocene]dichloropalladium(II), complex with dichloromethane (159.45mg, 
0.2000mmol). The solution was purged with Ar(g), then N-propargylphthalamide 
(1807.88mg, 9.76mmol) and triethylamine (1360.74uL, 9.76mmol) were added. The 
reaction is heated to 140ºC for 1hr in a microwave reactor, then cooled, filtered through 
celite, and evaporated to dryness under reduced pressure. The resulting oil is purified 
by silica chromatography (0-25% EtOAc/hexanes) to yield the pure product as a tan 
solid (577.4mg, 38.8% yield). 1H NMR (400MHz, CDCl3) δ 8.02 (s, 1H), 7.91 (tt, J = 5.0, 
2.4 Hz, 2H), 7.80 (td, J = 5.3, 2.1 Hz, 2H), 6.11 (d, J = 7.1 Hz, 1H), 4.72 (s, 2H), 4.48 (h, 
J = 6.9 Hz, 1H), 2.19 – 2.04 (m, 2H), 1.86 (ddd, J = 11.8, 5.4, 2.4 Hz, 2H), 1.77 – 1.57 
(m, 4H). LCMS (TQD) m/z calculated 381.11 (M+H)+, found 381.10. 
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5-(3-aminoprop-1-yn-1-yl)-2-chloro-N-cyclopentylpyrimidin-4-amine (47). To a 
suspension of intermediate 46 (529.1mg, 1.39mmol) in ethanol (40mL) was added 
hydrazine hydrate (409µL, 8.34mmol, 6eq). The resulting suspension was heated to 
50ºC for 2hr, then let cool overnight. The suspension was filtered and washed with 
ethanol, and the resulting filtrate was concentrated under reduced pressure. The 
resulting solid was dissolved in EtOAc, washed with brine, dried with Na2SO4, filtered, 
and concentrated under reduced pressure to yield pure intermediate (47), which was 
carried forward without further purification (340.4mg, 97.7% yield). LCMS (TQD) m/z 
calculated 251.11 (M+H)+, found 251.11. 
 
(2-chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)methanamine (48). To a 
solution of intermediate 47 (340.4mg, 1.36mmol) in THF (1mL) was added 
tetrabutylammonium fluoride (1M solution in THF; 5.43mL, 5.43mmol, 4eq). The 
resulting solution was heated to 40ºC for 1hr, then cooled and concentrated under 
reduced pressure. The resulting oil was dissolved in EtOAc, washed with saturated 
NaHCO3, dried with Na2SO4, filtered and concentrated under reduced pressure. The 
final product was isolated by silica chromatography as an off-white solid (162.5mg, 
47.7% yield). 1H NMR (400MHz, CDCl3) δ  8.69 (s, 1H), 6.44 (t, J = 0.9 Hz, 1H), 4.88 (p, 
J = 8.7 Hz, 1H), 4.11 – 4.03 (m, 2H), 2.47 – 2.31 (m, 2H), 2.20 – 1.98 (m, 4H), 1.83 – 
1.64 (m, 2H). LCMS (TQD) m/z calculated 251.11 (M+H)+, found 251.11. 
 
General procedure for the synthesis of intermediates 49-51.  
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To a solution of the appropriate carboxylic acid (2eq) in THF (1mL) under Ar(g) was 
added diisopropylethylamine (34.7µL, 0.199mmol, 2.5eq) and HATU (63.7mg, 
0.1675mmol, 2.1eq) and the resulting solution was stirred at RT for 20min. The reaction 
was cooled to 0ºC on ice, then intermediate 48 (20mg, 0.0798mmol) was added 
portionwise and the reaction was allowed to warm to RT. After 1.5hr, the reaction was 
concentrated under reduced pressure, dissolved in saturated NaHCO3, extracted with 
EtOAc, dried with Na2SO4, filtered and concentrated under reduced pressure. The final 
product was isolated by silica chromatography. 
 
N-((2-chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)methyl)-3-
(trifluoromethyl)benzamide (49). White solid (7.0mg, 35.5% yield). LCMS (TQD) m/z 
calculated 423.12 (M+H)+, found 423.13. 
 
N-((2-chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)methyl)-3-
(dimethylamino)benzamide (50). White solid (27.2mg, 85.7% yield). LCMS (TQD) m/z 
calculated 398.17 (M+H)+, found 398.17. 
 
N-((2-chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)methyl)-4-((4-
methylpiperazin-1-yl)methyl)benzamide (51). White solid (22.7mg, 60.9% yield). 
LCMS (TQD) m/z calculated 467.23 (M+H)+, found 467.21. 
 
General procedure for the synthesis of intermediates 52-53.  
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To a solution of intermediate 48 (20mg, 0.0798mmol) in MeCN (1mL) under Ar(g) was 
added triethylamine (22.2µL, 0.160mmol, 2eq) and the resulting solution was chilled to 
0ºC on ice. The appropriate isocyanate (1.5eq) was then added dropwise, and the 
reaction was allowed to warm to RT. After 2hr, the reaction was concentrated under 
reduced pressure, dissolved in saturated NaHCO3, extracted with EtOAc, dried with 
Na2SO4, filtered and concentrated under reduced pressure. The final product was 
isolated by silica chromatography. 
 
1-(4-chloro-3-(trifluoromethyl)phenyl)-3-((2-chloro-7-cyclopentyl-7H-pyrrolo[2,3-
d]pyrimidin-6-yl)methyl)urea (52). White solid (29.8mg, 79.1% yield). LCMS (TQD) 
m/z calculated 472.09 (M+H)+, found 472.08. 
 
1-((2-chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidin-6-yl)methyl)-3-(3-
(trifluoromethyl)phenyl)urea (53). White solid (29.0mg, 83.0% yield). LCMS (TQD) 
m/z calculated 438.13 (M+H)+, found 438.11. 
 
General procedure for the synthesis of intermediates 54-58.  
A solution of the appropriate intermediate 49-53, intermediate 60 (2eq), and cesium 
carbonate (4eq) in 1,4-dioxane (1.5mL) in a 10mL microwave vial was purged with 
Ar(g). Pd2(dba)3 (0.05eq), XANTPhos (0.05eq), and tBuXPhos Pd G3 (0.05eq) were 
then added and the resulting solution was purged with Ar(g). The reaction was heated 
to 140ºC for 45min in a microwave reactor, cooled, filtered through celite, and washed 
with EtOAc. The resulting filtrate was concentrated under reduced pressure and 
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separated by silica chromatography to yield intermediates 54-58 that were carried 
forward without further purification or characterization. 
 
General procedure for the synthesis of CDK4i-## 
To a solution of intermediates 54-58 in DCM (2mL) was added trifluoroacetic acid 
(400µL) and the resulting solution was stirred until judged complete by LCMS (~1hr). 
This solution was added to saturated NaHCO3, extracted with DCM, dried with Na2SO4, 
filtered, and concentrated under reduced pressure. The resulting oil was purified by 
reverse-phase chromatography (0-70% MeCN/water) and lyophilized to yield the final 
product. 
 
CDK4i-11. 1H NMR (400 MHz, DMSO-d6) δ 9.31 (t, J = 5.5 Hz, 1H), 9.12 (d, J = 1.8 Hz, 
1H), 8.65 (s, 1H), 8.25 (d, J = 1.9 Hz, 1H), 8.21 (dd, J = 7.8, 1.9 Hz, 1H), 8.14 (d, J = 9.1 
Hz, 1H), 8.00 – 7.90 (m, 2H), 7.75 (t, J = 7.8 Hz, 1H), 7.39 (dd, J = 9.1, 3.0 Hz, 1H), 
6.40 (s, 1H), 4.78 (q, J = 8.8 Hz, 1H), 4.71 (d, J = 5.4 Hz, 2H), 2.51 (p, J = 1.9 Hz, 2H), 
2.09 – 1.81 (m, 2H), 1.65 (q, J = 6.4, 4.3 Hz, 2H). LCMS (TQD) m/z calculated 565.26 
(M+H)+, found 565.28. 
 
CDK4i-12. 1H NMR (400 MHz, DMSO-d6) δ 9.09 (s, 1H), 8.89 (t, J = 5.6 Hz, 1H), 8.65 
(s, 1H), 8.14 (d, J = 9.1 Hz, 1H), 7.97 (d, J = 3.0 Hz, 1H), 7.39 (dd, J = 9.1, 3.1 Hz, 1H), 
7.26 (t, J = 7.9 Hz, 1H), 7.21 – 7.15 (m, 2H), 6.87 (ddd, J = 8.3, 2.7, 1.0 Hz, 1H), 6.35 
(s, 1H), 4.80 (p, J = 8.9 Hz, 1H), 4.66 (d, J = 5.5 Hz, 2H), 3.01 (dd, J = 6.3, 3.6 Hz, 4H), 
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2.93 (s, 6H), 2.85 (dd, J = 6.2, 3.6 Hz, 4H), 2.09 – 1.87 (m, 6H), 1.65 (q, J = 6.5, 5.7 Hz, 
2H).LCMS (TQD) m/z calculated 540.32 (M+H)+, found 540.39. 
 
CDK4i-13. 1H NMR (400 MHz, DMSO-d6) δ 9.10 (s, 1H), 8.97 (t, J = 5.6 Hz, 1H), 8.64 
(s, 1H), 8.17 (d, J = 9.1 Hz, 1H), 7.99 (d, J = 2.9 Hz, 1H), 7.86 (dd, J = 8.3, 3.1 Hz, 2H), 
7.43 (dd, J = 9.2, 3.0 Hz, 1H), 7.39 (dd, J = 8.4, 3.0 Hz, 2H), 6.36 (s, 1H), 4.86 – 4.77 
(m, 1H), 4.67 (d, J = 5.5 Hz, 2H), 3.51 (d, J = 1.7 Hz, 2H), 3.17 (dd, J = 6.4, 3.4 Hz, 4H), 
3.11 – 3.00 (m, 4H), 2.44 – 2.24 (m, 10H), 2.17 (s, 3H), 2.08 – 1.88 (m, 4H), 1.74 – 1.58 
(m, 2H). LCMS (TQD) m/z calculated 609.38 (M+H)+, found 609.32. 
 
CDK4i-14. 1H NMR (400 MHz, DMSO-d6) δ 9.72 (s, 1H), 9.07 (s, 1H), 8.63 (d, J = 2.5 
Hz, 1H), 8.20 – 8.07 (m, 2H), 7.96 (d, J = 3.0 Hz, 1H), 7.63 (dd, J = 8.8, 2.6 Hz, 1H), 
7.55 (d, J = 8.8 Hz, 1H), 7.39 (dd, J = 9.1, 3.0 Hz, 1H), 6.33 (s, 1H), 4.77 (p, J = 8.7 Hz, 
1H), 4.48 (dd, J = 11.8, 5.4 Hz, 2H), 3.48 (t, J = 5.0 Hz, 1H), 3.01 (dd, J = 6.3, 3.6 Hz, 
4H), 2.85 (dd, J = 6.2, 3.6 Hz, 4H), 2.51 (s, 2H), 2.01 (s, 4H), 1.68 (s, 2H). LCMS (TQD) 
m/z calculated 614.24 (M+H)+, found 614.19. 
 
CDK4i-15. 1H NMR (400 MHz, DMSO-d6) δ 9.41 (br s, 1H), 9.07 (s, 1H), 8.63 (s, 1H), 
8.15 (d, J = 9.1 Hz, 1H), 8.04 – 7.98 (m, 1H), 7.96 (d, J = 3.0 Hz, 1H), 7.60 – 7.52 (m, 
1H), 7.46 (t, J = 7.9 Hz, 1H), 7.39 (dd, J = 9.1, 3.0 Hz, 1H), 7.27 – 7.19 (m, 2H), 6.34 (s, 
1H), 4.78 (p, J = 8.7 Hz, 1H), 4.50 (d, J = 5.7 Hz, 2H), 3.01 (dd, J = 6.3, 3.5 Hz, 4H), 
2.85 (dd, J = 6.1, 3.7 Hz, 4H), 2.56 – 2.42 (m, 2H), 2.09 – 1.93 (m, 4H), 1.76 – 1.58 (m, 
2H). LCMS (TQD) m/z calculated 580.28 (M+H)+, found 580.28. 
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CDK4i-20. LCMS (TOF) m/z calculated 542.2986 (M+H)+, found 542.2987. 
 
Scheme 3 
 
tert-butyl-4-(6-nitropyridin-3-yl)piperazine-1-carboxylate (59). 5-bromo-2-
nitropyridine (1.0g, 4.93mmol), tert-butyl piperazine-1-carboxylate (1.84g, 9.85mmol, 
2eq), potassium carbonate (1.36g, 9.85mmol, 2eq), and tetrabutylammonium iodide 
(18.2mg, 0.049mmol, 0.01eq) were dissolved in DMSO (5mL) and the resulting 
suspension was heated to 120ºC overnight. After cooling, the reaction was added to 
EtOAc, washed with brine, dried with Na2SO4, filtered and concentrated under reduced 
pressure. The resulting solid was purified by silica chromatography to yield the pure 
product as a yellow solid (1359.4mg, 89.5% yield). 1H NMR (400MHz, CDCl3) δ 8.21 (d, 
J = 9.1 Hz, 1H), 8.16 (d, J = 3.0 Hz, 1H), 7.23 (dd, J = 9.1, 3.1 Hz, 1H), 3.66 (dd, J = 
6.6, 4.1 Hz, 4H), 3.48 (dd, J = 6.5, 4.2 Hz, 4H), 1.51 (s, 9H). LCMS (TOF) m/z 
calculated 309.1557 (M+H)+, found 309.1523. 
 
tert-butyl-4-(6-aminopyridin-3-yl)piperazine-1-carboxylate (60). To a solution of 
intermediate 59 (400mg, 1.30mmol) in 1,4-dioxane (5mL) and water (3mL) was added 
zinc (339mg, 5.19mmol, 4eq) and ammonium chloride (693.9mg, 12.97mmol, 10eq), 
and the resulting suspension was heated to 50ºC for 2hr. The cooled solution was 
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dissolved in EtOAc/water, filtered through celite, extracted with EtOAc and the organic 
layers were isolated, dried with Na2SO4, filtered and concentrated under reduced 
pressure. The resulting oil was purified by silica chromatography (0-10% MeOH/DCM) 
to yield the pure product as a brown solid (128.0mg, 35.5% yield). 1H NMR (400MHz, 
CDCl3) δ 7.80 (d, J = 2.9 Hz, 1H), 7.19 (dd, J = 8.8, 2.9 Hz, 1H), 6.51 (d, J = 8.8 Hz, 
1H), 4.21 (s, 2H), 3.59 (t, J = 5.1 Hz, 4H), 2.98 (t, J = 5.1 Hz, 4H), 1.50 (s, 9H). LCMS 
(TOF) m/z calculated 279.1816 (M+H)+, found 279.1808. 
 
Scheme 4 
 
General procedure for the synthesis of intermediates 61-67.  
To a solution of the appropriate nitrile in isopropanol (3mL) was added hydrochloric acid 
(10µL, catalytic) and the appropriate hydrazine hydrochloride (1eq). The resulting 
solution was heated to 120ºC overnight, then cooled and evaporated to dryness under 
reduced pressure. The resulting oil was dissolved in EtOAc, washed with NaHCO3, and 
the organic layer was dried with Na2SO4, filtered and concentrated under reduced 
pressure. The resulting oil was purified by silica chromatography to yield intermediates 
61-68. 
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3-(tert-butyl)-1-isopropyl-1H-pyrazol-5-amine (61). White solid (92.4mg, 63.8% 
yield).1H NMR (400MHz, CDCl3) δ 5.42 (s, 1H), 4.32 (p, J = 6.7 Hz, 1H), 1.45 (d, J = 6.7 
Hz, 6H), 1.26 (s, 9H). LCMS (TOF) m/z calculated 182.1652 (M+H)+, found 182.1623. 
 
1,3-di-tert-butyl-1H-pyrazol-5-amine (62). White solid (97.1mg, 62.2% yield).1H NMR 
(400MHz, CDCl3) δ 5.43 (s, 1H), 1.62 (s, 9H), 1.25 (s, 9H). 
 
3-(tert-butyl)-1-isobutyl-1H-pyrazol-5-amine (63). White solid (206.5mg, 66.2% 
yield).1H NMR (400MHz, CDCl3) δ 5.42 (s, 1H), 3.70 (d, J = 7.5 Hz, 2H), 2.27 – 2.11 (m, 
1H), 1.27 (s, 9H), 0.92 (d, J = 6.7 Hz, 6H). LCMS (TOF) m/z calculated 196.1808 
(M+H)+, found 196.1815. 
 
3-(tert-butyl)-1-cyclopentyl-1H-pyrazol-5-amine (64). White solid (55.2mg, 33.3% 
yield).1H NMR (400MHz, CDCl3) δ 5.42 (s, 1H), 4.43 (p, J = 7.5 Hz, 1H), 2.16 – 2.05 (m, 
2H), 2.02 (ddd, J = 12.8, 5.5, 3.0 Hz, 2H), 1.97 – 1.87 (m, 3H), 1.70 – 1.59 (m, 2H), 1.26 
(s, 9H). LCMS (TQD) m/z calculated 208.18 (M+H)+, found 208.21. 
 
1-(tert-butyl)-3-isopropyl-1H-pyrazol-5-amine (65). White solid (309.2mg, 75.8% 
yield).1H NMR (400MHz, CDCl3) δ 5.42 (s, 1H), 3.49 (br s, 2H), 2.86 (p, J = 6.9 Hz, 1H), 
1.63 (s, 9H), 1.21 (d, J = 6.9 Hz, 6H). 
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1-(tert-butyl)-3-cyclopentyl-1H-pyrazol-5-amine (66). White solid (224.7mg, 74.3% 
yield).1H NMR (400MHz, CDCl3) δ 5.41 (s, 1H), 3.49 (br s, 2H), 2.96 (p, J = 8.2, 7.5 Hz, 
1H), 2.01 (dddd, J = 12.7, 8.2, 6.0, 2.3 Hz, 2H), 1.81 – 1.67 (m, 2H), 1.64 (s, 13H). 
 
1-(tert-butyl)-3-phenyl-1H-pyrazol-5-amine (67). White solid (222.1mg, 56.5% 
yield).1H NMR (400MHz, CDCl3) δ 7.76 (dt, J = 8.1, 1.6 Hz, 2H), 7.37 (td, J = 7.0, 1.6 
Hz, 2H), 7.28 – 7.23 (m, 1H), 5.93 (s, 1H), 3.59 (br s, 2H), 1.72 (s, 9H). LCMS (TOF) 
m/z calculated 216.1495 (M+H)+, found 216.1501. 
 
 
Scheme 5 
 
General procedure for the synthesis of intermediates 68-69.  
A solution of 2-(4-nitrophenyl)acetonitrile (250mg, 1.54mmol) and the appropriate 
dibromoalkane (1.05eq) in DMSO (0.5mL) was slowly added to a suspension of 
potassium hydroxide (216mg, 3.85mmol, 2.5eq) in DMSO (1mL) over 5min, with the 
reaction vial in a cool water bath to avoid temperatures >30ºC. After 24hr, the reaction 
was added to brine and extracted with EtOAc. The organic layer was dried with Na2SO4, 
filtered, and concentrated under reduced pressure. Intermediates 68-69 were isolated 
by silica chromatography. 
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1-(4-nitrophenyl)cyclobutane-1-carbonitrile (68). Red oil (69.3mg, 22.2% yield).1H 
NMR (400MHz, CDCl3) δ 8.34 – 8.26 (m, 1H), 7.64 (d, J = 8.9 Hz, 1H), 2.93 (dddd, J = 
11.0, 8.8, 4.4, 1.9 Hz, 1H), 2.68 (qd, J = 9.4, 2.9 Hz, 1H), 2.54 (dp, J = 11.7, 8.8 Hz, 
1H), 2.17 (dtt, J = 11.8, 9.1, 4.3 Hz, 1H). 
 
1-(4-nitrophenyl)cyclohexane-1-carbonitrile (69). Red oil (192.9 mg, 54.3% yield).1H 
NMR (400MHz, CDCl3) δ 8.28 (d, J = 8.9 Hz, 1H), 7.71 (d, J = 8.9 Hz, 1H), 2.20 (d, J = 
11.5 Hz, 2H), 2.03 – 1.74 (m, 6H), 1.42 – 1.23 (m, 1H). 
 
General procedure for the synthesis of intermediates 70-71.  
To a solution of the appropriate nitroaniline (1eq) in 1,4-dioxane:water (5:3) was added 
zinc (4eq) and ammonium chloride (10eq). The resulting solution was heated to 100ºC 
for 1hr, then cooled, filtered through celite and washed with EtOAc. The filtrate was 
washed with NaHCO3, dried with Na2SO4, filtered, and concentrated under reduced 
pressure. The resulting oil was purified by silica chromatography to yield intermediates 
70-71. 
 
1-(4-aminophenyl)cyclobutane-1-carbonitrile (70). Brown solid (36.1mg, 61.2% 
yield). 1H NMR (400MHz, CDCl3) δ 7.32 – 7.23 (m, 1H), 7.23 – 7.15 (m, 2H), 6.91 – 
6.81 (m, 1H), 6.76 – 6.66 (m, 2H), 3.76 (br s, 2H), 2.85 – 2.73 (m, 3H), 2.57 (dtt, J = 
11.3, 7.1, 2.1 Hz, 3H), 2.48 – 2.33 (m, 1H), 2.13 – 1.98 (m, 1H). 
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1-(4-aminophenyl)cyclohexane-1-carbonitrile (71). Brown solid (147.2mg, 87.7% 
yield). 1H NMR (400MHz, CDCl3) δ 7.28 (dd, J = 6.8, 1.7 Hz, 1H), 6.75 – 6.68 (m, 2H), 
3.72 (br s, 2H), 2.20 – 2.08 (m, 2H), 1.91 – 1.67 (m, 6H), 1.27 (dtd, J = 13.6, 10.7, 10.0, 
6.9 Hz, 2H). LCMS (TQD) m/z calculated 202.13 (M+H)+, found 201.14. 
 
Scheme 6 
 
tert-butyl-4-(6-(methylamino)pyridine-3-yl)piperazine-1-carboxylate (72). To a 
solution of intermediate 60 (102mg, 0.366mmol) and formaldehyde (55.0mg, 1.83mmol, 
5eq) in methanol (5mL) was added sodium methoxide (25wt% in methanol, 388.2µL, 
1.83mmol, 5eq) and the resulting solution was stirred at RT for 2hrs. The reaction was 
then cooled to 0ºC on ice, and sodium borohydride (55.5mg, 1.47mmol, 4eq) was added 
portionwise and the reaction was heated to 70ºC for 1hr. After cooling, the solution was 
evaporated to dryness under reduced pressure, dissolved in EtOAc and washed with 
saturated NaHCO3. The organic layer was dried with Na2SO4, filtered, and concentrated 
under reduced pressure. The final product was isolated by silica chromatography as a 
light brown solid (102.6mg, 95.8% yield). 1H NMR (400MHz, CDCl3) δ 7.85 (d, J = 2.8 
Hz, 1H), 7.22 (dd, J = 8.9, 2.9 Hz, 1H), 6.41 (d, J = 8.9 Hz, 1H), 4.31 (s, 1H), 3.63 – 
3.55 (m, 4H), 3.00 – 2.94 (m, 4H), 2.92 (s, 3H), 1.50 (s, 9H). LCMS (TOF) m/z 
calculated 293.1972 (M+H)+, found 293.1988. 
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Scheme 7 
 
General procedure for the synthesis of intermediates 73-78.  
A solution of the appropriate intermediate 6-26, intermediate 72 (2eq), and cesium 
carbonate (4eq) in THF (1.5mL) in a 10mL microwave vial was purged with Ar(g). 
Pd2(dba)3 (0.05eq), XANTPhos (0.05eq), and tBuXPhos Pd G3 (0.05eq) were then 
added and the resulting solution was purged with Ar(g). The reaction was heated to 
120ºC for 45min in a microwave reactor, cooled, filtered through celite, and washed with 
EtOAc. The resulting filtrate was concentrated under reduced pressure and separated 
by silica chromatography to yield intermediates 73-78 that were carried forward without 
further purification or characterization. 
 
General procedure for the synthesis of CDK4i-##m. 
To a solution of intermediates 73-78 in DCM (2mL) was added trifluoroacetic acid 
(400µL) and the resulting solution was stirred until judged complete by LCMS (~1hr). 
This solution was added to saturated NaHCO3, extracted with DCM, dried with Na2SO4, 
filtered, and concentrated under reduced pressure. The resulting oil was purified by 
reverse-phase chromatography (0-70% MeCN/water) and lyophilized to yield the final 
product. 
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Ribociclib-m. 1H NMR (400 MHz, DMSO-d6) δ 8.70 (s, 1H), 8.34 (br s, 1H), 8.08 (d, J = 
2.8 Hz, 1H), 7.46 (d, J = 8.9 Hz, 1H), 7.38 (dd, J = 9.0, 2.9 Hz, 1H), 6.55 (s, 1H), 4.64 
(p, J = 8.6 Hz, 1H), 3.55 (s, 3H), 3.15 – 3.10 (m, 4H), 3.04 (s, 6H), 2.93 (m, 4H), 2.26 
(dt, J = 16.5, 5.0 Hz, 2H), 1.94 – 1.89 (m, 2H), 1.77 (p, J = 7.1, 5.9 Hz, 2H), 1.54 – 1.50 
(m, 2H). LCMS (TOF) m/z calculated 449.2772 (M+H)+, found 449.2757. 
 
CDK4i-5m. 1H NMR (400 MHz, DMSO-d6) δ 10.53 (s, 1H), 8.83 (s, 1H), 8.30 (br s, 1H), 
8.10 (d, J = 3.0 Hz, 1H), 7.85 – 7.75 (m, 2H), 7.51 – 7.44 (m, 3H), 7.40 (dd, J = 9.0, 3.0 
Hz, 1H), 7.13 (s, 1H), 5.41 (p, J = 8.8 Hz, 1H), 3.56 (s, 3H), 3.14 (t, J = 4.9 Hz, 4H), 
2.93 (t, J = 5.0 Hz, 4H), 2.37 (dddd, J = 27.3, 8.3, 6.2, 4.2 Hz, 4H), 2.14 – 2.00 (m, 2H), 
2.01 – 1.84 (m, 6H), 1.84 – 1.74 (m, 2H), 1.54 (qd, J = 7.4, 6.9, 3.0 Hz, 2H). LCMS 
(TOF) m/z calculated 590.3350 (M+H)+, found 590.3358. 
 
CDK4i-6m. 1H NMR (400 MHz, DMSO-d6) δ 8.56 (s, 1H), 8.32 (br s, 1H), 8.06 (d, J = 
3.0 Hz, 1H), 7.47 (d, J = 9.0 Hz, 1H), 7.37 (dd, J = 9.0, 3.0 Hz, 1H), 7.21 – 7.14 (m, 2H), 
6.76 – 6.66 (m, 2H), 6.35 (s, 1H), 6.28 (t, J = 5.7 Hz, 1H), 4.70 (p, J = 8.6 Hz, 1H), 4.40 
(d, J = 4.8 Hz, 2H), 3.54 (s, 3H), 3.15 (dd, J = 6.5, 3.6 Hz, 4H), 2.97 (dd, J = 6.2, 3.7 Hz, 
4H), 2.31 (dq, J = 13.2, 3.8, 2.7 Hz, 4H), 2.02 – 1.89 (m, 4H), 1.88 – 1.73 (m, 6H), 1.54 
(q, J = 6.4 Hz, 2H). LCMS (TOF) m/z calculated 576.3558 (M+H)+, found 576.3517. 
 
CDK4i-8m. 1H NMR (400 MHz, DMSO-d6) δ 8.58 (s, 1H), 8.32 (s, 1H), 8.05 (d, J = 3.0 
Hz, 1H), 7.46 (d, J = 8.9 Hz, 1H), 7.36 (dd, J = 9.0, 3.1 Hz, 1H), 6.38 (s, 1H), 5.70 (t, J = 
5.6 Hz, 1H), 5.43 (s, 1H), 4.73 (p, J = 8.7 Hz, 1H), 4.27 (d, J = 5.4 Hz, 2H), 3.54 (s, 3H), 
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3.47 (s, 3H), 3.10 (dd, J = 6.4, 3.6 Hz, 4H), 2.91 (t, J = 5.0 Hz, 4H), 2.39 – 2.23 (m, 2H), 
1.95 (s, 2H), 1.86 – 1.73 (m, 2H), 1.54 (m, 2H), 1.17 (s, 9H). LCMS (TOF) m/z 
calculated 543.3667 (M+H)+, found 543.3668. 
 
CDK4i-17m. 1H NMR (400 MHz, DMSO-d6) δ 8.58 (s, 1H), 8.32 (s, 2H), 8.05 (d, J = 3.0 
Hz, 1H), 7.46 (d, J = 8.9 Hz, 1H), 7.36 (dd, J = 9.0, 3.0 Hz, 1H), 6.36 (s, 1H), 5.57 (s, 
1H), 5.11 (t, J = 5.5 Hz, 1H), 4.84 (p, J = 8.7 Hz, 1H), 4.25 (d, J = 5.4 Hz, 2H), 3.54 (s, 
3H), 3.11 (t, J = 4.9 Hz, 4H), 2.92 (t, J = 4.9 Hz, 4H), 2.40 – 2.25 (m, 2H), 2.02 – 1.87 
(m, 2H), 1.86 – 1.73 (m, 2H), 1.62 – 1.45 (m, 11H), 1.17 (s, 9H). LCMS (TOF) m/z 
calculated 585.4136 (M+H)+, found 585.4131. 
 
CDK4i-24m. 1H NMR (400 MHz, DMSO-d6) δ 8.59 (s, 1H), 8.37 (br s, 1H), 8.05 (d, J = 
3.0 Hz, 1H), 7.45 (d, J = 9.0 Hz, 1H), 7.36 (dd, J = 9.0, 3.0 Hz, 1H), 6.37 (s, 1H), 5.64 (t, 
J = 5.5 Hz, 1H), 5.40 (s, 1H), 4.74 (p, J = 8.7 Hz, 1H), 4.26 (d, J = 5.4 Hz, 2H), 3.63 (d, 
J = 7.4 Hz, 2H), 3.54 (s, 3H), 3.08 (d, J = 5.0 Hz, 4H), 2.89 (s, 4H), 2.40 – 2.27 (m, 2H), 
2.05 (dt, J = 13.7, 6.8 Hz, 1H), 1.98 – 1.88 (m, 2H), 1.84 – 1.73 (m, 2H), 1.57 – 1.45 (m, 
2H), 1.17 (s, 9H), 0.81 (d, J = 6.7 Hz, 6H). LCMS (TOF) m/z calculated 585.4136 
(M+H)+, found 585.4131. 
 
Scheme 8 
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General procedure for the synthesis of intermediates 79-82. 
To a solution of intermediate 5 (20mg, 0.0755mmol) in THF (1.5mL) under Ar(g) was 
added N,N-diisopropylethylamine (26.2µL, 0.15mmol, 2eq) and HATU (31.5mg, 
0.0828mmol, 1.1eq) and the resulting solution was stirred at RT for 20min. The reaction 
was cooled to 0ºC on ice, then the appropriate alcohol (1.5eq) was added dropwise. 
The reaction was allowed to warm to RT and stirred overnight. The reaction was added 
to brine and extracted with EtOAc. The combined organic layers were dried with 
Na2SO4, filtered, and concentrated under reduced pressure. The resulting oil was 
purified by silica chromatography (0-20% EtOAc/hexanes) to yield intermediates 79-82 
as pure products. 
 
4-methoxyphenyl-2-chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidine-6-
carboxylate (79). 1H NMR (400MHz, CDCl3) δ 8.98 (s, 1H), 7.59 (s, 1H), 7.23 – 7.12 
(m, 2H), 7.03 – 6.93 (m, 2H), 5.82 (p, J = 8.8 Hz, 1H), 3.86 (s, 3H), 2.43 (dq, J = 12.5, 
7.4, 6.0 Hz, 2H), 2.20 – 2.05 (m, 4H), 1.71 (qd, J = 8.3, 7.3, 2.6 Hz, 2H). LCMS (TOF) 
m/z calculated 372.1109 (M+H)+, found 372.1137. 
 
4-fluorophenyl-2-chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylate 
(80). 1H NMR (400MHz, CDCl3) δ 8.99 (s, 1H), 7.61 (s, 1H), 7.27 – 7.12 (m, 4H), 6.99 – 
6.89 (m, 2H), 6.85 – 6.76 (m, 2H), 5.82 (p, J = 8.8 Hz, 1H), 2.44 (tdd, J = 12.4, 9.3, 5.1 
Hz, 2H), 2.20 – 2.05 (m, 4H), 1.79 – 1.64 (m, 2H). LCMS (TOF) m/z calculated 
360.0910 (M+H)+, found 360.0905. 
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2,2,2-trifluoroethyl-2-chloro-7-cyclopentyl-7H-pyrrolo[2,3-d]pyrimidine-6-
carboxylate (80). 1H NMR (400MHz, CDCl3) δ 8.96 (s, 1H), 7.47 (s, 1H), 5.75 (p, J = 
8.7 Hz, 1H), 4.73 (q, J = 8.3 Hz, 2H), 2.50 – 2.30 (m, 2H), 2.12 (dtd, J = 14.3, 8.1, 3.2 
Hz, 4H), 1.76 (ddt, J = 10.5, 7.6, 4.5 Hz, 2H). LCMS (TOF) m/z calculated 348.0721 
(M+H)+, found 348.0737. 
 
1,1,1,3,3,3-hexafluoropropan-2-yl-2-chloro-7-cyclopentyl-7H-pyrrolo[2,3-
d]pyrimidine-6-carboxylate (81). 1H NMR (400MHz, CDCl3) δ 9.01 (s, 1H), 7.59 (s, 
1H), 5.98 (hept, J = 5.9 Hz, 1H), 5.73 (p, J = 8.6 Hz, 1H), 2.38 (dt, J = 15.7, 7.8 Hz, 2H), 
2.14 (q, J = 13.3, 10.3 Hz, 4H), 1.77 (dd, J = 12.4, 6.3 Hz, 2H). LCMS (TOF) m/z 
calculated 416.0595 (M+H)+, found 416.0589. 
 
General procedure for the synthesis of CDK4i-1##.  
A solution of the appropriate intermediate 79-82, intermediate 84 (2eq), and cesium 
carbonate (4eq) in THF (1.5mL) in a 10mL microwave vial was purged with Ar(g). 
Pd2(dba)3 (0.05eq), XANTPhos (0.05eq), and tBuXPhos Pd G3 (0.05eq) were then 
added and the resulting solution was purged with Ar(g). The reaction was heated to 
120ºC for 45min in a microwave reactor, cooled, filtered through celite, and washed with 
EtOAc. The resulting filtrate was concentrated under reduced pressure and separated 
by silica chromatography to yield pure CDK4i-1##. 
 
CDK4i-101. White solid (2.5mg, 17.6% yield). LCMS (TOF) m/z calculated 552.2718 
(M+H)+, found 552.2739. 
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CDK4i-102. White solid (1.4mg, 5.2% yield). LCMS (TOF) m/z calculated 540.2518 
(M+H)+, found 540.2517. 
 
CDK4i-103. White solid (10.1mg, 31.7% yield). 1H NMR (400MHz, CDCl3) δ 8.86 (s, 
1H), 8.36 (d, J = 9.1 Hz, 1H), 8.20 (br s, 1H), 8.07 (d, J = 2.8 Hz, 1H), 7.38 (s, 1H), 7.38 
– 7.34 (m, 1H), 5.76 (p, J = 8.8 Hz, 1H), 4.69 (q, J = 8.4 Hz, 2H), 3.42 (d, J = 2.4 Hz, 
2H), 3.32 – 3.21 (m, 4H), 2.85 – 2.78 (m, 4H), 2.69 – 2.51 (m, 2H), 2.17 – 2.01 (m, 4H), 
1.85 – 1.72 (m, 2H). LCMS (TOF) m/z calculated 528.2329 (M+H)+, found 528.2348. 
 
CDK4i-104. White solid (2.7mg, 19.8% yield). 1H NMR (400MHz, CDCl3) δ  8.89 (s, 1H), 
8.35 (d, J = 9.0 Hz, 1H), 8.19 (br s, 1H), 8.07 (d, J = 2.7 Hz, 1H), 7.50 (s, 1H), 7.37 (dd, 
J = 9.1, 2.9 Hz, 1H), 5.97 (dt, J = 12.2, 6.0 Hz, 1H), 5.71 (p, J = 9.0 Hz, 1H), 3.42 (d, J = 
2.4 Hz, 2H), 3.31 – 3.23 (m, 4H), 2.84 – 2.76 (m, 4H), 2.67 – 2.52 (m, 2H), 2.32 (t, J = 
2.4 Hz, 1H), 2.17 – 2.02 (m, 4H), 1.86 – 1.71 (m, 2H). LCMS (TOF) m/z calculated 
596.2203 (M+H)+, found 596.2201. 
 
Scheme 9 
 
1-(6-nitropyridin-3-yl)-4-(prop-2-yn-1-yl)piperazine (83). 5-bromo-2-nitropyridine 
(450mg, 2.22mmol), 1-propargyl-piperazine (2.66mmol, 1.2eq), potassium carbonate 
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(766mg, 5.54mmol, 2.5eq) and tetrabutylammonium iodide (8.19mg, 0.022mmol, 
0.01eq) were dissolved in DMSO (3mL) and the resulting suspension was heated to 
120ºC overnight. The reaction was cooled, added to water and extracted with EtOAc. 
The combined organic layers were dried with Na2SO4, filtered, and concentrated under 
reduced pressure. The resulting solid was purified by silica chromatography (35-100% 
EtOAc/hexanes) to yield the product as a yellow solid (472.2mg, 86.5% yield). 1H NMR 
(400MHz, CDCl3) δ 8.19 (d, J = 9.2 Hz, 1H), 8.17 (d, J = 3.0 Hz, 1H), 7.23 (dd, J = 9.2, 
3.1 Hz, 1H), 3.56 – 3.50 (m, 4H), 3.43 (d, J = 2.4 Hz, 2H), 2.81 – 2.74 (m, 4H), 2.32 (t, J 
= 2.4 Hz, 1H). LCMS (TOF) m/z calculated 247.1190 (M+H)+, found 247.1201. 
 
5-(4-(prop-2-yn-1-yl)piperazin-1-yl)pyridine-2-amine (84). To a solution of 
intermediate 83 (472.2mg, 1.92mmol) in 1,4-dioxane (4mL) and water (2.4mL) was 
added zinc (501.4mg, 7.67mmol, 4eq) and ammonium chloride (1.03g, 19.17mmol, 
10eq) and the resulting solution was heated to 80ºC for 2hr. The reaction was cooled, 
filtered through celite, washed with EtOAc and concentrated under reduced pressure. 
The resulting oil was added to a solution of K2CO3, and extracted with EtOAc. The 
combined organic layers were dried with Na2SO4, filtered, and concentrated under 
reduced pressure. The resulting oil was purified by silica chromatography (10% 
MeOH/DCM) to yield intermediate 84 as a light brown solid (246.7mg, 59.5% yield). 1H 
NMR (400MHz, CDCl3) δ 7.81 (d, J = 2.6 Hz, 1H), 7.20 (dd, J = 8.8, 2.9 Hz, 1H), 6.51 
(dd, J = 8.8, 0.6 Hz, 1H), 4.18 (s, 2H), 3.39 (d, J = 2.4 Hz, 2H), 3.16 – 3.09 (m, 4H), 
2.80 – 2.71 (m, 4H), 2.30 (t, J = 2.4 Hz, 1H). LCMS (TOF) m/z calculated 217.1448 
(M+H)+, found 217.1439. 
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